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Abstract
Magnetic resonance (MR) is a robust platform for non-invasive, high-resolution anatomical imaging.
However, MR imaging lacks the requisite sensitivity and contrast for imaging at the cellular level. This
represents a clinical impediment to greater diagnostic accuracy. Recent advances have allowed for the in
vivo visualization of populations and even of individual cells using superparamagnetic iron oxide (SPIO)
MR contrast agents. These nanoparticles, commonly manifested as a core of a single iron oxide crystal or
cluster of crystals coated in a biocompatible shell, function to shorten proton relaxation times. In MR
imaging these constructs locally dephase protons, resulting in a decrease in signal (hypointensity)
localized to the region of accumulation of SPIO. In the context of immune cell imaging, SPIO can provide
insight into the cellular migration patterns, trafficking, temporal dynamics and progression of diseases
and their related pathological states. Furthermore, by visualizing the presence and activity of immune
cells, SPIO-enabled cellular imaging can help evaluate the efficacy of therapy in immune disorders.
This thesis examines the production, modification and application of SPIO in a range of in vitro and in vivo
immune-response-relevant cellular systems. The role of different nanoparticle characteristics including
diameter, surface charge and concentration are investigated in the labeling of T cells in culture. Following
optimization of SPIO loading conditions for lymphocytes, the effect these particles have on the activation
of primary B cells are elucidated. B cells are tracked using a variety of modalities, with and without the
application of B cell depleting therapy. This is to evaluate the efficacy of SPIO as in vivo marker for B cell
distribution.
Unmodified SPIO were applied to monitor macrophage infiltration in a transient nerve root compression
model, with implications for neck pain diagnosis and treatment. Nanoparticle accumulation and MR
hypointensity was correlated to the presence of activated macrophage at the site of injury. Taken
together, the application of SPIO to study nanoparticle uptake in vitro and visualization of immune cells in
vivo provide a basis for advanced study and diagnosis of diverse pathologies.
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ABSTRACT
MONITORING OF IMMUNE CELL RESPONSE TO B CELL DEPLETION THERAPY AND NERVE
ROOT INJURY USING SPIO ENHANCED MRI

Daniel L.J. Thorek

Andrew Tsourkas, Thesis Advisor

Magnetic resonance (MR) is a robust platform for non-invasive, high-resolution
anatomical imaging. However, MR imaging lacks the requisite sensitivity and contrast
for imaging at the cellular level. This represents a clinical impediment to greater
diagnostic accuracy. Recent advances have allowed for the in vivo visualization of
populations and even of individual cells using superparamagnetic iron oxide (SPIO) MR
contrast agents. These nanoparticles, commonly manifested as a core of a single iron
oxide crystal or cluster of crystals coated in a biocompatible shell, function to shorten
proton relaxation times. In MR imaging these constructs locally dephase protons,
resulting in a decrease in signal (hypointensity) localized to the region of accumulation of
SPIO. In the context of immune cell imaging, SPIO can provide insight into the cellular

vii
migration patterns, trafficking, temporal dynamics and progression of diseases and their
related pathological states. Furthermore, by visualizing the presence and activity of
immune cells, SPIO-enabled cellular imaging can help evaluate the efficacy of therapy in
immune disorders.
This thesis examines the production, modification and application of SPIO in a
range of in vitro and in vivo immune-response-relevant cellular systems. The role of
different

nanoparticle

characteristics

including

diameter,

surface

charge

and

concentration are investigated in the labeling of T cells in culture. Following optimization
of SPIO loading conditions for lymphocytes, the effect these particles have on the
activation of primary B cells are elucidated. B cells are tracked using a variety of
modalities, with and without the application of B cell depleting therapy. This is to
evaluate the efficacy of SPIO as in vivo marker for B cell distribution.
Unmodified SPIO were applied to monitor macrophage infiltration in a transient
nerve root compression model, with implications for neck pain diagnosis and treatment.
Nanoparticle accumulation and MR hypointensity was correlated to the presence of
activated macrophage at the site of injury. Taken together, the application of SPIO to
study nanoparticle uptake in vitro and visualization of immune cells in vivo provide a
basis for advanced study and diagnosis of diverse pathologies.
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CHAPTER 1. Magnetic Resonance Imaging, SPIO, and Cell Tracking
1.1 - Overview
Magnetic resonance (MR) imaging is a powerful diagnostic platform in
widespread clinical use. MR demonstrates visualization of healthy and disease relevant
features in both time and space through the display of high-resolution anatomical
information. Image formation is dependent on the intrinsic contrast of adjacent tissues.
This distinction in signal is provided by the different rates of realignment of hydrogen
nuclei within an external magnetic field, following a radio frequency pulse sequence.
However, the modality is often restricted as a result of low sensitivity to changes between
tissues and tissue states.
The use of MR for molecular and cellular imaging (MCI) is an emerging subfield
with significant potential to impact clinical and research applications. MCI has been
defined as the non-invasive, quantitative and repetitive imaging of biomolecules and
biological processes in living organisms (1). Unfortunately, the applicability and
translation of MCI approaches, such as more accurate, earlier detection of disease or the
study of biological phenomena, is hindered by MR imaging's inherently low signal-tonoise ratio. This deficiency is mitigated through the use of contrast agents (CA). Unlike
direct signal detection or interference as caused by CA in x-ray imaging applications, MR
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CA function by altering characteristics of surrounding water protons through their
magnetic properties.
This chapter will provide a brief overview on the fundamentals of MR and recent
advancements in the disciplines relevant to cellular magnetic resonance imaging. First, an
overview of the quantum mechanical principles underlying nuclear spin relaxation will be
discussed. Image generation for biological samples will be described. This will be
followed by an examination of issues of tissue contrast and a description of T2* contrast
agents. A detailed overview of the physical and biological properties of
superparamagnetic iron oxide nanoparticle agents will be given. Finally, the imaging
approach used in the tracking and identifying of immune cells for biomedical purposes
will be discussed. A special emphasis will be placed on the application of SPIO
particulates for immune and inflammatory cell relevant imaging.
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1.2 - Nuclear Magnetic Resonance and Spin Relaxation Processes
Magnetic resonance (MR) is a versatile instrument for non-invasive imaging of
living specimens in the clinic and in research. In the United States alone, there were over
26 million MR procedures at approximately 7000 hospital and non-hospital MR imaging
sites in 2007 (2). This imaging modality is based on the same principles as its forbearer in
research, nuclear magnetic resonance spectroscopy (NMR). As the vast majority of
clinical research on MR and all of the work detailed in this thesis relate exclusively to the
hydrogen nucleus, the description of MR imaging relates only to proton (1H) MR.
However, the fundamentals discussed below can be extended to MR studies of other
nuclei with quantum spin numbers of 1/2.
All quantum particles have the property of spin, a fundamental property of nature
like electrical charge or mass. The proton, with its unmatched positive charge, can be
thought of a spinning charged particle with a spin of 1/2. Spinning charged particles,
similar to rotating electrically charged bodies, have a magnetic dipole (north and south)
and MR imaging is predicated on the manipulation of this dipole through the use of radio
waves in a static magnetic field.
The nuclear spin angular momentum, or spin, of 1H can be described as (S), a
vector that can be quantified in Equation 1.1. Here, h is Planck's constant and s is the
nuclear spin quantum number. For the proton s is equivalent to 1/2.
| S |=

h
2"

s(s + 1)

Equation 1.1

When placed in an external magnetic field of strength (B0) the spin vector (S) of the
!
proton aligns in the direction of the applied field. This 'atomic magnet' is now said to be
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in a low energy state, as it is aligned with the applied field. The proton can undergo a
transition to a high-energy state (anti-parallel to the applied field) through the absorption
of a photon of specific energy. In quantum mechanics the energy transferred has a
discrete value, ie. it is quantized.
The energy of this photon is equivalent to the energy difference between the two
states; parallel (or aligned) and anti-parallel. Protons can absorb photons that have a
frequency, !, as defined in Equation 1.2. The gyromagnetic ratio of the particle, ", for 1H
is equal to 42.58 MHz/T.

" =#$B

Equation 1.2

This frequency, ! , is known as the Larmor or resonant frequency of the nuclei. The
frequency of the photon can!be converted to energy through the wave-particle duality as
described in Equation 1.3.

E = h"

Equation 1.3

This allows for the calculation of the energy necessary (through absorption) to switch a
proton from the high to low!energy state. This is shown in Equation 1.4.

E = h"#"B

Equation 1.4

The field strength of an MR must be high in order to align the weak magnetic dipole

! increases, the spectral resolution and sensitivity increase,
moment of 1H. As field strength
resulting in improved signal to noise as the energy difference between states increases. At
high field, photon frequencies for excitation to alter nuclear spin states are in the
radiofrequency (RF) range (MHz).
Moving from a single proton or a single magnetic dipole moment to a collection
of spins, first randomly aligned as seen in Figure 1.1A and then aligned with an external
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field B0 along the z-axis, we see the emergence of a net magnetization vector (Mz) in
Figure 1.1B.
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Figure 1.1 - Magnetic Dipole Moment Alignment.
(A) The spinning and precessing nuclei generate a magnetic dipole moment (red). These
moments are randomly aligned in the absence of an external magnetic field. (B) With the
application of that field (B0) the net magnetization the dipole moments generates an
equilibrium net magnetization vector (M0). At equilibrium, this is equal to the z-axis
component of the magnetization vector (Mz, blue).
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With an applied magnetic field along the z-axis a net magnetization vector
develops, aligned with the applied field. This net vector (Mz) increases when placed in
the field as the 1H become preferentially aligned in the low energy state until reaching an
equilibrium distribution between the states. It is then equal to the equilibrium
magnetization vector (M0). Further, there is no net magnetization of protons' magnetic
dipoles in either the x- or y-directions. With the application of a RF pulse equal to the
Larmor frequency of the precessing, aligned nuclei, the z-component of the net
magnetization vector can be reduced to zero. As the system relaxes back to a lower
energy state (globally) after the removal of the radiofrequency source, Mz = 0 returns
back to the equilibrium condition Mz = M0. The recovery of the longitudinal
magnetization is described in Figure 1.2.
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Figure 1.2 - Longitudinal Magnetization and T1.
(A) Following the application of a radiofrequency pulse at the Larmor frequency, the net
magnetization is saturated and no longer possesses a longitudinal bias. Immediately
following the removal of the radio energy, the system returns to its lower energy state,
with a majority of 1H aligned with the field. (B) The growth of the z-component
magnetization vector (Mz) back to a fraction (1-1/e or 63%) of the equilibrium state is
described by the time constant T1. The time (t) refers to time after removal of
radiofrequency.
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Equation 1.5 describes the T1 or spin lattice relaxation time, a value used to
describe the exponential recovery of Mz. T1 is a constant that is equal to the time
required for the recovery of 63% of the longitudinal magnetization.
"t &
#
M z = M 0 %1" e T1 (
$
'

Equation 1.5

The net magnetic moment can be placed, or flipped, into the orthogonal xy-plane

!
through the application of specific
radiofrequency pulses that result in phase coherence of
the magnetic dipoles of the 1H nuclei. This means that an xy-component of the net
moment (Mxy) is generated and this will rotate about the axis of the applied field. The
frequency of this rotation will be equal to the Larmor frequency (3).
This state does not last following the removal of the pulse, as perturbations in the
local magnetic field by other nuclei as well as imperfections in the applied field lead to
reduction and finally absence of coherence. As the transverse magnetization vector
rotates about the applied field, the Mxy will decrease as illustrated in Figure 1.3. The
decrease in transverse magnetization can be described by T2 or the spin-spin relaxation
time. This is the time needed for Mxy to be reduced by 63%. Mathematically, this is
expressed in Equation 1.6. It must be stressed that the T1 and T2 relaxation are
independent processes. They are related through the bulk direction of net magnetic dipole
moment and occur simultaneously but describe separate physical events.
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Figure 1.3 - Transverse Magnetization and T2.
The net magnetization vector can be flipped into the transverse plane whereupon it is
denoted Mxy, green. In (A), following the removal of the radiofrequency pulse the vector
continues to rotate around the direction of the applied field, indicated by the arrow head
on the perimeter path of the transverse vector. The rapid loss of phase coherence leads to
the decay of Mxy. In (B), the time constant of decay of magnetization, spin-spin
relaxation or T2 is shown. Please note the change in frame of reference.
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# "t &
M xy = M xy %e T 2 (
'
0$

Equation 1.6

In an ideal system, all dephasing of spins would begin with all nuclei precessing

!
at the same phase. However, in application the field is never fully homogeneous, and in
all biological samples of interest there are chemical differences that disturb the phases of
1

H. This leads to enhanced non-random relaxation effects that are termed T2* decay. The

inverse of T2* is equal to the summation of the inverse of the T2 decay and the dephasing
produced by inhomogeneities.
To summarize, magnetic resonance is based on the electromagnetic properties of
hydrogen nuclei. Their nuclear spin, coupled with their charge, creates a magnetic dipole
moment. In bulk, the aggregate magnetic moment or net magnetization is zero in the
absence of a magnetic field. With the application of a field, a majority of protons align
with the field, generating a net magnetization vector aligned with the applied field. This
net magnetization can be manipulated by switching protons from a low energy (aligned)
to a higher energy (anti-parallel) state with the application of electromagnetic radiation of
a specific energy. For the purposes of MR imaging this is in the RF range. Following the
removal of the radio source, the net magnetization returns to equilibrium through two
forms of relaxation, T1 and T2. The former sees nuclei return energy to the surrounding
lattice or medium as the nuclei re-align preferentially with the applied field. In the latter
process, transverse magnetization decreases as nuclei lose phase coherence (as spins must
be in phase in the transverse direction to be detected) and through nuclei exchanging
energy with their neighbors.
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1.3 - Magnetic Resonance Image Formation
For clinical and research applications, the samples of interest are heterogeneous
and large. MR information that is relevant for diagnostic purposes requires that spatial
information be encoded into the signal in three directions; x, y and z. The discussion here
will focus on the generation of 2-dimensional MR images, as acquired for analysis in this
dissertation.
Spatial encoding is accomplished by time-varying the strength of the magnetic
fields. In the simplest case, a one-dimensional linear gradient (a variation of the magnetic
field with respect to position) along the direction of the applied field is created, termed
the Gz or z-gradient, as shown in Figure 1.4. Now each hydrogen nuclei at a distance zi
along the gradient precesses at a unique frequency. This frequency can be determined for
each local field strength along the gradient, as previously shown in Equation 1.2. This
will be termed the slice selection gradient, as we are interested in imaging a plane
perpendicular to the applied gradient.
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Figure 1.4 - Slice Selection.
(A) A magnetic gradient (dashed line) is applied along the z-direction. This results in
each plane perpendicular to the z-axis experiencing a different magnetic field. Thus, at
each zi, protons precess at different angular frequencies. These frequencies, !i vary
proportionately with their distance along the gradient, as the applied gradient is linear.
(B) This can be exploited for slice selection purposes by exciting a plane selectively with
a radiofrequency pulse of a power and bandwidth required to flip the 1H spins in the
desired plane. The number of arrows in the cartoon body, which differ along the gradient,
symbolize the field strength experienced at different anatomical locations.
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The next step in the imaging process is to spatially encode within the selected
slice using gradients applied perpendicular to the slice selection gradient. There are two
remaining directions, the x and the y, in which MR signal needs to be localized. First,
phase encoding is performed. This is accomplished with the brief application of a
gradient, Gy, in order to align the phases of the spinning nuclei within the slice,
according to their position relative to the gradient. This brief dephasing results in a slice
whose nuclei all spin at the same frequency, but at different phases relative to their
location within the slice. In conventional, supine, MR this gradient is applied
anterioposterially. As shown in Figure 1.5A this results in phase encoded nuclei that spin
in a phase proportional to their position in the gradient in the transverse plane. In other
words, the Larmor frequency for proton spin along the gradient is different at each
position along that gradient.
The third and final spatial encoding element is obtained through application of a
frequency encoding gradient. This results in 1H that precess at a rate that is equal for all
nuclei at a given distance along the applied frequency encoding gradient direction, as
shown in Figure 1.5B. This gradient is applied laterally, or in Gx for the employed
coordinate system, and is switched on during the acquisition of data. For this reason the
Gx gradient is also referred to as the readout gradient. The gradient is on during the
acquisition, resulting in a spectrum of frequencies (at each distance along the x direction)
being read, rather than a single frequency.
This signal is received by radiofrequency coils that surround the subject. The
magnetization direction and magnitude of spins at locations within a subject are relayed
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by these antennae as these magnetic fields will generate current. In order to determine the
x-position, the radiofrequency spectrum must first be analyzed using a Fourier transform.
This operation decomposes the spectrum into component frequencies for each position
along the applied gradient. The y-position is determined by analyzing the phase
distribution within each frequency. This requires that a second transform be employed as
the acquired data is the sum of all spins with the same frequency but different phases
(schematically within the double-lines in Figure 1.5B). The phases and thus the ylocation of the spins can be determined after all rows in a given slice are analyzed.
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Figure 1.5 - Phase Encoding.
(A) A phase encoding gradient, Gy, is applied and aligns the frequency of spins
perpendicular to the axis of the gradient (i.e. in rows at equal distances along the
gradient). The gradient is symbolized to be increasing with opacity of the Gy arrow. (B)
The frequency encoding gradient, Gx, is applied during the readout of the resonance
information. This gradient encodes the frequency, or rate of precession, in the selected
slice plane for all protons experiencing the same frequency encoding magnetic field
strength (for example within the double-lines). The gradient is symbolized to be
increasing with opacity of the Gx arrow. For clarity - decreased, nominal and increased
frequency of precession is noted at the top.

Chapter 1

17

1.4 - MR Imaging Contrast
MR as a modality for diagnostic imaging is dependent on its ability to resolve
distinct tissues and physiological features deep within opaque organisms. The ability to
discern between tissues and tissue states for imaging purposes is defined by the contrast
to noise ratio (CNR; Equation 1.7).

CNR =

(SI1 " SI2 )
noise

Equation 1.7

Here, SI is the signal intensity of adjacent regions in an image and these values

!
rely on the earlier discussion
of relaxation properties. To recapitulate - T1 is a description
of recovery of longitudinal magnetization (recovery of 63% of the equilibrium net
magnetization) while T2 is a measure of the decay of the transverse magnetization (loss of
63% of Mxy0).
In non-ideal systems, additional effects enhance the rate of decay of transverse
magnetization, termed T2* decay. Following removal of the RF energy, the relaxation
and decay processes initiate immediately. In biological imaging systems there always
exist some magnetic inhomogeneities, a result of both the field consistency and its
interaction with the sample. These magnetic inhomogeneities serve to enhance the rate of
decay of transverse magnetization. T2* decay is thus the combination of T2 decay added
to the dephasing due to these inhomogeneities. The time for T1 is always longer than T2,
which is always longer than T2*.
The differences in T1, T2 and proton density within a sample determine the
intensity of signal (SI) in a given region of a 2D image and therefore its discernment.
Using different radiofrequency (RF) and magnetic gradient pulse algorithms, hereafter
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called sequences, the tissues' contrast can be enhanced towards one of the three inherent
contrast parameters. This is possible because the T1, T2 and proton densities of tissues
(and noise) differ, as summarized in the relaxation time values in Table 1.1 and can be
exploited for the purposes of contrast throughout the body.

Tissue
Liver

T1 (msec)

T2 (msec)

576 ± 30

46 ± 6

Skeletal muscle

1008 ± 20

44 ± 6

Heart

1030 ± 34

40 ± 6

690 ± 30

55 ± 3

1441 ± 120

327 ± 4

Spinal cord

745 ± 37

74 ± 6

White matter

884 ± 50

72 ± 4

Grey matter

1124 ± 50

95 ± 8

Kidney
Blood

Table 1.1 - T1 and T2 Values for Human Tissues at 1.5 T
Accepted values for the T1 and T2 of commonly MR investigated tissues. This table was
adapted by Thorek, from (4).
It is useful to examine the resonance response of a single tissue. The longitudinal
magnetization recovery of a tissue after a 90˚ pulse (or flip into the transverse plane) is
shown in Figure 1.6A. Here we see the saturation of the signal with the 90˚ flip to zero
and then its exponential recovery dependent on its T1 value. In (B) we see that different
tissues or different tissue regions have variable T1 values and thus can be distinguished
by selecting appropriate TR, repetition time, and TE, echo time, to sample the signal. The
TR is a time value that describes the time from the application of one RF pulse to the
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application of the next RF pulse. It is measured in milliseconds (msec). The TE is the
time from the application of the RF pulse, to the peak of the signal induced in a receiver
coil and is also measured in msec. Nearly all imaging protocols sample the signal at this
echo time (peak signal). The TE determines how much decay of transverse magnetization
is allowed to occur before the signal is read.
Visualization of tissue contrast based on T2, or T2-weighting (T2-w), can be
accomplished by exploiting the equivalent T2 differences between tissues as shown for
T1-w imaging above. This imaging mode is described in Figure 1.7. Care must be taken
to note the superimposition of the Mxy decay curve onto that of the Mz recovery curve,
in Figure 1.7.
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Figure 1.6 - T1-w Tissue Contrast.
(A) The recovery of longitudinal magnetization in a tissue, following a 90˚ RF pulse that
has flipped the net magnetization into the orthogonal plane, is shown. The recovery is
described by T1, mathematically shown in Equation 1.5. The T1-weighted contrast
between different tissues; namely, white (solid) and grey (dashed) matter is shown in (B).
Each tissue has a different T1 and by selecting a repetition time (TR) to sample the signal
when these values have not recovered to their equilibrium values one is able to weight
contrast between them. This contrast is symbolized by the double-edged arrow.
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Figure 1.7 - T2-w Tissue Contrast.
(A) The decay of transverse magnetization (Mxy) is shown. Here, the T2 of the tissue
examined is a measure of the time needed for the exponential reduction of that signal in
the transverse plane, as described in Equation 1.6. The hash marks on the abscissa are
meant to indicate that the TR time is often an order of magnitude greater than the TE
time. (B) Demonstrates the principle by which contrast between tissues can be generated
based on their T2 properties. The echo time chosen and the contrast effected are indicated
by the double arrow between the present tissues.
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Finally, proton density weighted images can be generated by long TR and short
TE sequences. Essentially, the T1-w and T2-w are both removed. This can be observed
looking back at Figure 1.6 at long times. The SI for each tissue is said to be proportional
to the proton density of that tissue which can be measured following a 90˚ RF pulse and
giving enough time for full longitudinal relaxation.
An image depicting tissue contrast from a human brain under various weighting
strategies is shown in Figure 1.8. Structures of the brain can be discerned under each,
corresponding to cerebrospinal fluid (in the ventricles), white and grey matter as well as
to the presence of lesions in the blood brain barrier.
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Figure 1.8 - Tissue Contrast in the Brain.
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This image shows an axial section of the brain of a subject patient under (A) T -, (B) T -,
and (C) proton density (PD) weighting. Contrast of tissues is evident under each pulse
regime, however each possesses structurally distinct information. Here, we see the
contrast between tissues under different weighting for a patient. (A) We are able to
identify regions of fat as bright. Contrast enhancement of a lesion is evident (arrow). (B)
The bright regions are areas composed of a higher proportion of water, which highlights
the presence of CSF, while in (C) the PD-weighted image shows no abnormalities. The
Fig. 13.1
main
clinical utility of PD-weighting is to identify abnormalities in neuronal function (5).
The images presented in Fig. 13.1 also illustrate the general applicability of the
different parameter weightings discussed. T1-weighted scans (Fig. 13.1A) find application for depiction of detailed anatomy and detection of contrast enhancement, the latter
using a gadolinium chelate (the most commonly employed intravenous MR contrast
agent). Fat is high signal intensity, cerebrospinal fluid (CSF) low signal intensity, and
white matter is higher signal intensity than is gray matter. Depicted well in Fig. 13.1A,
due to enhancement on this postcontrast image, is a metastatic lesion (arrow) from lung
carcinoma. Heavily T2-weighted images, such as that illustrated in Fig. 13.1B, find application for visualization of fluid (such as CSF) and to a lesser extent edema. Anatomic
detail may also be high, depending upon the specific technique used. CSF is high signal
intensity and the gray matter-white matter signal intensity ratio is reversed compared
to that of T1-weighted images. Proton density–weighted images, illustrated in Fig. 13.1C,
have few applications, due to generally poor contrast between tissues. FLAIR, illustrated
in Fig. 13.1D, being specifically a T2-weighted scan with CSF suppression, depicts
extremely well edema within the brain (with high signal intensity; arrow).
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1.5 - MR Contrast Agents
1.5.1 - Overview
Confident radiological determination of the presence and extent of disease by MR
requires that the biological differences present in tissues be detected and distinguished
through changes in nuclear spin. Inherent contrast between tissues can be low, as can be
seen in several of the T1 and T2 values found for tissues above, in Table 1.1. This is
especially true in the case of particular tissues under normal (healthy) and pathological
conditions. The sensitivity of MR to detect these differences is also an issue as noise and
other artifacts can contribute to loss of signal and may require prohibitively long
acquisition times for imaging. These difficulties render accurate diagnosis based on
contrast from MR scans problematic (6).
To remedy the problem of low contrast between tissues and tissue states contrast
agents (CA) are often employed. These CA are used to selectively enhance the image
contrast in regions of interest by locally affecting the magnetic environment of protons.
So-called magnetopharmaceuticals differ from the CA conventionally used in X-ray and
X-ray computed tomography (CT), such as iodine, which are directly imaged because of
their interference or absorption of electromagnetic energy (7). MR CA function indirectly
through their affects on the surrounding 1H found in tissues, most often in water (8).
This section will provide an overview of the field of MR CA beginning from their
description and categorization. While the focus of the present dissertation is squarely on
iron oxide nanoparticulates for MR contrast enhancement, such materials are novel and
do not make up the majority of MR CA currently used in the clinic or for research
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purposes. As such, a discussion of the most commonly used CA for MR, gadolinium(III)
chelates, will also be provided, in Appendix A, which includes a description of the
chemical compounds in clinical and academic use. The present chapter is engaged in a
general description of the categorization of MR CA, their mechanism of action and issues
associated with their use. The remainder of this section will then be occupied by a
synopsis of the field of T2 and T2* CA founded on superparamagnetic particles.

1.5.2 - Classification and Measurement of Relaxivity
Contrast agents fall under the broad categories of T1-weighted (-w) or T2-w. This
is despite the fact that each agent will generally reduce both T1 and T2, as their relaxitive
effects interact with both transverse and longitudinal processes. Agents are thus classified
by the relaxation mechanism that they shorten the most, despite the fact that many agents,
such as metal oxides, shorten both significantly (9).
Contrast agents are measured by their efficiency in enhancing proton relaxation.
This can be described as the relaxivity of the contrast agent and is defined in Equation
1.8. Here, Ri is the T1 or T2 relaxivity corresponding to Ti and C is the concentration of
the agent.

Ri = "C " Ti

Equation 1.8

Thus, relaxivity can be described as the concentration dependent effect of a contrast agent
(CA) on proton relaxation. !
Relaxivity is most often written in the form of (mM!sec)-1 or (mmol/L!sec)-1.
These values are determined by a plot of the inverse of T1 or T2 time with respect to
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concentration of the agent. As from Equation 1.8, the slope of the linear portion of the
curve is the relaxivity. Quantitative measurement of relaxivity allows for the comparison
of agents and their usefulness under different conditions for diagnostic, in vitro and in
vivo systems.
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1.6 - T2 and T2* Contrast Agents and Superparamagnetic Iron Oxide
1.6.1 - Introduction
The vast majority of contrast aided clinical scans use gadolinium based agents
(10). This type of magnetopharmaceutical is effective at reducing the T1 recovery time
and thus results in brightening in T1-weighted imaging. While the focus of the work is on
T2* contrast agents, gadolinium based agents are currently the most widely used contrast
agents in the clinic. Thus, additional information on the background of and recent
advances in the use of gadolinium(III) chelates has been included in Appendix A.
The second class of contrast agents in widespread clinical and research use are T2
and T2* agents. There is a wide assortment of different manifestations of these agents
utilizing different material and biological strategies to produce localized contrast in vivo.
The most common T2-CA material consists of iron oxide particles on the order of
microns down to several nanometers. As these iron oxide materials, particularly
nanoparticles (NPs), are the focal point of the research described herein, the discussion of
other T2 and T2* CA (such as cobalt (11) or 17Oxygen based CA (12)) will be proscribed.
Using iron oxide in particulate form is common because of several advantageous
features of these materials. Iron oxide is a substance found through out the body and is
inherently biocompatible, even at very high concentrations. They provide high change in
signal per unit metal and as they are composed of many thousands if not millions of
atoms, they overcome the low sensitivity of MR. Further; they can be easily manipulated
during and after synthesis resulting in highly derivitized structures possessing
application-specific chemical, magnetic and biological properties.
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This section will review important features of superparamagnetic iron oxides
(SPIO). This discussion will include an overview of the different configurations of
particulate iron oxides developed for imaging, the mechanism of action of
superparamagnetism-affected transverse relaxation, the NPs' physical and chemical
properties and a discussion of their synthesis. An appraisal of the literature relating the
biodistribution and biomedical application of these particles, in their many different
forms, will also be given. The final section will focus on their utility for immune cell
tracking.

1.6.2 - Terminology
There are many forms of SPIO MR CA in academic and medical use, to the extent
that classification of the different manifestations of these agents has become necessary.
Categorization of SPIO as defined by their overall hydrated diameter is the most efficient
means to that end. However, it should be noted that the literature lacks consistency
beyond the groupings below and the nomenclature system often refers to the same
particle configurations several different ways. The most egregious are the multiple names
for ultrasmall-SPIO (USPIO), as detailed below.
The largest particles, Oral-SPIO have an overall diameter between 300 nm and
3.5 !m and are also referred to as micron-sized iron oxide (MPIO). The more commonly
used SPIO formulations are on the nanometer scale. These nanoparticles are defined as
particles with one dimension below 100 nm in length. SPIO in this classification include
Standard-SPIO (SSPIO) at 60-150 nm, Ultrasmall-SPIO (USPIO) of approximately 5-40
nm and monocrystalline iron oxide nanoparticles (MION - a subset of USPIO) range

Chapter 1
29
from 10-30 nm. A prevalent derivatization of MION, consisting of a chemically crosslinked polysaccharide shell, is referred to as CLIO (Cross-Linked Iron Oxide). Molecular
imaging of disease generally requires the use of the smaller agents in the category of
USPIO. In the literature USPIO is the most common name; however MION, VSOP (very
small iron oxide particles) and MNPs (magnetic nanoparticles) are used, among others.
SPIO will be used herein to refer to MPIO, SSPIO, MION, CLIO, and USPIO, unless
otherwise noted.
Trade names given to SPIO are also often confusing, primarily because the same
formulation is often given different pharmaceutical names depending on the specific
regional market. Ferumoxsil or AMI-121, an approximately 400 nm Oral-SPIO, is also
known as GastroMARK (USA) and Lumirem (EU and Brazil). This agent is approved for
use in Europe to distinguish between abdominal tissues and the bowels. Larger OralSPIO such as OMP (also known as Abdoscan) has a larger hydrated diameter at 3.5 µm.
Ferumoxide or AMI-25 is also known as Feridex IV (USA) and Endorem (EU). This
agent is an FDA approved SSPIO, 80-150 nm in diameter, for use in detection and
diagnosis of liver metastases. Ferumoxtran or AMI-227 (also known as Sinerem (EU)
and Combidex (USA)) is a dextran coated USPIO (of a diameter between 20 and 30 nm)
(13) currently in late-phase clinical trials for detection of lymph-node metastases (14, 15).
Ferucarbotran, Ferrixan, SHU 555, or Resovist (EU and Japan) is a carboxydextran
coated SPIO of approximately 60 nm hydrodynamic diameter approved for use in Europe
(16, 17). Table 1.2 contains a concise listing of SPIO, their alternate names, approval
status, application and size.
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Overall, the use of the term SPIO in the literature refers to nano- and
microparticles as defined above. These magnetopharmaceuticals of superparamagnetic
iron oxide are not the only forms of the contrast agents that exist. Ferritin is a well
conserved protein complex produced by all eukaryotes for intracellular iron-storage (18).
The core of iron surrounded by the protein subunits can be substituted with a
superparamagnetic crystal, however the rapid clearance (to the liver and spleen) of these
protein-based-SPIO have presented major restraints to their in vivo use (19-21).
In another biologically inspired strategy, iron oxide nanocrystals produced by
magnetotactic bacteria have also been exploited for imaging purposes, as an in vivo
transgene reporter (22). Here, an adenoviral vector was used to place the nanocrystal
manufacturing gene into cells of interest, whereupon subsequent production of SPIO
could be visualized using gradient echo sequences. This approach, while certainly novel,
has not seen widespread adoption to introduce SPIO biologically.
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Class

Agent

Trade name(s)

FDA Status

Application

Diameter

Oral-

AMI-121

Lumirem,

Approved

GI Lumen

> 300 nm

SPIO

(Ferumoxsil)

Gastromark

OMP

Abdoscan

Approved

GI Lumen

3.5 !m

AMI-25

Endorem

Approved

Liver

80-150 nm

(Ferumoxide)

Feridex

SHU555A

Resovist

Approved

Liver

62 nm

SSPIO

(Ferucarbotran

Blood pool

or Ferrixan)
USPIO

AMI-227

Sinerem,

Phase III

Lymph

20-40 nm

(Ferumoxtran)

Combidex

complete

Blood pool

NC100150

Clariscan

Discontinued

Blood pool

20 nm

CODE 7228

Advanced

Phase II

Blood pool

18-20 nm

(Ferumoxytol)

Magnetics

complete

Kidney

Table 1.2 - Commercially Available SPIO CA.
A list of SPIO commercially available or in development for clinical use. Updated by
Thorek, from (23).

1.6.4 - Iron Oxide Core and Magnetism
Despite the different manifestations of SPIO noted in the preceding section, they
typically share two common features. These are a core of iron oxide crystal(s) and an
exterior coating material, as depicted in Figure 1.9A. The cores of the particles are
composed of inverse spinel iron oxide crystals of magnetite (Fe3O4) and/or maghemite (!Fe2O3). The crystal structures are shown in Figure 1.9B. The cores of many SPIO are
composed of multiple crystals or of imperfect crystals, generally dependent on the
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synthesis method and conditions. The two magnetic oxides, magnetite and maghemite,
have similar crystal structures (lattice parameters of 8.396 and 8.346 Å, respectively) and
magnetic properties (24). In bulk, maghemite does have a lower saturation magnetization
(saturation refers to a plateau in the magnetic flux density following increasing
magnetization force).
This is not a major factor in nanoparticle magnetic properties for two reasons.
Firstly, at the magnetic fields that are utilized in MR imaging both forms of bulk
materials are invariably saturated. The second and perhaps a more important factor is that
at the nanoparticle length scale, the emergence of quantum magnetic effects predominate.
This renders the bulk lattice state less crucial in determining particle relaxivity and these
features are the real impetus behind the recent interest in nanoparticle and nanoscale
technologies. A description of this nanoscale magnetic phenomena (superparamagnetism)
follows after a description of the different categorizations of classical magnetic materials.
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Maghemite (!-Fe2O3)

Magnetite (Fe3O4)

Figure 1.9 - Schematic of SPIO and Crystal Structure.
(A) Representation of a superparamagnetic iron oxide nanoparticle. The iron oxide core
is surrounded by a polymer or polysaccharide coating, either formed during the synthesis
of the crystal or after. The surface coating can be chemically modified with functional
sites for bioconjugation to biological and chemical items of interest. (B) Crystal
structures of a single unit cell for the two predominant SPIO components, magnetite and
maghemite, using a ball and stick model. The large orbs are oxygen, denoted as O, the
smaller are iron (Fe) in the octahedral and tetrahedral sites. Information for the two
crystals were retrieved from the American Mineralogist Crystal Structure Database and
images were generated using CrystalMaker®.
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Empirically, magnetic materials are characterized by their response to being
placed in a magnetic field. The resulting magnetization of the material can take one of
several forms and the material is described as being diamagnetic, paramagnetic or
ferromagnetic. In the first instance, the orbital electrons in the material are moved to a
magnetic dipole moment in the opposite direction of the applied field. In other words, the
magnetic susceptibility (magnetization of a material in an applied field) is less than 0. In
bulk materials this manifests in repulsion of the material away from the magnetic field.
This phenomenon often occurs strongly within materials whose valence electrons are all
paired, however all ‘non-magnetic’ materials exhibit some level of diamagnetism.
Paramagnetic materials, like the gadolinium(III) ion, have a positive magnetic
susceptibility. Thus, the induced magnetization of the material is in alignment with the
applied field. However, in the absence of a field, the magnetic dipoles are randomly
aligned; in other words they have no remnant magnetization. This is often found in
elements with non-zero angular momentum (unpaired valence orbitals) and is found in
some metals. A schematic of a paramagnetic material’s magnetic dipole configuration is
found in Figure 1.10A.
Ferromagnetism is a phenomenon wherein some materials exhibit spontaneous
magnetization in the absence of a magnetic field. The magnetic properties of
ferromagnetic materials arise from the alignment of unpaired spins of electrons (magnetic
dipoles) in a cooperative fashion. This is observed in some transition metals and their
oxides. In a typical bulk ferromagnetic material, magnetic domains are aligned at short
range and separated by a transition region called a Bloch wall.
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C
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particle
Figure 1.10 – Magnetic Dipole Characterization of Materials.
(A) The random alignment of magnetic dipoles of a paramagnetic material. When
exposed to a magnetic field, these spins align and enhance the field. Also shown are the
aligned magnetic dipoles of ferromagnetic materials. (B) In a ferromagnetic material of
sufficient size to contain crystal sub-domains parallel and antiparallel alignment, a Bloch
wall exists to minimize inter-domain surface energy. (C) For a superparamagnetic
material, there exists a single magnetic dipole orientation as the crystal size discourages
the formation of Bloch walls. This creates a net magnetic dipole for the particle. Edited
by Thorek, from (25).
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At the nanometer scale, approximately 14 nm and below, the formation of the
Bloch walls (magnetic domain boundaries) become thermodynamically unfavorable. The
result is single magnetic domain crystals. Magnetite crystals at this scale exhibit very
strong paramagnetic behavior, lending them the name superparamagnetic (26, 27).
Superparamagnetic materials, like paramagnetic materials, retain no magnetization when
removed from the applied field. As such, they are described as having no remnant
magnetization. Any cooperative alignment of dipole moments at this nanoscale is
overcome by thermal energy at room temperature (28).
The phenomenon of superparamagnetism, first observed in 1938 (29), is now an
area of intense research for both magnetopharmaceuticals and data storage (30). The
nanoparticles employed for MR image contrast have very high magnetic susceptibilities
(much greater than 0). In essence they are saturated in any applied MR field. They
function so effectively as T2 and T2* CA because of two nanoscale processes: the (1)
Néel and (2) Brownian relaxation mechanisms.
The iron oxide crystal is again a single domain particle, but the lattice is
anisotropic and thus the NPs magnetization aligns in only so called easy directions. Any
non-cubic crystal has a degree of anisotropy energy, determined by Equation 1.9, where
Ea is the anisotropy energy of the crystal, Ka is the anisotropy constant and V is the
volume of the crystal. Nanoparticulates have high surface-to-volume ratios and so the
crystal or particle-core has a high anisotropy constant, but a small volume (31).

E a = K aV

Equation 1.9

This anisotropy energy determines the Néel relaxation time, !N, described as the time

!
required for the crystal's magnetization
to return to equilibrium after a perturbation. This
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relationship is described in Equation 1.10, following the Arrhenius law, where !0(Ea) is
the pre-exponential factor, k is the Boltzmann and T is the absolute temperature.

" N = " 0 (E a )e

Ea
kT

Equation 1.10

At ambient conditions, Ea<<kT (32, 33) and thus the exponential reduces to 1.
The Néel time thus depends!on the anisotropy energy; again, this value is high for single
crystal NPs. As the volume of the crystal decreases, the Néel time decreases and therefore
nanometer-sized crystals have very short magnetization angle relaxation times. This
results in a magnetization vector that fluctuates randomly in environments of sufficient
thermal energy (33, 34).
The impingement of surrounding water molecules upon the nanoscopic entity is
also able (at room and physiological temperatures), through transfer of momentum, to
randomly translocate and reorient the particle. This latter mechanism is known as
Brownian relaxation. This relaxation process is described in Equation 1.11 where !B is
the Brownian relaxation time and " is the damping constant.
"B =

3V#
kT

Equation 1.11

The two relaxation mechanisms contribute to a sum relaxation rate, Equation 1.12
(35).

!

1 1
1
=
+
" "N "B

Equation 1.12

Under conditions of very fast relaxation, where " B predominates, the system is always at
! This behavior is named superparamagnetic (27). An
thermodynamic equilibrium.
!
illustration of the two processes found to contribute to the short relaxation times of the
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magnetization vector is provided in Figure 1.11A. The NPs are able to recover their
equilibrium magnetization faster than any applied impingement upon their magnetic
state. The SPIO essentially behave as local magnetic field inhomogeneities leading to
rapid dephasing of coherent protons that lie within the SPIO's induced field, as illustrated
in Figure 1.11B.
It should be mentioned that nano- and micron sized particles in cells of 5-20 !m
can be routinely detected in MR applications using imaging resolutions of 50-100 !m
(36, 37). This is a result of the size of hypointensity susceptibility generation by
superparamagnetic agents in T2*-w imaging. Here, the offset phase dispersal in the sliceselection direction produces a triple-band shaped “blooming effect” (38). In phantoms
and clinical imaging, the effect produced is much larger than the site of accumulation,
producing darkening across a detectable voxel volume (39-41).
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Figure 1.11 - Relaxation Mechanisms of Superparamagnetic Crystals.
(A) The two relaxation mechanisms, Néel and Brownian, are schematically described in
an applied field in the top and bottom row of single domain crystals, respectively in top
and bottom rows. In the Néel phenomenon, the movement of the magnetization vector to
some other easy axis and then back to the equilibrium magnetization is described by N. In
the Brownian contribution, the rotation of the magnetization results from random
movement in water above absolute zero. In (B), we see the local effect of SPIO
nanocrystals on surrounding water protons (
). The effect decreases with an r6
dependence and thus is highly localized.
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SPIO possess both high longitudinal and transverse relaxivities. The majority of
uses for iron oxide NPs in the literature are for T2*-w imaging applications, but they have
been used in a variety of applications as T1-w imaging agents. For example, the high R1
properties are exploited in MR angiography protocols where long circulating SPIO
configurations are utilized as blood pool agents (42-44).

1.6.5 - SPIO Synthesis
SPIO can be manufactured with distinct sizes and distribution profiles, magnetic
character, physicochemical properties and coatings. The most commonly applied
methods for producing the NPs are chemical: the co-precipitation and microemulsion
techniques. Lesser-utilized routes include ultrasound irradiation (or sonochemcial
synthesis) (45), thermal decomposition (46), layer-by-layer deposition (47, 48) and spray
and laser pyrolysis (49). These latter methods can provide finer distributions and sizes of
NPs, as well as more complex core/shell structures, however they often require advanced
equipment and expertise.
In the most widely adopted procedure, that of co-precipitation, ferric and ferrous
salts in solution are precipitated by bringing the mixture to high pH, usually through the
addition of concentrated base. Equation 1.13 below details the chemical reaction of Fe3O4
in the aqueous medium.
Fe 2+ + 2Fe 3+ + 8OH " # Fe3O4 + 4H 2O

Equation 1.13

The base addition precipitation of Fe3O4 begins at pH 8, at a stoichiometric ratio of 2:1
(Fe3+/Fe2+). !
Absence of an oxidizing environment is required for limitation of sideproducts as magnetite lacks stability, therefore this chemical route is often run under N2
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or Ar (50, 51). The partial oxidation of magnetite to maghemite (!-Fe2O3) occurs
spontaneously, Equation 1.14. This is driven in the presence of oxygen, but may also
occur under aqueous conditions through ion transfer particularly at the surface of the asformed magnetite nuclei (52, 53).
Fe3O4 + 2H + " #Fe2O3 + Fe 2+ + H 2O

Equation 1.14

NPs manufactured using the co-precipitation technique offers great flexibility and
control over! the properties of the final product through relatively straightforward
chemical means (54). The advantages of co-precipitation synthesis, in particular large
batch volumes, scalability and ease of manufacture, are somewhat offset by wide SPIO
size distributions. This is a result of the two steps involved in the technique: (1)
nucleation (under inert gas, usually on ice), and (2) growth of the nuclei. The separation
of these two steps drives the formation of many small particles followed by the controlled
growth of these in the second. Strict size selection, usually by filtration and
centrifugation, are subsequently required.
The second most common synthesis method is the microemulsion technique. This
route generally achieves greater control of size and shape of the nanoparticles (55).
Customarily a water-in-oil approach is pursued that sees ‘nanodroplets’ of aqueous iron
salts dispersed and coated in a surfactant-organic solution. The size control over the
system is greater for the resulting SPIO as they are precipitated in these pre-sized reverse
micelles (again, often through the addition of an alkaline solution) (56, 57). These
methods are able to produce populations of particles with very tight distributions.
However, a significant tradeoff is that iron precipitates below 5 nm have been found to
possess amorphous (non-crystalline) iron oxides (58, 59) and therefore often lack uniform
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magnetic properties throughout a population of probes. The yields from this method are
also generally smaller in practice than those of the co-precipitation technique.

1.6.6 - SPIO Coating
The use of (typically hydrophilic) surface complexing agents is often required to
achieve stability and enhance solubility of iron oxide colloids in physiological conditions,
a requirement for use of SPIO in biomedical applications. Repulsive forces between the
particles must exist to maintain their stability in solution, as there is some trend towards
aggregation from magnetic and surface energy attraction. Bare magnetite particles have a
weak interaction with water, leaving the iron oxide surface hydroxyl functionalized.
These groups have an isoelectric point at approximately neutral pH (60), meaning that
particles will flocculate and precipitate out of biologically relevant solutions unless
otherwise coated.
The formation of iron oxides by the co-precipitation technique can either be
conducted in water or in the presence of a surface coating materials such as polyethylene
glycol (PEG), dextran or polyvinyl alcohol (PVA) (13, 61-63). More recently, chistosan
(64, 65) and alginate (66, 67) have been explored as coating polymers because of these
polymers' interesting electrostatic and degradation properties. Bare SPIO, which are often
produced in a citrate ion solution, can be subsequently coated in small molecules (68-71),
silica (72, 73) or polymers (74). Microemulsion produced nanoparticles are often not
directly soluble in aqueous solvents, making chemical surface alterations necessary. This
can be achieved using surfactants (added either during or after the synthesis).
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Beyond magnetically induced aggregation, another benefit of surface complexing
agents is to avoid quick opsonization (75). The introduction of bare iron oxide particulate
species in vivo is accompanied by rapid opsonization by plasma proteins, resulting in
rapid clearance by the reticular endothelial system. This greatly limits the ability of the
CA to circulate to bind targets, function as blood pool agents, or distribute effectively
into tissues (76). The effect of particular coatings on SPIO pharmacokinetics and
biodistribution is a fundamental reason for the wide variety of different materials that
have been tested as SPIO exteriors (77, 78). From a size perspective, carbohydrate or
polymer-coated SPIO typically vary from ~20 to above 100 nm in hydrodynamic
diameter (controlled by synthesis parameters such as the iron-to-polymer ratio) with iron
oxide core sizes ranging from ~2 and 15 nm (13).
Surface coatings are also an efficient platform for further modification of the MR
CA in that they can be derivatized with different surface chemical groups (79),
transfection agents (80), or targeting agents (81). The surfaces can also be used to
conjugate the MR probes to other imaging media, for example nuclear and optical
moieties to create multi-modal agents (82, 83).
A recent development in SPIO technology has been the investigation of the
surface coating effects on the relaxivity of the particles, rather than their biocompatible or
biodistribution consequences, as discussed below. The enhanced dephasing of water
surrounding the iron oxide core is dependent on that water being within the altered field
of the SPIO. With greater thickness coatings it can be realized that there would be less
water in the inhomogeneous magnetic region. While the diffusion of water through most
surface complexing materials (polymers and polysaccharides) makes computational
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modeling more difficult, both simulations and experimental evidence have shown that the
thickness of coating affects relaxation properties of the particles (84). Using a fixed iron
oxide core size it was found that increasing the thickness of a PEG micellar coating
resulted in a dramatic decrease in R2. Interestingly the drop-off in R1 was much less
severe, likely due to the rate-limiting step of longer longitudinal water relaxation times.

1.6.7 - Biocompatibility and Biodistribution
The broad biocompatibility of SPIO has been a significant reason for its clinical
acceptance and basis as a research nanoparticle platform. The metabolism and toxicity of
SPIO have been widely investigated since its introduction into the field of medicine (77).
Given that iron is an essential element for human beings, and is critical for the delivery of
oxygen and the proliferation/survival of all cells, it is no surprise that SPIO can enter the
body’s normal iron metabolism cycle following uptake by the reticuloendothelial system
(RES) (85). In fact, SPIO were originally developed as a ferritin substitute to treat
anemia (86-88).
One concern, however, has been that iron contained in SPIO could enter cells
independent of the transferrin pathway (used to closely regulate intracellular iron levels),
leading to high levels of non-chelated iron. This is potentially troubling as concentrated
iron may produce radical oxygen species. Studies have shown however, that the
breakdown of magnetite in cells leads to ferric (rather than ferrous) iron release (89).
This iron ion is efficiently chelated by citrate and rendered non-toxic (90).
Extensive research (in vivo and in vitro) has been carried out on the impact of
SPIO on cell viability and function. Recent in vitro studies have shown that SPIO are able
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to enter the cell (for example, in macrophage (91) and mesenchymal stem cells (92))
through endocytosis and can then either be released back into the extracellular space or
shuttled into low pH environments in lysosomes (92). It is in these compartments where
they breakdown over the course of several days (80, 93). Immortalized fibroblasts, when
incubated with PEG-coated SPIO, showed no discernable changes in cell adhesion
behavior or morphology (87) and the same was reported for T cells labeled with SPIO
(94). Transfection agents such as the HIV-Tat peptide, polyarginine and protamine, as
well as many small molecules, have been conjugated or complexed with SPIO in order to
achieve greater cellular uptake (95). The use of these agents alongside SPIO has also
been found to have minimal cellular toxicity revealing no significant effects on cell
viability (80), clonogenic efficiency (82), biodistribution or immunophenotypic changes,
for example - macrophages are not activated upon uptake (96). Many of these studies also
expose the cells to nanoparticles for long periods of time, up to 3 days, showing little
detriment to cell viability or division kinetics for embryonic (97) and neural stem cells
(98).
While many studies generally assert the indifferent response of cells to the
presence of the probes, further work is required to validate their use in specific
applications and the limitations therein. For example, Feridex IV (Bayer Healthcare
Pharmaceuticals) incubation in culture with human bone marrow-derived mesenchymal
stem cells had no discernible affect on viability, proliferation, adipogenesis or
osteogenesis. However chondrogenesis was found to be inhibited in a dose dependent
manner (99). Working with the same cell line under identical loading conditions, a
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polyvinyl pyrrolidone (PVP)-coated iron oxide nanoparticle SPIO formulation was found
to possess no phenotype inhibiting effects (100).
Upon intravenous administration of SPIO, anaphylactic-like reactions and
hypotension have been noted. Adverse events from SPIO are however usually mild and
short in duration (101). The most common complaints included headache, back pain,
vasodilation, and hives. Once introduced, the pharmacokinetics of each embodiment of
SPIO is dependent primarily on the size and surface characteristics of the agent. The
spleen and liver are able to screen SPIO that are approximately 200 nm or above, mainly
through mechanical filtration. SPIO below approximately 10 nm are removed through
extravasation and renal clearance (102). Agents with a diameter of 30-50 nm have
demonstrated longer plasma half-life, particularly when coated in amphiphilic polymers
including dextran, PEG and polyvinyl alcohol (PVA) (103). The so-called stealth effect
of coatings that inhibit recognition by the RES are thought to act through either
avoidance of immune responses that stimulate opsonating proteins or conversely through
the absorption of serum proteins that the body recognizes as benign (76).
In the case of targeted SPIO agents, longer circulation times can be equated with
an enhanced probability of the probe binding its ligand (104, 105). Longer residency in
the blood is also of benefit for non-targeted applications that seek to avert quick clearance
by the liver and spleen (106). It should also be noted that large particle size may prevent
effective extravasation and reduce diffusion of the agent through the interstitium,
important considerations for many SPIO imaging objectives such as lymph node imaging.
This is not so much an issue for the imaging of the vascular endothelium (81, 107) or
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tumor sites possessing leaky vasculature. Here particles have routine access and tend to
accumulate through the 'enhanced permeability and retention' effect (108, 109).
Exploitation of this mechanism of passive (non-targeted) accumulation is used to
generate contrast in two ways. The first is through SPIO accumulation at the pathological
site, thereby darkening it. This has been applied for the detection of cancer and
inflammation in many models, including blood-brain-barrier degradation following
stroke (110, 111) and neoplasm (112, 113), bone metastases detection (114, 115) and
occult lymph node detection (14, 15).
The second passive accumulation strategy is essentially an inverse of that
described above. The SPIO may be excluded from accruing in tissue or cells of interest,
thus darkening the surrounding region where SPIO access is possible. This effectively
results in brightening of the site of interest. This inverse contrast approach is the principal
application of SPIO, for the delineation of hepatic metastases. Administered SPIO are
found to accumulate in the healthy liver within Kupffer cells, whose primary function is
to recycle and accumulate iron from the blood. The absence of Kupffer cells in
malignancies allows for SPIO, under T2 and T2*-weighted imaging, to specifically darken
the surrounding healthy liver (116-118). This represents a significant improvement over
conventional non-contrast enhanced imaging of hepatic tumors It has been reported that
non-contrast-agent enhanced imaging is limited to detection of lesions greater than 3 cm
(119), however MR imaging of 1 cm growths is possible with SPIO enhanced approaches
(120).
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1.7 - Immune Cell Imaging
1.7.1 - Relevance
Directed migration of specific cell types to target organs or tissues is a critical
feature of fundamental biological processes. From development through to the
maintenance of any complex organism, this trafficking feature is of great scientific
interest. With its direct impact on maintaining healthy physical conditions and protecting
the body from disease, an area of particularly concentrated research focus has been on the
distribution of key cellular players in the immune system.
The immune system is composed of two interacting components; the innate and
adaptive. The adaptive immune system is responsible for specific responses to (usually
foreign) pathogens, and relies upon T and B cells through processes such as the
production of antibodies. This contrasts with the non-specific, but immediate and wide
ranging, response mounted by innate immune cells, such as macrophage and mast cells,
against a wide range of foreign pathogens. The ability to monitor the selective
recruitment, activation, arrival and departure of specific immune cells in homeostatic and
disease conditions is a compulsory requirement towards greater knowledge of immune
response and function.
Complicating deeper understanding of immune cell responses to pathogenesis and
treatment is the fact that imaging of these migratory pathways is inherently difficult. This
section will provide a review of the approaches employed to overcome the limitation
posed to cellular tracking in the deep tissue of opaque organisms. The alternative
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modalities and significant work in cell tracking will be presented. The particular case of
utilizing SPIO for MR-based immune cell imaging will then be discussed.

1.7.2 - Tracking Strategies
In order to track specific cell types of interest in vivo it is necessary to deliver
contrast media, regardless of modality, directly to that population. There are two general
strategies that accomplish this task: 1) ex vivo loading of cells with CA and 2) the in vivo
targeting of the population. Each method has unique strengths and weaknesses.
In the first approach, control over the loading of NPs, dyes or genetic constructs
into the cells is greater, as in vitro conditions can be optimized for specific cell types. The
amount of the CA loading that can be obtained is also much higher as delivery of the
agents is direct. This strategy is often also simpler (although exogenous transfection
agents may be required) as uptake in unwanted compartments within an organism is not a
concern. This means that the addition of supplementary modification such as the addition
of a stealth coating (for long circulation) may not be required. The benefit of greater
sensitivity upon subsequent implantation (through high levels of accumulated agent) and
simpler probe design is balanced by the obligation to first acquire the cells of interest
from a biological sample. This may have detrimental effects upon the in vivo function
and distribution of these cells. Further, the duration of imaging is limited to the lifetime
of the cells (or the residency time of the SPIO within the cells).
The second strategy sees the in vivo application of contrast with some form
targetability, usually in the form of peptides or proteins, directed at the cells of interest.
These constructs can be repeatedly administered to target the same (or even different) cell
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populations of interest. Derivation of the particle with specific ligands is also not always
needed, as in specialized applications, for example the investigation of liver metastases
using SPIO (121). However, in most applications the non-specific uptake, deposition or
accumulation of agent is detrimental to the imaging process. It reduces signal-tobackground levels between the population of interest and all non-specifically targeted
tissues. This is further complicated by the fact that it is rarely possible to achieve the
same loading levels of CA as compared to an ex vivo situation. To overcome this
problem of lower signal, interesting tactics are sometimes employed. One example for
use in targeting radionuclides has been the two-step system, also called pre-targeting,
wherein an antibody-avidin is administered first. Time is given for this first agent to clear
before introduction of a biotinylated radiotracer, which has a very high affinity for
binding specifically with avidin (122, 123).

1.7.3 - Optical Imaging
Diverse technologies have been used to reveal the spatiotemporal distribution of
immune cells in vivo. These include but are not limited to fluorescent and bioluminescent
proteins, fluorescent molecules, intravital microscopy, radionuclide-based single-photon
and positron emission tomography (SPECT and PET), MR contrast agents and even
ultrasound particulate contrast (124). The most commonly used of these options are the
optical technologies because of their relative ease of use, and reduced equipment cost.
The major limitation of using light to probe cell distribution within an organism is
its limited depth of tissue penetration. It has long been understood that the absorption
and autofluorescent properties of tissue is wavelength dependent. This is seen in the
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absorption versus wavelength chart in Figure 1.12. Early spectroscopic studies of protein
within in intact tissues revealed presence of a near-infrared (NIR) window. This window
refers to the much greater NIR transparency of tissue, particularly skin, to light of
wavelength in the range 700 - 1300 nm (125). Thus, for effective in vivo studies of cells
and cell populations either long wavelength fluorescent molecules or proteins can be
effective. Shorter wavelength proteins and dyes can be used, but applications usually
involve intravital microscopy. Such techniques are inherently invasive and usually
involve surgical exposure of the tissue(s) of interest (126).
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Long wavelength fluorescent sources have been employed in vivo to identify and
track immune cell populations. The targeting approach for detection of a cell population
centers primarily on organic dye conjugated antibodies. These have been used with some
success in visualizing cancers and specific cell types (128, 129). Nanoparticulate forms of
optical contrast also exist. Quantum dots (QD) are composed of semiconductor materials
with a diameter of several nanometers and are of widespread research focus. They are
also found to be phagocytized by activated macrophage when administered intravenously
(130). Specific targeting of these NP has not been shown with immune cells.
Ex vivo loading of optical agents for the subsequent in vivo visualization of cells
is a common approach for fluorescent imaging. No longer dependent upon applying celltype specific antibodies (which may be difficult to obtain for the sub-population of
interest), lipophilic dyes that bind indiscriminately to the cell membrane have been
investigated. In one study, multiple NIR dyes were used in conjunction with specialized
laser scanning equipment to concomitantly visualize the whole mouse distribution of
activated and naïve primary T cells labeled ex vivo (131). The cells were tracked to the
lymph nodes and spleen as well as to tumors implanted in the mouse brain. Labeling of
cells with such NIR dyes have been shown to have no effect on T cell proliferation,
viability or function (132). Non-targeted QD have also been loaded in cells ex vivo for
the in vivo visualization of macrophage and lymphocytes (133).
A concern with the use of any dye is that over long study times, dilution of the
dye occurs through cell division. A recent advance in this field has been the development
of red (584 nm excitation) and NIR fluorescent protein (684 nm excitation) that can be
used to image sites in deep tissue (134, 135). For example transgenic mice, engineered to
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express red fluorescent protein in lymphatic tissues have been generated to study T cell
migration (136).
Luciferases, luminescent proteins, are also useful for in vivo imaging of cells.
Although the light produced is of a short wavelength, the fact that no external excitation
source is required means that luciferases can be detected with extremely high sensitivity
using specialized imaging systems (137). Only the desired cell types need to be
engineered to stably and constitutively express luciferase and the assays are relatively
inexpensive. Several transgenic models have used this approach to study human biology
and disease (138, 139) detecting as few as 1000 cells in the peritoneal cavity (140).
The majority of in vivo bioluminescent imaging has focused on tumor cells
transformed ex vivo to express luciferase and then subsequently implanted. However,
immune cells have also been tracked in longitudinal in vivo imaging studies using this
strategy. These studies can be divided generally into those that have utilized
bioluminescence either to image cells in cancer immunotherapy or to visualize
lymphocyte trafficking in basic immune and autoimmune disease models. With respect to
the former, the ability of biospecific antibodies to direct cytokine induced killer (CIK)
cells towards tumor targets in vivo was rapidly assessed in real time using luciferase
(141). The distribution of CIK cells was determined immediately following injection and
tracked as they homed to sites of interest 72 hours later (142). Direct imaging of the
spread of lymphoma has also been achieved using luciferase. In this work, lymphoma
cells were transduced with a fluorescent and bioluminescent construct and implanted into
SCID mice. Tumor growth and response to treatment was directly measured (143).
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In order to better understand the complex workings of the immune system,
visualization of lymphocyte trafficking has been achieved in several transgenic models.
In one example, mice have been engineered to only express a luciferase transgene in T
cells, enabling highly sensitivity imaging of the migration dynamics of primary
lymphocytes (144). This was an effective means to study the antigen initiated clonal
expansion and response of CD4+ T cells. Several approaches have also sought to use
bioluminescence as a means to better understand the etiology and therapeutic response in
autoimmune disorders. In a joint inflammation model of arthritis in a transgenic mouse, T
cell hybridomas that bind to collagen peptides were found to target joints (145).
Trafficking of this cell population following administration revealed that lymphocytes
migrate nonspecifically to sites of inflammation, but are able to linger once exposed to
those sites. In an additional study devoted to the early preclinical detection of
autoimmunity, a luciferase reporter transgene has been paired to nuclear factor (NF)-!B.
Activation by inflammatory responses of NF-!B in a systemic lupus erythemotosus-like
disease model generated bioluminescent signal in organs prior to the gross manifestation
of disease or the presence of amplified antibody production (146).
The application of optical methodologies for the detection, tracking and function
of immune cells has taken many forms. While several of these techniques and studies
have expanded our understanding of cellular function and response in healthy and
diseased states, a major limitation to their expanded use is that these agents cannot be
used clinically. In order for translational imaging studies to be performed on the
distribution of immune cells beyond small animal or in vitro models, the applied cellular
and molecular imaging technique must have a clinical counterpart. Current radiological
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techniques for cellular and molecular imaging in pre- and clinical study include
radionuclide and magnetic resonance modalities.

1.7.4 - PET and SPECT Imaging
Radionuclide imaging technologies have been widely employed for visualization
of immune cells in healthy and diseased animals. The primary advantage of !+- and "-ray
detection systems is that their sensitivity potentially allows for the detection of single
cells. Positron emission tomography (PET) has a detection sensitivity in the pM (10-12 M)
concentration range; single photon emission computed tomography (SPECT) is slightly
less sensitive at 10-10 M (1). Both imaging modalities rely on the decay of short-lived (t1/2
on the order of minutes to hours) or unstable metals. PET isotope materials are produced
in expensive, and somewhat rare, cyclotron equipment and decay through positron
production that leads to release of two high-energy "-rays. These agents have been used
for detection by attachment and incorporation in small molecules, conjugated directly to
antibodies or mediated through the pre-targeting approach, as described in section 1.7.2.
The most frequently used nuclear imaging agent is the PET radiotracer isotope of
Fluorine,

18

F.

18

Fluorodeoxyglucose (18FDG), a glucose analogue, is used for clinical

detection of cancer cells with upregulated metabolism (147). The agent is extensively
used in the clinic for detection and evaluation of neoplasms before and after treatment
(148). Uptake at sites of inflammation has long been noted as a source of false positive
detection. 18FDG based PET tests for the detection of atherosclerotic plaque inflammation
and ischemic stroke have been completed in both pre- and clinical work (149). The prelabeling of immune cells (for example white blood cells (150)) with 18FDG for tracking
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to sites of inflammation, rather than localized uptake of small radiopharmaceuticals, has
also been successful.
Single-photon imaging using radionuclides such as

99m

Technicium or

111

Indium

have been applied clinically for the detection of otherwise occult inflammation (151,
152). The lower sensitivity of SPECT tracers is offset by their imaging system’s
increased resolution (versus PET), generally longer half-lives and greater availability to
clinicians (chemically rather than cyclotron derived tracers, excepting 99mTc). SPECT has
been used for immune cell tracking as well, with particular effect in lymphocyte tracking
in inflammatory models of bowel disease such as colitis (153, 154).
Radionuclide imaging approaches, while translatable and extremely sensitive for
detection and tracking of immune cells, place restrictions on study type and duration.
This is primarily due to the shortened window during which signal can be detected as the
probes decompose. Further, the resolution afforded by PET and SPECT approaches is
limited by quantum effects and detector design. This is made an even greater challenge
by the closer proximity of organs at the small animal scale (1, 155). The functional
information provided by PET and SPECT can be augmented by pairing these systems
with X-ray computed tomographic (CT) systems. While this represents a major advance
in both clinical and academic imaging, evidence has been presented that these systems
incidentally deliver therapeutic doses of radiation (156, 157). This raises serious health
concerns for both subjects and scientists and renders results much more ambiguous (158).
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1.7.5 - SPIO and Immune Cell Imaging
MR enables whole body, non-invasive imaging over long time spans, but its low
sensitivity requires contrast agents to be present for the imaging of single or groups of
cells. Optical and nuclear medical approaches offer their own distinct advantages,
however the limited depth penetration (<1 cm for bioluminescence and <10cm for NIR
probes) of the former and the ionizing radiation and lack of anatomical detail in the latter
impede their translational potential. Cell monitoring studies are difficult with the most
common MR CA, gadolinium-ion chelates, which require very high metal concentration
to make individual or groups of cells visible. However, it is worth noting that conjugates
such as HIV-Tat-DOTA, transferrin-polylysine-DTPA and folate-dendrimer-DTPA have
been shown to accumulate in cells and thus could be used to monitor cell migration (159162). Nevertheless, the intracellular accumulation of toxic gadolinium remains a serious
concern.
Biocompatible SPIO particulates offer obvious advantages. SPIO have been used
in clinical and academic studies to investigate a variety of biomedical disorders. While
the contrast agents have been used in a range of applications (from targeted (105, 163165) and passive cancer detection (14, 118, 120), diagnostics (166-168), direct (169, 170)
and drug therapy (171, 172)), the tracking of cells is a a task to which SPIO are
particularly adept. First, investigating phagocytic cell types, such as activated
macrophage at the sites of inflammation and Kupffer cells in the liver, is made
straightforward as these phenotypes readily take up circulating foreign bodies. SPIO have
been used to exploit this feature in order to accumulate at and reveal sites of medical

Chapter 1
59
interest; for example, at sites of injured endothelium (91), ischemic stroke (111) or to
detect liver cancers (39, 173).
To a considerable degree, the most common cell type detected or tracked using
SPIO have been macrophage. The accumulation of contrast agent by this immune cell
type renders visualization by MR relatively straightforward, as little additional
modification of as-synthesized nanoparticles (or even microparticles) need to be made.
Cellular imaging of monocyte/macrophage activity has been employed in a variety of
disease models where inflammation plays a critical role. In mice with experimental
autoimmune encyphalomyelitis (EAE), a model for central nervous system inflammatory
disorder multiple sclerosis, administered iron oxide accumulates at cerebral lesions (174).
SPIO uptake at these inflammatory sites enables monitoring of progress and staging of
disease (175, 176). The pre-clinical application of SPIO for detection of macrophage for
the study and detection of organ transplant rejection (177, 178), ischemia (179, 180) and
atherosclerosis (181-183) has also been achieved. Further, clinical work has attempted to
use the particles to enable better understanding of lesion formation in cerebral models
(184) as well as atherosclerosis (185).
Inflammation plays a central role in the pathophysiology of virtually all disorders,
and is thus of wide interest. It is also a complicated process involving many cellular
players. To this end, cells of many different phenotypes beyond macrophage have been
loaded with SPIO ex vivo in order to be followed once implanted. The tracking of
inflammatory cells, such as T cells (186), NK cells (187, 188) and dendritic cells (189,
190) has been accomplished. This is a powerful means to gain insight into the locations
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of immune cells and their subsequent migrations in response to injury, disease or as
therapeutic vehicles (for example engineered T cells or stem-cells (191)).
A focus of recent immunological research, dendritic cells (DCs) are able to
stimulate or inhibit immune responses. The important role this cell type plays in
marshaling the body’s defenses has made it attractive as a means to augment the native
immune response against malignancies (189). A reputed problem with this therapeutic
approach has been that the cells do not always localize or migrate to target organs as
desired. In vivo imaging of DC migration may substantially aid in the design and
administration of dendritic cell-based therapy. Initial studies have shown that when DCs,
intended as a cancer vaccine for melanoma, were loaded with SPIO there were no
unfavorable effect on phenotype, migration patterns or antigen-presenting functions
(192). Further, the utility of tracking as few as 1.5x105 cell with the high anatomical
resolution provided by MR has been demonstrated (190). Recently, this work has been
translated into the clinic, where trials have established that SPIO enable accurate
detection of small populations of DCs administered as therapy to late stage melanoma
patients (193).
Natural Killer (NK) cells also hold promise for cell-based therapies as they
exhibit high cytotoxic activity against multiple malignancies, while sparing normal cells
(188). A genetically modified NK cell line, NK-92-scFv(FRP5)-!, has been directed
against malignant cells over-expressing HER2/neu (a receptor over-expressed in many
cancers, notably breast) (194). MR monitoring of NK cells loaded with SPIO led to
distinct and long-lasting recognition of HER2/neu-positive NIH 3T3 mammary tumors in
mice (195). Persistent labeling and detection was evident by MR for at least 5 days.
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Lymphocytes have been used to detect and treat several classes of malignancies.
However, unlike the phagocytic uptake of SPIO by immature DC or macrophage (196),
delivery strategies must be employed in order to label T and B cells with SPIO. This can
be accomplished several ways including electroporation, lipofection agents and cell
permeating peptides (CPPs) (197). CPPs such as HIV-Tat (82, 95), protamine (80) and
polyarginine (198) have been used to greatly enhance cellular uptake, allowing for
greater loading of SPIO in cells. CLIO-HD, a Tat-conjugated SPIO with high Tlymphocyte uptake, has been used in a system where CD8+ T cells were able to
specifically target an antigen expressing tumor upon which it could be clearly delineated
by MR imaging (199). Furthermore, T-lymphocytes labeled with CLIO-HD did not lose
their ability to kill cells both in vitro or in vivo.
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1.8 - Summary
Cellular and molecular imaging holds great potential for the advanced detection
and monitoring of disease in vivo. Magnetic resonance (MR) is a well-suited imaging
modality to these ends as it provides high resolution anatomical information throughout
an organism. MR cellular tracking approaches require the application of relaxitive
contrast agents that alter MR signal in the vicinity of their accumulation.
One form of contrast agent found in widespread academic use are
superparamagnetic iron oxide (SPIO) particulates. These materials are often in the form
of polymer or polysaccharide coated iron oxide core nanopaticulates. These particles
generate contrast by enhancing surrounding 1H atoms relaxivity, thereby generating local
hypointensity on T2 and T2*-weighted images. The application of SPIO for the task of in
vivo tracking of immune cells is expected to provide insight into disease and therapeutic
mechanisms.
This thesis aims to identify SPIO synthesis and modification parameters that
enable the production of particles with desirable properties for optimal labeling of
immune cells. These include control over size, size distribution, magnetic and chemical
surface characteristics. The developed contrast agents will then be applied in a series of
in vitro and in vivo experiments whose objective it is to track immune cells in rodent
disease and therapy models.
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CHAPTER 2. Significance of Thesis and Specific Aims
2.1 - Overview
The use of magnetic resonance (MR) imaging has become an important platform
for investigating both basic biological and clinically relevant questions. The state of the
art for MR preclinical research is divided along two paths. The first is centered on
advancing the capabilities of scanners themselves by employing higher field strengths or
pursuing multimodal detection approaches. The compilation of work that is this thesis
concerns the second thrust of research - developing, characterizing and utilizing contrast
agents (CA). These agents are used to enhance the unfortunately limited endogenous
contrast in organisms between cells, tissues or specific sites of interest when visualized
by MR.
It has been envisioned that high-resolution longitudinal distinction of immune
cells can be of significant utility towards understanding and detection of disease as well
as preclinical monitoring of therapeutic efficacy. This chapter first outlines the technical
advances of efforts documented in this dissertation as well as the consequent applications
that this research will have on the field. This concerns the role of SPIO characteristics for
non-phagocytic cell loading and their use for the tracking of and targeting of B cells in
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vivo. As well, it involves the identification of sites of neuroinflammation in a rat pain
model. The particular goals detailed for each of these sections are then presented.
2.2 - Significance of Research
The ability to image individual or populations of cells in vivo is of great
biological and medical interest. The objective of this thesis is to develop and apply
biocompatible nanometer-scale contrast agents for immune cell imaging in multiple in
vivo and in vitro systems. Superparamagnetic iron oxide (SPIO) nanoparticles are
perhaps the most widespread MR contrast in use for molecular and cellular imaging. The
fundamental purpose behind the development and application of these agents is to enable
earlier and enhanced detection of disease. The use of SPIO specifically for cell tracking
and detection of immune cells is a significant component of that effort. This work
centered on development and use of SPIO in two medically relevant biological
paradigms: monitoring the efficacy of autoimmune therapy and detecting macrophage
infiltration at sites of nerve root injury.

2.2.1 - In vivo B Cell Tracking
Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune
disorder. Symptoms include fatigue, polyarthritis, pericarditis and dermatitis. Treatment
of this disease focuses on immunosupression to prevent organ damage and to combat
flare-ups.

Among

these

treatments

are

non-steroid

anti-inflammatory

drugs,

corticosteroids and, applied in the more serious renal and nervous system manifestations,
cytotoxic medicines such as cyclophosphamide (1).
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While the pathogenesis of SLE is not fully understood, B cells and B cell
dysfunction have been implicated in its etiology (2). Their central role in immune
processes has meant that they are a focus of research into the understanding and combat
of SLE (3). Recently, monoclonal antibody B cell depletion therapy, which has been
effective in treating B cell lymphoma, has been investigated as a therapy for autoimmune
diseases including SLE (4). Results from preliminary studies had been promising (5),
however under controlled study conditions it has been determined that antibody treatment
is ineffective at combating the disease (6-8).
It has been hypothesized that imaging of B cell populations in vivo would be a
powerful tool for the in vivo study of B cell response to depletion, particularly within
secondary lymphoid organs such as the spleen where long-lived B cells reside and mature
(9). We have shown that SPIO can be formulated for the specific task of non-toxic, high
uptake in non-phagocytic, non-adherent cells. These SPIO were able to readily label
primary murine B cells. Using these engineered particles, coupled with a cell membrane
binding near infrared (NIR) dye, primary B cells were tracked using MR and optical
techniques following in vivo administration. The data gathered from this work led to an
appreciation of the underlying response of cells targeted by antibody depletion treatment
and the issues associated with tracking them. Specifically, the work indicates that NIR
can be readily used to follow the in vivo migration of cells with organ specificity and a
degree of sensitivity such that localization of B cells to the spleen was readily visualized.
Further the impact of the MR tracking approach, inherently noisy and seemingly
interfering of B cell depletion, may help to mature the still nascent field of nanomaterial
application in biology and medicine.
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Cervical radiculopathy is defined as a neurological condition characterized by
dysfunction of a cervical spinal nerve, the roots of the nerve, or both (10). It presents as
pain, often debilitating, in the neck and one arm. This pain is also often accompanied by
sensory loss, loss of motor function and diminished reflexes in the dermatome of the
affected nerve root (11). The condition is relatively widespread, with studies showing
incidence as high as 107 per 100,000 for men and 63.5 per 100,000 for women (12). The
frequency of the disorder, coupled with its potential long term and severe impact on
quality of life, results in a significant economic impact (13, 14).
The central nervous system (CNS) proximal to the cervical spine, consisting of 7
vertebrae and 8 pairs of cervical nerve roots (in both rodents and humans) is susceptible
to injury from a variety of causes. The most common cause of cervical radiculopathy is
impingement of the spinal nerve through degenerative changes of the neuroforamen.
Radiological evidence of these changes such as spondylosis, foraminal occlusion or disc
protrusion is useful in determination of the pain-causing problem and for further decision
making in patient management. However, in many cases there is no noticeable
neuropathy associated with the report of pain symptoms (12). This presents a significant
clinical and radiological challenge.
It has been hypothesized that transient nerve injury may lead to lasting pain
without correlating radiological indication of permanent degeneration of vertebral
architecture. In a rat model, persistent mechanical allodynia (behavioral sensitivity to
otherwise benign stimulus) can be produced by unilateral transient compression of the
nerve root (15). The transitory axial loading of the neck that this model seeks to mirror
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include examples such as automobile accidents (16) and impact from contact sports (17,
18). Inflammatory cells, such as activated macrophage, have been reported to correlate
with pain in experimental models (19-22). Mechanical insult to the nerve root of
sufficient compression leads to Wallerian degeneration and remodeling of the neural
tissue (23). Macrophages are initially recruited to remove axonal and myelin debris and
stimulate nerve growth factor synthesis by Schwann cells. A host of other immune cells
are involved including microglia and the recruitment and activation of hematogeneous
leukocytes to the site of nerve root compression have been implicated in the etiology of
chronic pain resulting in hypersensitivity (24, 25). Further understanding of the
development of and the efficacy of treatment for transient nerve root injury would benefit
significantly from a means to non-invasively detect the presence of injured nerve roots.
Sequestration of SPIO by macrophages at sites of inflammation in vivo has been
demonstrated in a variety of disease models (26-28). This phenomenon has been
exploited to image neurologically relevant processes such as cerebral inflammation (2931), spinal cord (32, 33) and nerve injury (34, 35). No study to date has correlated the
uptake and MR detection of SPIO in vivo using a transient nerve root injury with a
characterized behavioral response. In the pain producing transient compression model
described above, the presence of persistent hypersensitivity has been associated with the
infiltration of activated (CD68 expressing) macrophages.
In work described in this thesis, dextran coated SPIO were administered to rats
after undergoing a transient nerve root compression to non-invasively detect macrophage
infiltration after nerve root injury. It was demonstrated that detection of the site of the
injury through accumulation of the SPIO by activated macrophage was possible. We
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envision that application of SPIO for the noninvasive, longitudinal imaging of the cellular
inflammatory response, correlated to the persistence of pain, will add valuable insight to
our knowledge of the underlying dynamics of macrophage infiltration at sites of cervical
radiculopathy. Furthermore, it may provide the foundation for enhanced clinical
assessment and subsequent treatment of nanoparticle.

2.2.3 - Technical Impact
We envision potential applications of the research described within this thesis will
include:
-

Study of the effect of size and surface properties on the non-phagocytic

cell phenotype uptake of nanoparticulate materials.
-

Facilitate the development and refinement of approaches to monitor

lymphocytes in vivo.
-

Detect the presence of otherwise occult nerve root inflammation resulting

from transient compression.
-

Identify sites for local administration of analgesic therapy.

-

Non-invasively monitor the response to treatment of nerve root injury to

treatment.
We envision that the SPIO synthesized, modified and applied in this work will be
a powerful and versatile tool for the study of a variety of biomedical problems. In
particular they have significant utility in imaging immune cell types of interest in
autoimmune and inflammatory processes through their efficient labeling of cells either in
or ex vivo.
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Molecular and cellular imaging (MCI) is an emergent field concerned with the
non-invasive, quantitative, and repetitive imaging of biological processes in living
organisms (36). Clinical end-goals include generation of image contrast for the purpose
of achieving earlier disease detection, more accurate stratification and monitoring of
response to therapy (37). Magnetic resonance (MR) is a powerful non-invasive, whole
body imaging modality used in numerous MCI approaches. When used in conjunction
with recently developed in vivo contrast agents, MR allows for the concomitant
acquisition of anatomically detailed images and molecularly specific information.
The overall purpose of this dissertation was to develop and apply nanometer-scale
contrast agents for immune cell imaging in multiple in vivo and in vitro systems.
Superparamagnetic iron oxide (SPIO) nanoparticles are T2* contrast agents consisting of
an iron oxide core surrounded by a polysaccharide coating. In this document we describe
the synthesis, modification and evaluation of SPIO for a variety of physical and chemical
properties. Further, the interaction of SPIO with cellular systems and animal models was
investigated. Initial work focused on development and differentiation of NP populations
for non-phagocytic cell uptake. Subsequently, these NPs were applied in vivo to two
disease models. The first of these systems concerned the ex vivo loading of contrast agent
into B cells for their subsequent tracking in mice with and without B cell depletion
therapy with implications for systemic lupus erthematosus (SLE) treatment. The second
animal model appraised the ability of systemically injected iron oxide nanoparticles to
specifically label sites of neuroinflammation correlated to persistent pain for diagnostic
purposes.
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2.3.1 - Aim 1. Synthesis, modification and optimization of SPIO probes for cellular
labeling

1.1 Synthesis and characterization of iron oxide nanoparticles – Nanoparticle synthesis
parameters were varied to develop a library of particles with a wide range of physical and
chemical properties. SPIO surfaces were cross-linked and functionalized with amines.
The chemical and magnetic properties of these particles were analyzed along with an
evaluation of their internal core morphological features.

1.2 Optimize SPIO loading of lymphocytes – We determined a nanoparticle formulation
for maximum SPIO loading in cultured lymphocytes, while concurrently avoiding cell
toxicity. Flow cytometry, optical and MR techniques were utilized to examine particle
uptake. Factors such as particle size, surface properties, loading times and SPIO
concentration were isolated in order to determine their respective effects on
internalization and viability.

1.3 Evaluate effect of SPIO on B cell activation – SPIO loading conditions leading to
activation of primary B cells were assessed. The roles of surface charge, particle
diameter, concentration and time of incubation with cells were investigated. Further, B
cell activation following SPIO internalization was tested to determine any interfering
contrast agent influence on normal B cell function and subsequent depletion.
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2.1 Refine imaging of SPIO-loaded B cells – Imaging parameters and a logistical protocol
were optimized for the detection of SPIO-loaded and NIR dye labeled B cells injected
into mice for both MR and optical (fluorescent) modalities. Following imaging,
immunohistological evaluation was utilized to ensure co-localization of SPIO and
fluorescent dyes with B cells.

2.2 Image B cell distribution following therapeutic depletion - Anti-CD79 therapeutic
depletion of systemically administered SPIO- and near infrared dye-loaded B cells was
investigated by MR and optical imaging in mice. Analysis of the dynamics of distribution
with and without therapeutic intervention, through loss of local hypointensity for MR and
loss of fluorescent signal by optical, was performed.

2.3.3 - Aim 3. Imaging the post-injury dynamics of macrophage infiltration
3.1 Optimize MR sequence and injury localization – Localization of transient nerve root
compression was carried out. Initially this involved posthumous subjects to resolve
animal handling during imaging and MR sequence issues. Living subjects were then
introduced to determine feasibility of imaging protocol. Delivery and optimization of
SPIO contrast by MR was also performed by varying scanning parameters for sequence
configuration.
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3.2 Imaging transient nerve root injury – Visualization of macrophage infiltration at the
injury was evaluated across injured and sham subjects at time points prior to and
following administration of contrast. Histological analysis of excised spinal cord and
nerve root were used to verify SPIO accumulation at sites of macrophage infiltration.

Chapter 2
2.3 - References

93

1.

Mills JA. Systemic Lupus Erythematosus. N Engl J Med 1994; 330:1871-1879.

2.

Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the
Fc{gamma}IIB receptor on memory B cells in SLE. J. Exp. Med. 2006;
203:2157-2164.

3.

Lahita RG. Systemic Lupus Erythematosus. Amsterdam: Elsevier Academic
Press, 2004.

4.

Thatayatikom A, White AJ. Rituximab: A promising therapy in systemic lupus
erythematosus. Autoimmunity Reviews 2006; 5:18-24.

5.

Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and
immunological effects of Rituximab in patients with lupus nephritis refractory to
conventional therapy: a pilot study. Arthritis Res Ther 2006; 8:R83.

6.

Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative
lupus nephritis. N Engl J Med 2004; 350:971-980.

7.

Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in
lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose
versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:21212131.

8.

Merrill J, Neuwelt C, Wallace D, Shanahan J, Latina sK, Oates Jea. Efficacy and
safety of rituximab in patients with moderately to severely active systemic lupus
erythematosus (SLE): results from the Randomized, Double-blind Phase II/III
Study EXPLORER. In:American College of Rheumatology National Meeting.
Abstract L12, 2008.

9.

Loder F, Mutschler B, Ray RJ, et al. B cell development in the spleen takes place
in discrete steps and is determined by the quality of B cell receptor-derived
signals. J Exp Med 1999; 190:75-89.

10.

Polston DW. Cervical radiculopathy. Neurol Clin 2007; 25:373-385.

11.

Bogduk N. The anatomy and pathophysiology of neck pain. Phys Med Rehabil
Clin N Am 2003; 14:455-472, v.

Chapter 2
94
12.
Radhakrishnan K, Litchy WJ, O'Fallon WM, Kurland LT. Epidemiology of
cervical radiculopathy. A population-based study from Rochester, Minnesota,
1976 through 1990. Brain 1994; 117 ( Pt 2):325-335.
13.

Rempel DM, Harrison RJ, Barnhart S. Work-related cumulative trauma disorders
of the upper extremity. Jama 1992; 267:838-842.

14.

Waters TR. National efforts to identify research issues related to prevention of
work-related musculoskeletal disorders. J Electromyogr Kinesiol 2004; 14:7-12.

15.

Hubbard

R

WB.

Cervical

nerve

root

compression

elicits

behavioral

hypersensitivity dependent on the magnitude of applied load. . In:ASME
Bioengineering Conf, #152557. Amelia Island, FL. , 2006.
16.

Starkey C, Johnson G. Athletic Training and Sports Medicine. Sudbury, MA:
Jones & Bartlett, 2005.

17.

Torg JS, Naranja RJ, Jr., Pavlov H, Galinat BJ, Warren R, Stine RA. The
relationship of developmental narrowing of the cervical spinal canal to reversible
and irreversible injury of the cervical spinal cord in football players. J Bone Joint
Surg Am 1996; 78:1308-1314.

18.

Tencer AF, Mirza S, Bensel K. Internal loads in the cervical spine during motor
vehicle rear-end impacts: the effect of acceleration and head-to-head restraint
proximity. Spine 2002; 27:34-42.

19.

Watkins LR, Maier SF, Goehler LE. Immune activation: the role of proinflammatory cytokines in inflammation, illness responses and pathological pain
states. Pain 1995; 63:289-302.

20.

Obata K, Yamanaka H, Dai Y, et al. Differential activation of extracellular signalregulated protein kinase in primary afferent neurons regulates brain-derived
neurotrophic factor expression after peripheral inflammation and nerve injury. J
Neurosci 2003; 23:4117-4126.

21.

Obata K, Yamanaka H, Fukuoka T, et al. Contribution of injured and uninjured
dorsal root ganglion neurons to pain behavior and the changes in gene expression
following chronic constriction injury of the sciatic nerve in rats. Pain 2003;
101:65-77.

Chapter 2
95
22.
Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic
pain. Nat Rev Neurosci 2005; 6:521-532.
23.

Hubbard RD, Quinn KP, Martinez JJ, Winkelstein BA. The role of graded nerve
root compression on axonal damage, neuropeptide changes, and pain-related
behaviors. Stapp Car Crash J 2008; 52:33-58.

24.

Kobayashi S, Yoshizawa H, Yamada S. Pathology of lumbar nerve root
compression. Part 2: morphological and immunohistochemical changes of dorsal
root ganglion. J Orthop Res 2004a; 22:180-188.

25.

Kobayashi S, Yoshizawa H, Yamada S. Pathology of lumbar nerve root
compression. Part 1: Intraradicular inflammatory changes induced by mechanical
compression. J Orthop Res 2004; 22:170-179.

26.

Bulte JWM, Kraitchman DL. Iron oxide MR contrast agents for molecular and
cellular imaging. Nmr in Biomedicine 2004; 17:484-499.

27.

Yancy AD, Olzinski AR, Hu TC, et al. Differential uptake of ferumoxtran-10 and
ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit:
critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging
2005; 21:432-442.

28.

Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Jr., Enochs WS. MR
imaging of phagocytosis in experimental gliomas. Radiology 1995; 197:533-538.

29.

Brochet B, Deloire MS, Touil T, et al. Early macrophage MRI of inflammatory
lesions predicts lesion severity and disease development in relapsing EAE.
Neuroimage 2006; 32:266-274.

30.

Linker RA, Kroner A, Horn T, Gold R, Maurer M, Bendszus M. Iron particleenhanced visualization of inflammatory central nervous system lesions by high
resolution: preliminary data in an animal model. AJNR Am J Neuroradiol 2006;
27:1225-1229.

31.

Stoll G, Wesemeier C, Gold R, Solymosi L, Toyka KV, Bendszus M. In vivo
monitoring of macrophage infiltration in experimental autoimmune neuritis by
magnetic resonance imaging. J Neuroimmunol 2004; 149:142-146.

Chapter 2
96
32.
Dunning MD, Lakatos A, Loizou L, et al. Superparamagnetic iron oxide-labeled
Schwann cells and olfactory ensheathing cells can be traced in vivo by magnetic
resonance imaging and retain functional properties after transplantation into the
CNS. J Neurosci 2004; 24:9799-9810.
33.

Sykova E, Jendelova P. Magnetic resonance tracking of transplanted stem cells in
rat brain and spinal cord. Neurodegener Dis 2006; 3:62-67.

34.

Bendszus M, Stoll G. Caught in the act: in vivo mapping of macrophage
infiltration in nerve injury by magnetic resonance imaging. J Neurosci 2003;
23:10892-10896.

35.

Stoll G, Bendszus M. Imaging of inflammation in the peripheral and central
nervous system by magnetic resonance imaging. Neuroscience 2009; 158:11511160.

36.

Herschman HR. Molecular imaging: looking at problems, seeing solutions.
Science 2003; 302:605-608.

37.

Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular
system. Circ Res 2004; 94:433-445.

Chapter 3

97

CHAPTER 3. Synthesis, Modification and Characterization of SPIO
3.1 - Overview
3.1.1 - Preface
A promising new direction for contrast-enhanced magnetic resonance (MR)
imaging involves tracking the migration and biodistribution of superparamagnetic iron
oxide (SPIO)-labeled cells in vivo. Despite the fact that a number of cell labeling studies
have been performed with SPIO particles of differing size and surface charge, it remains
unclear which SPIO configuration provides optimal contrast in cells of interest. One of
the central goals of this thesis was to accomplish immune cell tracking in multiple disease
models. To that end, an engineering approach to manufacture and characterize nano- and
microparticles was undertaken. The initial aim was to develop good manufacturing
processes for a SPIO formulation that enabled efficient delivery of contrast agent to cells
in an ex vivo loading regime.
The present and following three chapters are connected components of a single
research thread. The overall goal was for the use of SPIO nanoparticulates to enable
imaging of lymphocyte trafficking in vivo. SPIO were developed and their interaction
with cells investigated for that purpose (see Chapter 4). The specific application was to
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track B cells in the mouse and monitor their in vivo distribution following administration
of a B cell depleting therapy (see Chapter 5).
It can be seen that there are two general strategies for SPIO-enabled visualization
of a population of cells; 1) loading the cells ex vivo with SPIO and 2) specific targeting
of cells of interest in the organism. In the former, higher sensitivity for cell tracking is
afforded as the ex vivo loading of cells with SPIO is high. Thus high contrast per cell can
be achieved. However, cells must first be isolated.
In the latter system, cells need not be removed or exposed to an ex vivo
environment. Targeting of the SPIO to cells of interest would involve their modification
with a ligand for cell specificity, for example antibodies, and enable repeated
administration of such an agent (see Chapter 6). As a result, loading efficiency is lower
following this approach and there is the likelihood of greater background uptake (for
example by the reticuloendothelial system).
The present chapter is concerned with the basic processes of manufacture and
characterization of the nanoparticles used throughout this thesis. Production of particles
with desirable features (including size, distribution, surface and magnetic properties). The
following chapter utilizes these particles to address the problem of labeling nonphagocytic cells, such as T and B cells. Subsequently, the application of this work was
undertaken in an animal model for the non-invasive spatiotemporal visualization of
murine B cells loaded ex vivo and injected into host mice.
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The high efficiency delivery of SPIO to cell types that do not actively internalize
foreign material has presented a significant problem within the field of cell tracking. In
phagocytic cell types, such as macrophage, achievement of loading levels on the order of
tens of picograms of iron per cell is not difficult. Facile incubation in culture for a period
of several hours is all that is required (1). For non-phagocytic cells the intracellular
loading levels needed for MR visualization are most often realized through application of
potentially toxic biological or chemical modifications to the SPIO or the use of disruptive
treatment of the cells (such as electroporation) (2).
Despite the size of this body of work, it remains unclear what configuration of
SPIO provides optimal contrast for non-phagocytic cell types. The presence of
contradictory findings, elaborated upon below, can be attributed to a significant degree to
variability and imprecise control over particle size or surface charge and the limited
number of particle configurations examined in any given study. In the present chapter, we
have manipulated the synthesis procedure for SPIO nanoparticulates as well as
systematically characterized these and commercially available NP. Dextran coated iron
oxide particles in a continuum of sizes were generated with low polydispersity. These
materials were subsequently cross-linked for stability and functionalized with surface
amine groups. Control of the density of these amines was demonstrated. The core
structure of the particles was also evaluated and surprisingly revealed that the ultrasmall
and standard SPIO (USPIO and SSPIO, respectively) were multi-core in nature.
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3.2 - Background
The growing field of nanoparticle (NP) research includes a plethora of different
types of materials. These include (but are not limited to) particles composed of metals
and metal oxides (such as gold, silver and SPIO), lipid and polymeric micelles or vesicles
and protein complexes. Further, many are composites of several classes of materials,
notably the polysaccharide and metal-oxide SPIO particles used throughout this
dissertation. Characterization of these materials involves considerable effort as it is their
nanoscopic physical and chemical features that drive interest in their design, fabrication,
modification and application.
Traditional materials characterization technologies that rely on sampling bulk
properties, while still important, are just the beginning of the descriptive route when
working with nanoparticulate matter. This section seeks to provide the reader with an
understanding of the field of materials characterization as it applies to NPs and
specifically SPIO. This is significant because material properties optimization and
manipulation are substantial elements of this thesis as we investigate the application of
SPIO to ex vivo and in vivo cellular systems.

3.2.1 - Size and Mass Measurement
Techniques that are applied widely in the field of colloidal nanoscale research
begin with size measurement. There are several methods to characterize a NP's size, most
notably atomic force microscopy (AFM), electron microscopy (EM) and dynamic light
scattering (DLS). Other solutions based methods that are less common include
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sedimentation velocity and size exclusion chromatography. Conceptually the simplest
method, AFM sees the deposition of a NP solution to an ultra-flat surface (usually
cleaved mica), which is then rastered using micron-sized cantilevered-beam with an
atomically fine (usually silica) tip. In many ways the system can be thought of as the
needle of a phonograph that is sensitive to the pits of a record. A laser beam is directed to
the cantilevered-beam. When moved across the surface containing the deposited particles,
interaction of the atomic tip with the deposited material deflects the beam which is
measured by changes in the laser reflection (3). The result is non-destructive topology of
the materials on the surface, measured in either air or water, that can extend all the way to
atomic (attometer) resolution (4).
With one notable exception (the measurement of SPIO interaction with
telomerase as an enzymatic nanosensor (5)) SPIO are not often measured using AFM.
Instead DLS and transmission EM (TEM) techniques are often employed. The reason for
this is that this NP configuration of polymer-coated iron oxide core is both stable in
solution and possesses an electron dense core. This means that additional information,
generally in higher throughput, can be obtained regarding their size distributions than is
possible with AFM.
DLS probes particulates on the 1 - 1000 nm scale. NP in solution are placed in a
cuvette and irradiated with the polarized light of a laser. The vast majority of light passes
through the sample, however some is scattered to a detector. The intensity of scattered
light, detected at some fixed angle (usually 90˚ from the incident laser) is dependent on
the diffusive motion of the particles in the solution (6). An autocorrelation function
applied to the scattered light intensity of the nanoparticles reveals the Brownian motion
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(diffusivity) of the particles, which can be used to calculate their size (following the
Einstein-Stokes relationship). This autocorrelation of the intensity is why the technique
is sometimes referred to as photon correlation spectroscopy. The autocorrelation function
employed influences the final results. Most assume the presence of monodisperse
spherical particles. While that is not often a true representation of the physical reality,
comparison of several sizing models, standards and verification by other methods (for
example TEM) has shown them to be quite accurate (7). Sample preparation for DLS is
extremely easy, and requires only that particles remain in suspension throughout the
measurement (often on the order of several minutes). DLS measures the hydrated
particulate diameter as the sample is in solution. This is relevant for SPIO
characterization because it reports the composite particles' inclusive size.
Transmission electron microscopy (TEM) provides some of the most detailed
views of matter. Passing a focused high voltage beam of electrons through a sample is the
basis for this technique. Sample preparation is onerous and time consuming, requiring
particulate samples be carefully dried onto specialized 10 mm diameter grids. Ideally the
sample is dried into a monolayer, as the working distance of this microscopic technique is
limited to several hundred nanometers. The grid upon which they are placed is usually a
metal mesh (often copper, titanium or nickel) that is then sparsely coated with thin layers
of carbon or silicon. The presence of a particle that absorbs much of directed electron
beam on this thin (minimally absorbing) layer allows for the distinction and measurement
of the particle size. In the case of the many NP materials composed of or containing
electron-transmitting substances (usually carbon-rich materials such as polymers, lipids
or polysaccharides) absorbent material such as gold or carbon must be coated onto the
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particles. In the case of non-metal coated SPIO this is actually an advantage for
characterization purposes. For example, with the NPs synthesized and applied in this
thesis, the electron-transparent dextran is generally not detectable rendering the iron
oxide cores visible. This enables the direct measurement of the magnetic cores of the
particles. When combined with data gathered from DLS measurements, information
about the core composition and size, the entire diameter and the thickness of coating can
be compiled.
These methods give information regarding particle dimensions, however it should
be noted that none give a direct measurement of the mass of the particles. Acidic
degradation of iron oxide particles can be used to spectrophotometrically assess the iron
content in a solution, but without an understanding of the mass per particle, this gives no
correlating information to the particle concentration in solution. Determination of core
size from TEM can be used to compute the mass per particle (assuming an appropriate
atomic packing factor and geometry). This estimation method is however limited to a
small sample size (as cores must be measured one-by-one). Other methods exist for mass
quantification of particulate samples. One is to take a quantity of sample and dry it at
high temperature (8). The recovery of iron residue from the sample can be assessed by
weight to estimate the iron per particle. This method depends on the assumption that all
iron is present as iron oxide that the DLS measured volume is monodisperse and is
heavily dependent on assumptions regarding the mass of any coating material. A third
method for the determination of core size relies on the viscosity of a solution that
contains suspended particles. A relationship exists between the viscosity of a dilute
solution of nanoparticles and the volume fraction of particles in that solution.
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Determination of this volume fraction of particles in solution, again coupled with DLS
information regarding the entire particle diameter (and therefore volume), enables
calculation of the number of particles in solution. In turn, spectrophotometric analysis of
a solution of nanoparticles provides the iron concentration, which when divided by the
number of particles of an equal volume provides an estimation of core size (9). The
assumptions employed in this approach are that the particles are spherical and that the
contribution of mass of iron greatly outweighs that of the coating material.

3.2.2 - Chemical Surface Profiling
Equally important as the size and mass of NPs for their in vitro and in vivo
application is their surface makeup. There exist several methods to assess the physicochemical properties on particle surfaces. Fourier transform infrared spectroscopy is a
relatively inexpensive technique that relies on long wavelength light interference by dried
or aqueous materials. Atomic bonds absorb this low energy electromagnetic radiation in
specific spectral domains. This method is only somewhat quantitative but has been used
to determine the presence or absence of specific chemical species on iron oxide NP
surfaces (10, 11).
Spectrophotometric methods (UV/Vis) have been widely used to determine
nanoparticle surface functionalization. Quantitative surface group assessment can be
accomplished in several ways: 1) through the direct detection of small molecules on
particles surfaces through specific absorption bands, for example to detect folate (10) or
2) the reaction of surface groups with secondary absorbent (or fluorescent molecules)
(12). An example of the latter that has been used with great success to determine the
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amine surface content of SPIO has been the use of the thiol cleavable agent succinimidyl
3-(2-pyridyldithio)propionate (SPDP). SPDP can be used to react with surface amines
which, following cleavage and purification, yields the 2-pyridinethione chromophore.
This molecule absorbs 343 nm light once cleaved allowing for determination of its
quantity in solution. SPIO are reacted with SPDP and the excess chemical is removed
from solution. The SPDP is then cleaved and the 2-pyridinethione is quantified. The
concentration of this molecule divided by the concentration of particles in solution is a
sensitive estimate of the number of amines per particle (13, 14).
The catalog of SPIO surface compositions is nearly endless. Different polymer or
metal coating materials have been used that present, or are subsequently modified to
possess, nearly every conceivable functional group. Only a small subset of these,
including amines, carboxyls, thiols and azides are discussed in this thesis.

3.2.3 - Magnetic Properties
The advantages of cellular and molecular imaging using MR are considerable. It
allows for determination of the presence and in some cases the state of chemical,
biological and cellular items of interest. This information is conveyed with high
spatiotemporal distinction non-invasively. The use of contrast agents are in many cases
required for this imaging. The characterization of relaxivity of materials, a description of
their concentration dependent affect on local magnetic field, was introduced in section
1.5. Material magnetic properties may be assessed either in dedicated instruments (such
as superconducting quantum interference magnetometers) or directly in MR imaging
systems. Dilutions of sample are prepared and read, and the requisite curves are
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computed. The linear portion of the 1/T1 of 1/T2 versus iron concentration yields the R1
or R2 measurement, respectively.
Another characteristic of magnetic materials is their saturation
magnetization. This refers to the magnetic field strength at which no greater enhancement
of material magnetic field can be generated. This is a useful defining characteristic of
magnetic materials for applications such as electronics and specifically data information
storage. Assessment of NP magnetization hysteresis curves and saturation values are
often drawn from a superconducting quantum interference device (SQUID) or vibrating
sample magnetometry (15). Extremely accurate measurements, even of single particles
using SQUID can be made (16). However, the field strengths of MR imaging are of
sufficient strength (approximately six orders of magnitude greater than the earth's
magnetic field) that all magnetic materials are saturated.
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3.3 - Materials and Methods
3.3.1 - Nanoparticle Synthesis
Three different formulations of dextran-coated superparamagnetic iron oxide
nanoparticles were prepared using the co-precipitation method (17). All three
formulations were prepared following the same procedure, as described below, with the
only difference being the amount of FeCl2 and FeCl3 added. Specifically, 25 g of dextran
T10 (GE Healthcare; Piscataway, NJ) was dissolved in 50 mL of dH2O and heated to 80˚
C for 1 hour. The solution was allowed to return to room temperature and continued to
mix overnight. Subsequently, the dextran was cooled to 4˚ C on ice and degassed with N2
for 1 hour. FeCl2 (0.7313 g, 1.5 g, or 2.2 g) and FeCl3 (1.97 g, 4 g, or 6 g, respectively)
were each rapidly dissolved in 12.5 mL of degassed dH2O and kept on ice for
approximately 10 minutes. The iron solutions were added to the dextran simultaneously
and allowed to mix for 30 minutes. Keeping this mixing solution at 4˚ C, 15 mL of
ammonium hydroxide was added. The resulting black viscous solution was then heated to
90˚ C for 1 hour then cooled overnight, followed by ultracentrifugation at 20k rcf for 30
minutes. Pellets were discarded and the supernatant was continually diafiltrated using a
100 kDa MWCO cartridge (GE Healthcare) on a peristaltic pump (E323, Watson
Marlowe Bredel; Wilmington, MA). The particles were exchanged into 0.02 M citrate,
0.15 M sodium chloride buffer until all unreacted products had been removed. Aminated
silica-coated iron oxide micro-particles were purchased from Bioclone Inc. (San Diego,
CA). Amine functionalized styrene-copolymer coated iron oxide particles (Adembeads)
were purchased from Ademtech SA (Pessac, France).
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3.3.2 - Modification of Particles
Amination and cross-linking of the coating on the dextran-SPIO was
accomplished through reaction of the SPIO with 25% 10 M NaOH and 33%
epichlorohydrin (18). After mixing for 24 hours, the particles were transferred into
regenerated cellulose dialysis membranes (8-14 kDa MWCO, 50 mm flat width) and
dialyzed against 0.02 M citrate for 10 minutes. After transfer back into glassware,
additional ammonium hydroxide was added to the solution, bringing the volume fraction
to 25% ammonium hydroxide, and the reaction was allowed to proceed for another 24
hours. The particles were then exhaustively purified via diafiltration. The resulting
particles were amine functionalized cross-linked iron oxide.
All SPIO particles were labeled with FITC at a FITC-to-iron molar ratio of
19.2:1. FITC (389.4 g/mol) was dissolved in dimethylformamide and added (10% v/v) to
SPIO. SPIO concentration was determined spectrophotometrically (following 6 M HCl
decomposition in the presence of 3% H2O2) against a standard curve to yield molar iron
values. FITC was reacted with particles for 4 hours followed by two rounds of gel
purification, once on a NAP-5 column and then on a PD10 column (GE Healthcare), both
equilibrated with PBS. The FITC-labeled SPIO were subsequently reacted with various
volumes of glycidol (0.01% to 50%) to produce populations of particles with different
surface amine content. The particles were cleaned of excess glycidol through repeated
precipitation in isopropanol and resuspension in phosphate buffered saline (PBS). Amineblocking was also attempted with particles 200 nm and greater, however this
modification impelled immediate particle insolubility.
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3.3.3 - Overall and Core Size Measurements
The hydrodynamic diameter of the dextran-coated and commercial iron oxide
particles was measured using a Zetasizer Nano-z (Malvern Instruments, Malvern, UK)
through dynamic light scattering (DLS). The dextran-coated SPIO particles were diluted
in PBS to a concentration of approximately 0.5 mg/mL and read in triplicate. The
commercial particle diameters were read in the same manner, but only after undergoing
three washes by precipitation in the presence of a strong magnet and resuspension in
PBS. The values reported for all samples are the intensity peak values.
Transmission electron micrographs of all iron oxide particles were taken using a
JEOL 2010 at 200 kV. Samples were prepared for imaging by evaporating the particles
onto a carbon-coated copper grid (Holey carbon - mesh 200, Structure Probe Inc., West
Chester, PA). Salt was removed from all of the samples prior to evaporation by
exchanging the particles into dH2O. Images of particle cores were analyzed using ImageJ
(National Institutes of Health, Bethesda, MD). Since many of the particles were found to
be composed of a cluster of multiple iron oxide cores, the average diameter of each core
and the average number of cores per particle were determined. Assuming each core to be
spherical, the amount of iron per particle type was determined from the aggregate core
volume.
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The longitudinal (R1) and transverse (R2) relaxivity of each particle was
calculated as the slope of the curves 1/T1 and 1/T2 against iron concentration,
respectively. T1 and T2 relaxation times were determined using a Bruker mq60 MR
relaxometer operating at 1.41 T (60 MHz at 40˚ C; Bruker Optics Ltd, Billerica, MA). T1
measurements were performed by collecting 12 data points from 5.0 to 1000 msec with a
total measurement duration of 1.49 minutes. T2 measurements were made using ! = 1.5
msec and 2 dummy echoes, and fitted assuming monoexponential decay.

3.3.5 - Chemical Assessment
The number of amines per particle was determined following the general
procedure described by Zhao et al. (14). Briefly, iron oxide particles at a concentration of
2 mg Fe/mL were reacted with excess N-Succinimidyl 3-(2-pyridyldithio) propionate
(SPDP, Calbiochem, San Diego, CA) for 4 hours. SPIO were washed of excess SPDP
through repeated precipitation in isopropanol and resuspension in PBS. The particles
were then run through a 50 kDa MWCO centrifugal filter (YM-50, Millipore, Billerica,
MA) either with or without the addition of disulfide cleavage agent tris(2carboxyethyl)phosphine (TCEP). The difference of the absorbance of these two samples
at 343 nm was used to determine the concentration of 2-pyridinethione in the filter flow.
Adjusting for dilution, the number of amines per particle was determined, assuming one
100% conjugation of one SPDP per amine. The stability of cross-linking of dextran was
measured by heating the particles in a dry bath to 80˚ C for several days. Samples were
run through a 50 kDa MWCO filter at different time points. The presence of freed

Chapter 3
111
dextran was colorimetrically revealed using the phenol:H2SO4 sugar method (19). The
concentration of flow-through dextran was compared to a standard curve of dextran in
dH2O.
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3.4 - Results and Discussion
3.4.1 - Particle Synthesis and Modification
Three different formulations of dextran-coated superparamagnetic iron oxide
nanoparticles were prepared via co-precipitation. All three syntheses utilized a ratio of
approximately 3 ferrous to ferric iron chloride; however, the total amount of iron was
increased by whole numbers, i.e. 2x and 3x iron respectively. This deviation in the
amount of iron present during synthesis allowed for the manufacture of SPIO with a
range of different sizes and properties.
A wide range of synthesis conditions were assessed in order to determine a
working procedure that enabled repeatable production of stable, superparamagnetic, high
yield nanoparticles. Parameters in the synthesis that were altered in order to determine
their role in nanometer SPIO production included; 1) reaction temperature, 2)
atmosphere, 3) molar ratio of iron salts, 4) type of base, 5) rate of base addition, 6)
stirring speed, 7) post-precipitation heating time, and 8) ratio of iron to complexing agent.
The complete characterization of the SPIO was not attempted until high quality
nanomaterials were first produced, and thus the results of the initial engineering of the
SPIO were predominantly observational rather than quantitative.
Several of the reaction components were deemed to be critical towards production
of useable magnetopharmaceutical. First, an inert atmosphere was found to be required to
produce magnetite and maghemite. This observation was based on the color of the
complexes formed during reactions conducted at both 4˚ C and 25˚ C in the presence of
polymer (dextran) or surface complexing ions (such as citrate). The formation of a red or
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orange complex followed by detection of large iron precipitates was noted when reactions
were initiated in air. This color is indicative of the presence of iron oxyhydroxides that
are diamagnetic (20, 21). Reaction under N2 was found to prevent the oxidation of
material during the synthesis, as reported generally in the literature (22).
Critical parameters were the temperature of the reaction and the rate of base
addition. It was assessed that these two elements of the procedure were intimately related.
The reduction of the thermal energy present in the aqueous reaction was mediated
through the presence of an ice bath and the addition of base at a slow rate. The slow
addition of base (regardless of type, sodium hydroxide or ammonia) and the effective
dissipation of heat produced from acid/base titration was critical. Together, they
controlled the heterogeneous nucleation of the iron oxides (in the presence of polymer)
delaying the ripening of particles (23, 24). This is illustrated schematically in Figure 3.1.
This finding may also apply to the observation that larger reaction volumes were not
effective for production of particles with sufficient polydispersity. Although only a
limited number of larger (250 mL) reaction batches were attempted, it is hypothesized
that the lack of a thermal jacket or more specialized cooling equipment resulted in
inadequate temperature control.

nanoparticle size

Chapter 3

114

nucleation phase
4˚ C

growth phase
90˚ C

reaction time
Figure 3.1 - Nucleation and Growth of Nanoparticles.
Controlled synthesis of particles, mediated primarily by presence of solute and
temperature, allowed for the segregation of the nucleation and growth phases of the
nanoparticles. During the nucleation phase (at 4˚ C) the iron ions do not spontaneously
form stable nuclei of NP as the reaction conditions are conducted below saturation
concentration of metal ions. However, upon the addition of base there is the
heterogeneous nucleation of NP on dextran polysaccharides. By keeping the thermal
energy in the mixture minimal, while still allowing for efficient mixing, a very large
number of small particles are formed. These are then grown into larger particles with the
application of heat, likely through a ripening process, to produce fairly uniform particles.
Adapted from Sugimoto et al., (25).
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Post-precipitation heating, at levels of between 80˚ and 100˚ C was found to be
required for contrast applicable magnetic properties. The reason for this is not exactly
known, as the temperatures used here are far below that required for the conversion of
iron oxides to maghemite and magnetite (24). It is likely that high relaxitive properties
result solely from growth of pre-nanoparticle nuclei into actual nanoparticles, however it
is also possible that relatively low temperature (90˚ C) heating of an iron oxide
nanomaterial may provide sufficient thermal energy for a crystal structure phase change.
It should be noted that further heating for greater than the (often used) 1 hour did not
produce larger SPIO. This may be because the formation of particles of a defined size are
sterically stable. Therefore, agglomeration at a SPIO-size plateau is reached after some
size apparently dependent on initial synthesis parameters.
When altered, several parameters provided little observable difference in the
products of synthesis. The concentration of the iron salts was found to be of little
importance and several reactions were run with lower concentrations (and corresponding
lower concentration of dextran) that resulted simply in production of less final product. It
had been hoped that lowering the concentration (dilution) of the initial material would
result in smaller or more monodisperse particles. Further, despite observations in the
literature that change in the molar ratio of the salts, for example a 3:1, 2:1, 1:1 or 1:2 ratio
of Fe2+:Fe3+, having an effect on the final product, all apparently yielded nanoparticles.
Another factor of little significance was stirring speed. Effort was expended to
determine if stirring speed of the solution could result in, again, smaller or more
monodisperse particles. The hypothesis here was that better mixing conditions would
ensure that minimal heat would be evolved from acid-base titration and that greater
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mixing in general would provide a more homogeneous reaction. Difficulties were
encountered using external (non-magnetic stir bar) top down stirrers. While faster mixing
was attainable, it was at the cost of a less well contained inert atmosphere. Results were
not highly consistent between batches using top down mechanical stirring apparatus, and
there was little apparent difference between using magnetic stir bars.
Besides the rate of base addition, the parameter that had the greatest effect on the
geometric and magnetic properties of the nanoparticles was the molar ratio of the
complexing agent to the iron salts. A wide variety of concentrations of both of these
components were used (keeping the Fe2+:Fe3+ ratio at 3:1). Increasing the ratio by means
of more dextran relative to a fixed iron amount quickly resulted in a viscous reaction
volume that inefficiently mixed. Thus, a fixed amount of dextran was used with varying
amounts of iron salts. It was found, as discussed in detail below, that increasing SPIO
size and magnetic properties resulted from increasing the ratio of iron to dextran. When
the total amount of iron was increased beyond 8.2 g, the co-precipitation solution became
extremely viscous and yielded highly dispersed aggregates that precipitated out of
solution.
Core analysis of the particles was carried out in order to study the internal
structure of the variously synthesized particles and to correlate these features to bulk
colloidal properties. It was revealed by characterization that individual component cores
between all particles were similar and it was the number of cores that differed. This
suggests that the phenomenon leading to greater size and relaxivity was not greater size
of particle nuclei but greater agglomeration during the growth phase.
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Finally, the chemical surface features were analyzed. It was found that
modification of the particles, due to the excess of reactants used, was a highly consistent
process in all of the cross-linking, functionalizing and blocking procedures. At the time
that the cross-linking and amination procedures were undertaken here there was no
defined literature on the subject. Subsequently, an excellent source method, from Pittet, et
al. (18), has been published that closely mirrored the finalized protocol used here. The
only major difference occurs during the transition step just prior to adding ammonia for
the amine-functionalization of the particles. We found that a brief dialysis step, followed
by addition of fresh NaOH, allowed for a more consistent product. We can only speculate
that the result of this quick wash removed some (primarily spent) epichlorohydrin from
the volume and enable more efficient amination with the diamine ammonia. The glycidol
blocking of amines was also conducted in very high initial excess conditions. The SPIO
were not greatly affected in even 50% volume of glycidol (they remained in solution; a
rare phenomenon when mixing the particles with non-aqueous media at that volume
ratio) allowing for conversion of the required ratio of amines.

3.4.2 - Shell and Core Characterization
Characterization of the SPIO size was accomplished using optical scattering and
TEM measurements. These techniques determined the overall diameter and core diameter
of the particles, respectively. The DLS of the SPIO, following cross-linking and
amination of the dextran coating, indicated an average hydrodynamic diameter of 33.4,
53.5, and 107 nm respectively, with the larger nanoparticles corresponding to syntheses
that utilized greater iron to dextran ratio. Nanoparticles ranging from 200 nm to 1 !m in
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diameter were acquired from commercial sources in order to supplement the assynthesized particles (which were limited in size beyond an initial iron concentration due
to viscosity of the solution becoming too great). Specifically, superparamagnetic iron
oxide particles of 200 and 300 nm diameter with an amine functionalized styrenecopolymer coating (Amino-Adembeads) were purchased from Ademtech, while amine
functionalized silica coated 1!m diameter particles were purchased from Bioclone. This
allowed particle sizes across nearly three orders of magnitude to be compared.
The particle sizes as determined by DLS, as peak intensity values, are compared
in Figure 3.2. The 33.4 nm, 53.5 nm and 107 nm dextran-coated SPIO samples were fully
soluble at physiological conditions. Conversely, it was found that the large size of the 289
nm and 1430 nm particles led to precipitation.
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Figure 3.2 - Hydrodynamic diameter of SPIO.
The hydrodynamic diameter of SPIO particles was determined by DLS. Intensity
measurements are reported and the peak intensity is provided for each distribution.
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Analysis of the iron oxide core size and structure of the magnetic particles was
conducted using TEM. Representative micrographs are shown in Figure 3.3. Aggregation
of particles in salt free solution was a problem during TEM sample preparation; however,
reduction in sample concentration allowed for imaging of discretely distributed particles
after solvent exchange to water. Iron cores were easily distinguished from carbon coated
copper grids, while dextran and styrene copolymer were not visible because of their low
electron density. The edge of the holey grids is evident in image panels D, E and F.
An interesting and unexpected feature of the dextran-coated nanoparticles was
that each particle consists of a cluster of one or more iron oxide cores. Furthermore, each
core was found to be approximately equal in size. Specifically, the distribution of cores is
centered at approximately 6 nm for all three dextran-coated nanoparticles (Figure 3.4);
however, the average number of cores per particle increases with overall hydrodynamic
diameter. In contrast, the larger 207 nm and 289 nm styrene copolymer-coated particles
exhibited a single large spherical iron oxide core, while the 1.43 !m silica-coated
particles exhibited an amorphous iron oxide core of no discrete size or shape.
It had been initially assumed that a larger particle diameter as determined from
solution based DLS would contain a larger single core. It had been predicted that the iron
cores would be imperfect magnetite or maghemite crystals, due to the fact that the
crystals were produced using an agitated aqueous solution reaction approach. Discovery
of the multicomponent core indicates that under the reaction conditions used, nuclei size
of approximately 6 nm is produced independent of the ratio of iron ions to dextran. This
ratio affects the ultimate size and core composition by altering the number of these nuclei
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per particle. Core diameters from a large sample of TEM measurements were used to
compute the average diameter as well as undertake a determination of the mass per
particle. Using a packing factor of 0.68 and assuming a spherical geometry (9), the
number of iron atoms per core and particle is given in Table 3.1.
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Figure 3.3 - TEM of SPIO Cores.
High magnification transmission electron microscopy images of the iron oxide particles
were obtained with a JEOL 2010 operating at 200 kV. Structure analysis revealed the
multiple core nature of the (A) 33.4 nm, (B) 53.5 nm and (C) 107 nm dextran-coated
SPIO. Larger particles were composed of single cores; (D) 207 nm, (E) 289 nm and (F)
1430 nm. All scale bars are 50 nm, excluding (F) 1 !m.
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Figure 3.4 - Size Distribution of SPIO Core Diameters.
TEM measurements of the SPIO core diameter for (A) 33.4 nm, (B) 53.5 nm, (C) 107 nm
and (D) all cores. The core diameters were analyzed assuming that they were spherical
and the frequency and cumulative distributions are plotted. Particle size appears to be
determined by the number of cores per particle rather than the size of those constituent
cores.
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3.4.3 - Surface Chemistry
The SPDP assay was used to spectrophotometrically determine the concentration
of surface amines on the synthesized and modified particles. Consistent with
expectations, the number of amines per particle increased with increasing diameter and
therefore surface area. The values of the functional groups per particle for fully aminated
particles is found in Table 3.1, summarizing the physical and chemical attributes of all
investigated particles.

Table 3.1 - Physical and Magnetic Properties of SPIO
* R1 values for 207, 289, and 1430 nm particles may be underestimated due to
precipitation during measurements.
** Measurement of Fe (atoms) / particle for the commercial particles was made using the
company provided relative iron mass per particle data, rather than the core size
determination from TEM.
Blocking of the functional groups was accomplished through crude reaction with
glycidol. Previous use of glycidol in the literature for use with NPs had centered on
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attempts to use it to reduce the charge-dependent cytotoxicity of polymer NP such as
dendrimers (26). This approach was adopted with the iron oxide NP and facile mixture
with the agent consumed amines. Further, purification of the nanoparticles from excess
spent or still-reactive glycidol was possible through the addition of isopropanol. Removal
of the organic phase was complete after several washes.
Stability of the dextran shell was determined by an examination of the dextran
that could be detected in solution (no longer complexed to SPIO) following residence in
harsh conditions. The conditions used were meant to simulate accelerated lifetime of the
particles in vivo, 80˚ C over roughly 100 hours. Two groups of samples from the same
batch of SPIO, one having been cross-linked the other not, were run through a filter at
various time points over the course of the heating. Using a colorimetric assay for the
detection of polysaccharide, it was possible to determine the concentration of dextran that
was being dissociated from the nanoparticle. The results, as shown in Figure 3.5, show
that particles that had not been cross-linked gave off more dextran over time.
Examination by eye also revealed that the non-cross-linked solution became cloudy after
approximately 2 days of heating, while the cross-linked particle solution did not change.
These results indicated that the cross-linking of the dextran shell significantly enhanced
the stability of the particles.
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Figure 3.5 - SPIO Stability.
The stability of the cross-linked (CLIO) and as-synthesized (MION, non-cross-linked) 33
nm SPIO is shown. Particles were filtered and the flow through volume was assessed for
the presence of dextran. As-synthesized samples were found to continually release
dextran, which is hypothesized to be from degenerating nanoparticles. Free dextran in the
solution of cross-linked particles was detectable to some degree. It is possible that this is
a background level of non-cross-linked dextran electrostatically-associated with a particle
and/or free dextran not purified from the synthesis solution.
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The magnetic characteristics of an MR CA are key to their application as in vitro
and in vivo contrast agents. The R1 and R2 data (Figures 3.6A-B), indicate that there is a
trend of increasing R2 and decreasing R1 with size up to the 107 nm particles. For
particles of greater size, the single large core of the 207 nm and 289 nm particles does not
result in proportionately higher R2. This likely reflects lower crystallinity of the larger
single iron oxide cores in comparison to smaller crystals (27). Furthermore, according to
the Solomon-Bloembergen theory, which relates the relaxation rate to particle properties,
the total volume of the particle is not critical to the magnitude of R2 as the susceptibility
effect falls off from the surface with an exponential (r6) dependence (28, 29).
It is hypothesized that as water has limited surface access, especially in the
diffusive time span over which magnetic measurements (and images) are taken, such size
is detrimental to dephasing of proximal protons. It should be noted that the R1 values
reported for particles greater than 200 nm are likely underestimates due to precipitation
of the particles during T1 measurements. For instance, determining T1 relaxation times
required more than 100 seconds per sample, which was ample time for the micrometersized particles to precipitate out of suspension.
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B

C

D

Figure 3.6 - Relaxivity Measurements of SPIO.
SPIO of various size were diluted in PBS to iron concentrations between 1 and 200 !g
Fe/mL for measurement at 1.41 T and 40˚ C. T1 (A-B) and T2 (C-D) values were then
obtained. The inverse of the relaxation times, in seconds, was linearly fit against
concentration to yield the particle R1 and R2. Non-linearity of 1430 nm particles in T1 and
T2 measurements was a result of sedimentation during magnetic measurement.
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3.5 - Conclusion
Iron oxide nanoparticles were prepared using a chemical coprecipitation
synthesis. At the outset, reaction conditions were varied to determine a suitable protocol
for the production of SPIO following good manufacturing processes. High quality
particles, possessing attributes such as limited polydispersity, high transverse relaxivity,
small size and long term colloidal stability were sought. In order to probe the effects, if
any, of the modification of reaction conditions on the resultant particles detailed
macroscopic and nanoscale characterization was performed. Measurements included the
hydrodynamic and core size and mass, surface chemical functional density and magnetic
relaxivity.
It was found that synthesis conditions could be reliably varied to produce particles
over roughly an order of magnitude of size and multi-component core number. To
complement our understanding of particle characteristics over a larger size domain,
commercial particles were used to supplement the synthesized group. The number of
surface amines and the iron per particle increased with greater particle diameter over the
size scale from 33 nm to 1430 nm. Comparison of core and magnetic properties revealed
that initial assumptions that greater size, and therefore greater iron content per particle,
would result in larger NP cores and greater T2 relaxivity were incorrect for the entire
range of particle sizes. The number of cores, and thus the amount of iron per particle, was
found to significantly influence the relaxivity of the laboratory-synthesized particles, but
not the larger, commercially obtained, samples. For dextran-coated SPIO the number of
cores was found to increase with hydrodynamic radii and ratio of iron to dextran, while
constituent core size remained relatively constant. The transverse and longitudinal
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relaxivities were greatest for the particle with the greatest number of cores and not the
particle with the greatest iron content.
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CHAPTER 4. Size, Charge and Concentration Dependent Uptake of SPIO by NonPhagocytic Cells
4.1 - Abstract
We have evaluated the cellular uptake of superparamagnetic iron oxide (SPIO) in
non-phagocytic T cells over a continuum of particle sizes ranging from 33 nm to nearly
1.5 !m, with precisely controlled surface properties. Further, this has been accomplished
without the need for potentially cytotoxic transfection agents. SPIO labeling of T cells
was analyzed by flow cytometry and contrast enhancement was determined by
relaxometry.
SPIO uptake was dose dependent and exhibited sigmoidal charge dependence,
which was shown to saturate at different levels of cationic surface functionalization.
Efficient labeling of cells was observed for particles up to 300 nm, however micron-sized
particle uptake was limited. We have shown that an unconventional highly cationic
particle configuration of aminated 107 nm diameter standard-SPIO (SSPIO) particles
maximized magnetic resonance (MR) contrast of T cells. These SPIO surprisingly
outperformed the widely utilized ultrasmall-SPIO (< 50 nm) configuration and
demonstrated sufficient loading for subsequent in vivo visualization.
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4.2 - Introduction
Continuing advancements in the fields of cell-based and cell-targeted therapy,
such as engineered cytotoxic T cells or cell depleting antibodies, respectively, hold great
promise for combating disease. Future development of these methods require greater
knowledge than is currently available regarding the cellular distribution of the therapies
and targets in vivo. This has led to the emergence of cellular imaging as a strategy to
track the migration and biodistribution of target cells in living organisms. Pre-clinical
studies have shown that cellular imaging can be used to evaluate stem cell distribution
and homing in cell-based regenerative therapies (1, 2). Recently, cellular imaging has
also allowed for improved assessment of functional efficacy and applicability of
immunotherapeutic treatments in disease models for cancer (3-5) and AIDS (6). These
studies have shown that the ability to determine the cellular effect of treatment,
quantitatively and over long periods of time, using non-invasive approaches can have a
significant impact on the development of therapeutic protocols.
In addition to evaluating cell-based therapies, cellular imaging has the potential to
provide a great deal of insight into diverse physio- and pathological phenomena.
Interesting applications include the observation of monocyte recruitment to
atherosclerotic lesions for the mapping of disease development and therapeutic
intervention (7), imaging embryonic stem cell movement during embryonic (8) and organ
development (9) and the monitoring of metastatic cellular extravasation and tissue
invasion (10, 11).
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Tracking of labeled cells has been accomplished with a variety of imaging
modalities including optical methods, positron emission tomography (PET), single
photon emission computed tomography (SPECT), and MR (12-14). MR imaging presents
a particularly promising approach because of its high spatial resolution in three
dimensions and exquisite soft tissue contrast, which can be acquired concomitantly with
the contrast-enhanced cellular distribution.
MR detection of cells in vivo is often accomplished following labeling with
superparamagnetic iron oxide (SPIO) particles. SPIO are negative contrast agents that are
typically composed of an iron oxide crystal core surrounded by a polymer or
polysaccharide shell (15). A variety of manifestations of SPIO have been used to track
cells, which can be broadly categorized as:
1)

Ultrasmall-SPIO (USPIO) with an overall diameter of 30 - 50 nm (16)

2)

Standard-SPIO (SSPIO) with a diameter of 50 - 250 nm

3)

Micron-sized paramagnetic iron oxide (MPIO) having a diameter

approaching or greater than 1 !m (17).
To date, USPIO have perhaps been the most widely utilized SPIO configuration
for cell labeling. Although they provide less contrast enhancement per particle as
compared to SSPIO and MPIO, large numbers of particles can be loaded into each cell,
allowing for large magnetic susceptibilities to be generated (18, 19). Cationic surfaces
have been shown to facilitate cellular internalization (20, 21), and thus USPIO are often
modified with polycationic cell permeating peptides (CPP) such as HIV-Tat (22) or
protamine (23). Other transfection techniques such as electroporation, sometimes in
concert with CPPs, have also been used (24, 25).

Chapter 4

137

An exciting new direction for cell tracking involves labeling cells with MPIO (26,
27). The large iron oxide cores present in these particles provide enough contrast for
single cells to be imaged by MR. However, work with such large particles generally
confines application of iron oxide-labeling to phenotypes such as macrophages (18),
dendritic cells (28) or hepatocytes that actively internalize foreign material. MPIO uptake
in non-phagocytic cells has been accomplished, however several non-trivial
modifications to the particles were required. The additional conjugation steps and
associated cost of using the antibody-mediated loading of MPIO is likely prohibitive to
many for cell tracking purposes (29). As well, any such antibody targeting approach
renders the contrast agents species specific and may induce adverse cellular events.
Recently, several studies have attempted to define an optimized particle
configuration for iron oxide labeling of both phagocytic and non-phagocytic cell types.
These attempts are part of a maturation of the nascent nanomedicine field to understand
how NPs interact with biological systems. Most of this work has been directed at the role
of NP chemical and physical attributes with respect to tumor targeting (30, 31). With
respect to phagocytic monocyte loading, it was found that these cells are more effectively
labeled with SSPIO (150 nm) compared with USPIO (30 nm) although MPIO was
excluded from all of these studies (18, 32). Further, it was found that ionic
carboxydextran-coated SSPIO (i.e. ferucarbotran) performed better than non-ionic
dextran-coated SSPIO (i.e. ferumoxide) (18). It remains unclear how MPIO compares
with these agents. It should be noted that the ability to conduct single cell detection using
MR imaging systems has been achieved in phagocytic cells with both SPIO
configurations (33, 34).
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The optimal SPIO configuration for labeling non-phagocytic cells has been much
more elusive and findings have been contradictory. For example, in one study it was
found that the delivery of carboxydextran SPIO and dextran-labeled SSPIO into nonphagocytic cancer cells and leukocytes (with the assistance of lipofection agents) was
similar in terms of iron uptake (21). Both particles led to higher iron uptake than
carboxydextran-coated USPIO. This indirectly suggests that larger particles with ionic
coatings are superior to non-ionic USPIO. However, in a different study it was found
that, in the presence of poly-L-lysine, ionic (aminated) USPIO exhibited significantly
higher iron uptake in non-phagocytic cells compared with SSPIO. These data suggest that
smaller ionic particles are internalized into non-phagocytic cells more efficiently (35).
These contradictory findings likely stem from the variability and imprecise control over
surface charge and the limited number of particle configurations examined, particularly
with respect to diameter (ranging only from ~17 to 150 nm).
This chapter systematically evaluates the cellular uptake of SPIO in nonphagocytic T cells over a continuum of particle sizes ranging from 33 nm to nearly 1.5
!m and with precisely controlled surface properties, as detailed in the previous chapter. T
cells were selected as a model non-phagocytic phenotype since visualization of their
distribution is expected to be of importance for adoptive T cell therapy for cancer and T
cell homing in autoimmune diseases. Extremely fine control was exerted on the surface
properties of SPIO by direct chemical modification of particle surfaces rather than
attempting to modulate the density of supplemental transfection agents. The main reason
for this approach was to avoid the interfering and generally detrimental effects posed
through use of charged peptide or cell membrane destabilization technologies.
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Beyond the role of surface modification, concentration effects and incubation
time were also tested in the interest of isolating the role particle size exerts on individual
cell uptake and overall contrast enhancement. Our work shows that in a space between
USPIO and MPIO exist configurations of relatively small particles (~100 nm) that
efficiently label non-adherent, non-phagocytic T cells and generate higher relaxivity (per
cell) relative to particles of other sizes.
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4.3 - Materials and Methods
4.3.1 - Nano- and Microparticle SPIO
Rigorous characterization of the iron oxide contrast agents utilized in this in vitro
study were detailed in Chapter 3. To recapitulate; nano- and microparticles of six
different size configurations were analyzed for their hydrodynamic diameter, core size
and composition, magnetic and surface properties. The particles are referred to by their
overall (hydrodynamic) diameter throughout this chapter and include the laboratory
synthesized 33.4 nm USPIO, 53.5 and 107 nm SSPIO and the commercially obtained 207
and 289 nm SSPIO and 1430 nm MPIO. All particles were functionalized with cationic
amine groups. Further, we have demonstrated the ability to control the surface amine
content of the laboratory-synthesized particles. Additional details regarding synthesis and
modification protocols as well as characterization can be found in Chapter 3.

4.3.2 - Cell Culture and Labeling
Immortalized human T cells, Jurkat Clone E6-1 (ATCC), were maintained at 37˚
C in 5% CO2 in RPMI 1640 (Mediatech, Manassas, VA) media supplemented with 10%
FBS (Hyclone, Logan, UT) and penicillin/streptomycin (Mediatech). T cells were labeled
with iron oxide particles (between 0 and 200 !g Fe/mL) by incubating the commercial
and lab-made particles with 2 x 106 cells in 400 !L of fully supplemented media for 1 or
4 hours, at 37˚ C in 5% CO2. Cells were washed of non-internalized particles through two
methods. Synthesized dextran-coated particles were washed from cells using
centrifugation. Specifically, cells were pelleted at 0.5k rcf for 5 minutes and resuspended
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in PBS. This was repeated three times. The dextran-coated particles are highly soluble in
aqueous solvents and do not precipitate at these centrifugation speeds. Removal of noninternalized commercial particles was accomplished through a density gradient. The cells
and particles were diluted to 1 mL with PBS and overlayed on 4 mL of room temperature
Ficoll-Paque PLUS (GE Healthcare). The sample was centrifuged at 0.4k rcf for 40
minutes. Cells loaded with particles were retrieved from the interface layer.
To determine if particles were internalized or merely adsorbed on the cell
exterior, surface receptor cleavage enzyme trypsin was used. Following particle
incubation, as described above, cells were exposed to 0.025% trypsin-EDTA (Invitrogen)
for 5 minutes. Purification of non-internalized particles was carried out as detailed. No
statistical difference was seen in either flow cytometry or relaxometry between groups
washed with or without enzyme.

4.3.3 - Assessment of Labeling
Immediately after non-internalized iron oxide particles were removed from T cell
samples, flow cytometry was performed on a Guava Easycyte (Guava Technologies,
Hayward, CA). For labeling and viability experiments, forward and side scattering were
used to identify the entire population of cells. Data analysis of flow cytometry data was
accomplished with FlowJo (TreeStar, Ashland, OR). Viability of T cells was determined
using the LIVE/DEAD cytotoxicity kit for mammalian cells (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Specifically the proportion of dead cells was
determined using the membrane-impermeant ethidium homodimer-1. This dye labels
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nucleic acids of membrane-compromised cells with red fluorescence. In order to evaluate
the decrease in T2 relaxation time of iron oxide internalized in T cells, purified cells were
lysed for 30 minutes in 0.1% SDS in PBS at 37˚ C. Samples were diluted to 0.5x106
cells/mL in 300 uL and T2 relaxation times were measured using a benchtop Bruker
mq60 MR relaxometer operating at 1.41 T (60 MHz at 40˚ C; Bruker Optics Ltd,
Billerica, MA). All flow and magnetic resonance measurements were made in triplicate
on at least two separate occasions.
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4.4 – Results
4.4.1 – Cell Loading
The extent to which T cells internalize iron oxide particles is dependent upon
more than mere particle size. Various other particle characteristics and cell loading
conditions, including surface charge, particle concentration, and incubation time play a
role. Thus, before it could be determined which particle size or configuration led to the
highest relaxivity per cell, it was first necessary to identify conditions whereby cell
loading was independent of these other parameters.
In the current study, all SPIO samples were fluorescently labeled with an
equivalent amount of FITC/iron. The use of fluorescently labeled iron oxide particles
combined with flow cytometry provided a facile method by which particle uptake could
be systematically assessed in a high-throughput manner. Following the exploration of
concentration, time and charge dependent uptake parameters, the contrast enhancement as
analyzed by magnetic relaxivity was determined.

4.4.2 - Concentration Dependence
In order to confirm that iron oxide particles were present in sufficient quantity for
maximum cellular uptake, T cells were incubated with increasing iron concentrations
until a saturating level was reached. As shown in Figure 4.1, dextran-coated particles
were efficiently internalized, all reaching a plateau at iron concentrations below 50 !g
Fe/mL. Greater than 100 !g Fe/mL was required to saturate the loading of the 207 nm,
289 nm and 1430 nm particles. The necessity for these higher iron concentrations may be
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attributed to the fact that the number of particles per unit of iron is far less than the
smaller agents. Further, there is likely less contact between the larger particles and
suspended cells because of their continual sedimentation. This was perhaps most evident
with MPIO, where cell labeling was poor across all particle concentrations. Even at 1000
!g Fe/mL (data not shown) labeling with MPIO did not reach the loading levels achieved
by the dextran-coated USPIO and SPIO.
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Figure 4.1 - Dependence of SPIO Loading on Particle Concentration.

Fluorescently labeled SPIO of various size and across a range of concentrations were
incubated with 2x106 T cells/mL at 37˚ C for 4 hours (excluding the 107 nm particle as
indicated). SPIO uptake was then measured by flow cytometry. Each experiment was
conducted in triplicate on at least two separate occasions and each data point represents
the average value for the mean fluorescent intensity (MFI). Note the difference in x- and
y-axes for (A) and (B). All particles were maximally aminated (for values see Table 3.1).
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4.4.3 - Role of Particle Charge
Surface charge is important for intracellular delivery of exogenous material. This
principle has been described for a variety of nanoparticles (examples include gold (36),
polymer (37, 38) and silica (39)) and biologicals (for example delivery of DNA with
cationic proteins, lipids and polymers (40)) contexts. It stems from the realization that
charged peptides enabled non-receptor mediated viral uptake (41). The aminated surfaces
of the particles used in this study provide an inherent surface charge, facilitating cellular
interaction. However, in order to study the role this property has in the intracellular
delivery of iron oxide contrast agent, it was necessary to manipulate the magnitude of the
surface charge. To do so we have applied glycidol, a hydroxyl terminating epoxide, to
generate subsets of particles with a gradient of surface amines.
Glycidol has been used previously in dendrimer chemistry to reduce the
chemotoxicity of highly-positively charged dendrimers (42). The tight control of surface
properties produced by consuming amines with glycidol allows for isolated examination
and evaluation of the role of surface charge on SPIO.
The summary of particle uptake on a per cell basis is shown in Figure 4.2A-C.
Each data point represents the normalized mean fluorescence intensity (MFI) of T cells
that were incubated with iron oxide particles at a saturating concentration (previously
determined) for 4 hours. Under these incubation conditions, it was found that particles in
their natural (fully aminated) state are maximally internalized. Any further increase in the
positive surface charge will not further augment SPIO loading. In other words, the
efficiency of cell labeling has become independent of surface charge. In all cases, uptake
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and internalization of the particles was rapid. Representative uptake of the 107 nm
particles as a function of time is shown in Figure 4.2D.
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Figure 4.2 - Dependence of SPIO Loading on Surface Charge.

T cell uptake of fluorescently labeled SPIO as a function of surface charge was examined
by modulating the number of amines per particle for the (A) 33.4 nm, (B) 53.5 nm and
(C) 107 nm particles. A gradient in the degree of functionalization was produced by
glycidol blocking of amines. SPIO were incubated with T cells at saturating
concentrations, 50 !g Fe/mL, under identical conditions. Flow cytometry was then
performed to assess the relative uptake of each SPIO. Each data point represents the
mean fluorescent intensity (MFI). The loading of SPIO was rapid; (D) shows the
representative uptake of fully-aminated 107 nm particles as a function of time.
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4.4.4 - Cell Viability
The impact and potential cytotoxicity of each iron oxide particle on T cells was
measured using a fluorescent cell viability marker. Negligible to low levels of cell death
were observed (Figure 4.3) for all particles at diminished and saturating concentrations of
iron oxide (10 and 50 !g Fe/mL, respectively). The exception was for the 107 nm SPIO,
which exhibited some adverse cell influence even at 10 !g Fe/mL. This effect was
exacerbated at increased concentrations. When the amines on the 107 nm particle were
completely blocked, cell death was reduced to negligible levels; however, internalization
was also reduced to negligible levels (Figure 4.2C).
T cell death is likely attributable to the high positive surface charge possessed by
the SPIO. Similar results have been seen with amine-terminated poly(amidoamine)
dendrimers (43). The extremely high driving force for cell internalization imparted by
positive SPIO surface charge can lead to cell death. We speculate this occurs through
non-reversible membrane degeneration resulting in either fatal cytoplasm leakage or
active cell death in response to highly charged foreign bodies.
In order to minimize the toxicity of the 107 nm particles, the incubation time with
T cells was decreased to 1 hour. As shown in Figure 4.2D, particle uptake is still
saturated within this time frame; therefore exposing T cells to excess SPIO for longer
periods of time was deemed unnecessary. No toxicity was observed with the 107 nm
particles after just 1 hour of incubation.
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Figure 4.3 - Viability of T Cells Incubated With SPIO.

SPIO were incubated with T cells at various iron concentrations: 10 !g/mL [black], 50
!g Fe/mL [white], and 100 !g Fe/mL [grey]. After 4 hours (unless otherwise noted),
viability was measured and normalized to cells grown in the absence of any particles
(blank). All SPIO exhibited negligible impact on cell survival after 4 hours, excluding the
107 nm diameter particles. Reducing incubation time of these particles to 1 hour
eliminated adverse effects at both low and saturating concentrations.
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4.4.5 - Contrast Enhancement
Flow cytometry was utilized to determine the saturating conditions for each SPIO;
however, these single cell measurements were conducted with some variation between
the number of fluorescent labels per particle making it difficult to accurately quantify the
number of particles per cell. Also, after labeling cells with superparamagnetic tracking
agents the critical assessment of ability to track cells is their relaxivity. Therefore, a
benchtop NMR spectrometer, near to the clinical field strength of 1.5 T, was utilized for
evaluating in vitro loading. As shown in Figure 4.4, T cells loaded with particles showed
a dose-dependent, negative contrast enhancement.
As befits their widespread application in the literature, the USPIO proved
effective at lowering the spin-spin relaxation time (T2). Despite delivering only a small
payload of iron per particle, the large numbers of 33.4 nm and 53.5 nm particles that
accumulate in the cells allows for a strong aggregate effect, producing an average T2
signal of 126.05 msec and 51.5 msec under saturating conditions, respectively. These
reduced signal values correlate to an 8.04 and 19.68 times reduction in signal from T
cells without any contrast agent (T2 = 1013 msec).
Performance of particles greater than 200 nm was ranked inversely with diameter.
Greater concentrations of large particles continued to reduce the T2 signal; however,
when the iron concentration was increased above 500 !g Fe/mL the methods used to
distinctly separate loaded-cells from free particles became less reliable. It should be noted
that this drawback does not exist for the flow cytometery measurements, as the particles
themselves could be excluded from the cells based on forward and side scatter. At 150 !g
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Fe/mL, the spin-spin relaxation signal from the 207 nm, 289 nm and 1430 nm particles
were 149.75 msec, 224.3 msec and 398 msec, respectively. These finding suggest that
despite their high R2 values and large iron content, particles greater than 200 nm seem to
have limited applicability in labeling non-phagocytic cells.
The highly-aminated SPIO with a diameter of 107 nm produced the greatest
contrast enhancement. These particles combined the high degree of internalization of the
USPIO with the superior relaxivity of larger particles. At the 1 hour loading time, to
avoid any longer term cytotoxic events, these SSPIO were able to reduce signal by
approximately two orders of magnitude, providing T2 signal of only 12.25 msec, or a
82.74 times reduction in signal from control. This reduction in signal was approximately
5 and 10 times greater than that produced by the 53.5 nm and 33.4 nm SPIO (for the same
concentration).
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Figure 4.4 - Contrast Enhancement.

T2 Relaxation times of T cells labeled with SPIO. T cells were labeled with SPIO of
various size and across a range of concentrations. The T2 relaxivity of 0.5x106 SPIOloaded T cells/mL in 300 µL was measured on a Bruker mq60 MR relaxometer operating
at 1.41 T (60 MHz). The signal decrease observed following internalization of SPIO is
dose dependent and saturation correlates well with values determined by flow cytometry.
The 107 nm SSPIO produced maximum signal decrease.
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4.5 - Conclusions
In this work, efficient iron oxide labeling, without the use of cell penetrating
peptides or transfection agents, was accomplished in a clinically relevant non-phagocytic
cellular system. The level of SPIO loading in T cells was determined by flow cytometry
and verified through evaluation of MR contrast enhancement. Using conditions under
which cell loading was independent of particle concentration, chemical surface
modification, and incubation time, particle size was isolated as an attribute to affect nanoand microparticle loading.
Large particles, over 200 nm in diameter, possess much greater amounts of iron
per particle, and thus theoretically require few or single particles per cell in order to be
detected. However, they suffered from gravitational sedimentation, decreased efficiency
of cell labeling, and in some cases free particles were incompletely removed from cells.
This may not be a problem with adherent and/or phagocytic cell systems, but
significantly hampered their use as magnetic probes for non-phagocytic suspended cells.
The vastly greater number of USPIO that accumulate within the cells made up for
their weaker R2 values. While a general trend correlating increased or decreased particle
size with labeling was not observed, it was clear that the 107 nm SPIO manifestation led
to the largest T2 signal decrease. The observation that SSPIO provide maximal contrast
amongst the SPIO configurations tested here is surprising given the ubiquity of USPIO
and current vogue of MPIO in the literature. These results may have a significant impact
on the SPIO configuration used to label and subsequently track non-phagocytic cells in
vivo.
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CHAPTER 5. B Cell Tracking in SLE Autoimmune Therapy Model
5.1 - Overview
Antibody mediated B cell depletion has been applied successfully to treat nonHodgkin's lymphoma (1). This strategy has been extended in trials to treat systemic
autoimmune diseases which also have B cell related pathologies. When applied to
systemic lupus erythematosus (SLE), a disease in which loss of B cell tolerance plays a
central role (2-5), B cell depleting antibody therapy has not yet demonstrated clinical
efficacy (6-8). Appreciation of the biological response to treatment would be beneficial
for greater understanding of underlying disease mechanisms and insight towards
development of effective therapies (9). Cellular and molecular imaging approaches to
track the in vivo distribution of B cells would allow for the repeated, non-invasive, and
quantitative determination of the extent of B cell depletion therapy effect and duration in
an intact animal.
We have made use of an ex vivo labeling approach to enable small animal
magnetic resonance (MR) and fluorescence imaging to accurately determine B cell
distribution in vivo. Superparamagnetic iron oxide (SPIO) and CellVue 815 near infrared
(NIR) dye were loaded into B cells and subsequently administered to mice. Distribution
of cells over a time course of 15 days, with and without the introduction of B cell
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depleting anti-CD79, was ascertained. The presence of the cells in the spleen was
observed longitudinally, and quantitatively analyzed between treated and non-treated
groups. Ex vivo fluorescence of organs of interest as well as immunohistology of the
spleen was performed in order to describe the fate of the B cells in this system. It was
seen that the cells loaded with SPIO and CellVue 815 were less responsive to
immunotherapy, as compared to cells labeled with CellVue 815 alone. Ultimately, it was
determined that SPIO were interfering with the depleting function of the antibody,
despite their apparent lack of effect in vitro on cell viability and function.
This chapter begins with an introduction to the motivation behind our work on
tracking lymphocytes and the clinical issues associated with the application of B cell
depleting antibody to SLE. Methods of lymphocyte tracking are detailed, with an
emphasis on optical and MR strategies. The development of our approach, the applied
scheme and techniques are comprehensively discussed. Following this introduction, the
results and implications of this work are discussed.
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5.2 - Background; Depletion Therapy
5.2.1 - Anti-CD20 and Non-Hodgkin's Lymphoma
Rituximab is a chimeric anti-CD20 monoclonal antibody used to effectively treat
B cell non-Hodgkin’s lymphoma (1). The antibody consists of the human IgG1 and kappa
constant regions along with mouse variable regions from a hybridoma directed at human
CD20. The mechanism of action of the antibody for therapy is to target and deplete the
CD20+ sub-population of B cells in the patient (10, 11). The exact biological role of
CD20 has not been defined (12, 13), however it is suspected to play a role in signaling
(14). Further, the means by which the antibody binding of this membrane-surface protein
is able to deplete the cells in vivo has not been fully elucidated, although the consensus
view is that cell death occurs by more than one mechanism (12, 15).
The primary methods through which B cells are depleted by anti-CD20 include
apoptosis, complement dependent cytotoxicity (CDC) and antibody dependent cell
mediated cytotoxicity (ADCC). Following administration of rituximab, the in vivo
activation of caspase-3 and -9 have been noted in the blood leukemia cells of patients
(16). It has been shown that this effect is dose and time dependent (17). CDC activity has
been observed as an antibody mediated means of cell disposal. CDC activity, including
complement activation (18), has been correlated to tumor cell death (19) and
translocation of CD20 to lipid rafts (20). Finally, ADCC events mediated by Fc!R have
been shown to be important for B cell depletion. Rituximab has been shown to bind
activation receptors for effector cell mediated cytotoxicity (21). Other means by which
the antibody could deplete the cells, such as antiproliferative effects, have also been
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suggested (22). The success of rituximab for treatment of B cell lymphoma has
encouraged its application in other B cell pathogenic diseases.

5.2.2 – Rituximab and SLE
B cells are a key component of the adaptive immune system and are responsible
for the maintenance of cellular and humoral protective memory. Autoimmune diseases,
including rheumatoid arthritis, systemic lupus erythematosus (SLE) and multiple
sclerosis, are associated with the presence of B cell hyperactivity and/or dysfunction (23).
Their role is central; it has been shown that autoimmune prone mice that lack B cells do
not develop characteristic autoimmune features such as kidney destruction, vasculitis or
autoantibodies (24).
SLE is a systemic autoimmune disorder characterized by autoantibody
production, not restricted to a single organ system, and inflammation of the joints, skin,
kidneys, heart, lungs, blood vessels and central nervous system. B cells are critical actors
in the immunopathogenesis of SLE even beyond the production of autoantibody (25, 26).
Pathogenesis is believed to be mediated through the B cells’ multiple roles as an antigen
presenting cell, involvement in T cell activation and production of cytokines (27, 28).
Rituximab is able to reduce B cells from the peripheral blood nearly completely
on the order of months and has been tested as a treatment for SLE (29). Early results were
promising (30-32), however clinical trials of the antibody have been disappointing (6-8).
For example, a collaborative Genetech and Biogen Idec multicenter Phase II/III trial in
2008 did not meet any of six endpoint goals demonstrating Rituxan (rituximab; Roche
Genentech, Inc, South San Francisco, CA and IDEC Pharmaceuticals, San Diego, CA)
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efficacy over placebo as measured by the British Isles Lupus Assessment Group
(BILAG) index. This metric is a validated clinical measure of lupus disease activity.

5.2.3 – Beyond Rituximab for SLE Immunotherapy
Additional approaches to B cell depletion as a treatment for SLE are in
development. These include other B cell cytotoxic antibodies that target process critical
to B cell function. For example, belimumab is a human monoclonal antibody that binds to
and inhibits the biologic activity of BLyS, which is essential for B cell survival (33, 34).
The fully human nature of the antibody reduces some safety concerns associated with
rituximab over long treatment regimes (81), which may lead to production of human antichimeric antibody (35). Pre- and clinical results to date show that belimumab and
epratuzumab (another humanized monoclonal antibody; targeting CD-22 (36)) can reduce
the levels of circulating CD20+ B cells (34). However, the circulating B cell depletion is
apparently less effective than rituximab (37). Another depleting antibody, anti-CD79,
targets the signaling complex of the B cell receptor (38). In mouse models of
autoimmune disease, it has been shown that B cell depletion was extensive and
contributed to enhanced survival (39).
Counts of peripheral blood lymphocytes are commonly used to assess anti-CD20
therapeutic effect. This method provides a quantitative cellular measurement of global
circulating B cells. However, it is insufficient in determining true therapeutic impact as
depletion from lymphoid tissues has been shown to be highly variable (40, 41). Failure to
deplete in these tissues may well lead to relapse of, or unabated disease. It has become
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apparent that the overall biological impact of the therapy, during the course of treatment,
must be better understood (9).
In animal models, it is possible to harvest spleens and lymph nodes for
lymphocyte subset analysis. However, such an approach is inherently limiting as it
presents an ex vivo, terminal view of these organs. We hypothesize that methods to
measure B cell depletion repeatedly in the intact patient or animal would be of great preand clinical interest. Such techniques would allow for the determination of effectiveness
of a treatment at the cellular level and correlation to clinical benefit without sacrifice. The
next section will provide a detailed account of attempts to track lymphocytes, and B cells
in particular, across a range of imaging modalities.
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5.3 - Background; Lymphocyte Tracking
A variety of methods have been used to study the in vivo distribution of
lymphocytes in animal models and human patients. These include radioactive tracers,
biological reporters, fluorescent moieties and magnetic resonance (MR) contrast agents.
This section will provide a description of these techniques.

5.3.1 - Radioactive Lymphocyte Tracking
A convenient method for the general overview of the distribution of injected
lymphocytes is through the use of radiotracers. Indium-111 labeled lymphocytes were
used to image biodistribution of radiation treated cells over 20 years ago (42). The most
commonly applied clinical radiolabel, [18F]fluoro-deoxy-glucose (FDG), has been used in
a limited number of studies to track lymphocytes, following incorporation in vitro (43).
Major drawbacks associated with this approach are the low incorporation of radiotracer
and, as with all radioactive based imaging, the loss of positron-emitting substance (FDG)
over time (as much as 20% over 1 hour) (44). This limits the duration over which
imaging of distribution can be performed. Further, there are radioactive health related
concerns for both the animals and scientists involved in such studies

5.3.2 - Biological Reporters
Several molecular biology constructs have been employed to enable in vivo
visualization of lymphocytes. These include fluorescent and bioluminescent proteins
which have been used to reveal information about T and B cell development, interaction
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and distribution (45, 46). Bioluminescent imaging (BLI) is a particularly attractive
platform for such molecular imaging applications due to its simplicity, sensitivity and the
ability to obtain temporal information (47). Relevant to the greater understanding of the
use of anti-CD20 antibodies, the luminescent approach has recently been used to quantify
the dose dependent effect of rituximab on luciferase-expressing lymphomas (48).
However, use of such constructs is hampered by the need for extensive animal model
development, depth penetration issues and general limitation to rodent models.

5.3.3 - Optical Methods
Optical tracking methods for the determination of lymphocyte distribution have
been practiced for over two decades (49). Dyes used for B and T cell tracking can be
classified into general categories; DNA-binding (50), cytoplasmic (51, 52), covalently
coupled (53) and membrane-inserting dyes (54, 55). A table, listing commonly used
lymphocyte tracking dyes is provided in Table 5.1. Initially, ex vivo dye-labeled cell
populations' distribution was resolved using microscopic techniques at specific time
points of interest. This approach is inherently limiting as it only allows for proliferation
and migration to be studied in a terminally invasive fashion (52, 56). In a related
approach, flow cytometry can be utilized for the detection of fluorescently labeled cells
from the blood (or tissues processed into single cell suspensions). This technique
provides an optical means to quantitatively determine, with high sensitivity, lymphocyte
proliferation characteristics (57).
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Absorption

Emission

Category

H33342

355

460

DNA

Thiazole Orange

501

547

DNA

Calcein

496

520

Cytoplasmic

BCECF-AM

505

545

Cytoplasmic

FDA

489

514

Cytoplasmic

CFDA

489

517

Cytoplasmic

CFDA-AM

489

517

Cytoplasmic

CFSE

491

518

Cytoplasmic

FITC

494

519

Covalent

TRITC

544

572

Covalent

DiO

484

501

Membrane

DiI

549

565

Membrane

PKH 2

490

504

Membrane

PKH 26

551

567

Membrane

CellVue NIR780 743

776

Membrane

CellVue NIR850 786

814

Membrane

Table 5.1 - Fluorescent Dyes Used for Lymphocyte Tracking
Common names of dyes used for T and B cell studies in vivo and in vitro. Expanded by
Thorek, from (49).
A powerful advantage of optical methodologies is that multiplexing is possible.
This is especially advantageous given the large library of dyes, as seen in Table 5.1. The
labeling of cells with distinct dyes enables subsequent visualization of distinct
populations at the same time (58). In one such approach reported by Roy, et al., two near
infrared dyes were used to concomitantly image distinct lymphocyte populations in
mouse lymphoid and brain tissues (54). An issue that accompanies all dyes is that their
persistent staining is difficult to accomplish. This can be an advantage for proliferation
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studies, where the loss of signal (read from a daughter cell) can be used to estimate the
number of divisions from the labeled cell (59, 60). More often though, the loss of signal
hinders long experimental duration. This also complicates interpretation of results as it is
difficult to discern if reduced signal is from loss of cells or loss of dye. Furthermore,
many of the dyes do not maintain their brightness over longer study lengths and may also
have toxicity issues (57, 61).

5.3.4 - MR Imaging of Lymphocytes
Radioactive methods suffer from poor spatial resolution and the requirement of
additional safety precautions. Optical imaging offers the advantage of high resolution, but
suffers from tissue penetration depth issues. An alternative is magnetic resonance (MR);
an attractive modality with translational capabilities for the long term tracking of cell
populations. High-resolution images over long periods of time, without harm to the
subject, can be performed. To track cells of interest, it is required that contrast agent used
be labeled to the lymphocytes. This is more difficult than the labeling of innate immune
cells, such as macrophage which, as part of their function in the immune system actively
uptake foreign particles. Several strategies have been developed in order to track
populations of lymphocytes in vivo by MR which can be categorized as either 1. In vivo
targeting or 2. Ex vivo loading.
In vivo imaging using to T and B cell targeted-SPIO has previously been
accomplished. Cell selective labeling in vivo with SPIO-antibody conjugates targeting
cells directed by antibody (anti-CD-8, anti-CD-4 and anti-Mac1) enabled specific
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labeling of lymphocytes in a CNS inflammation model (62). Anti-CD20 has also been
coupled to USPIO for in vivo detection of CD20 expressing tumors (63).
In an effort to avoid conjugation of targeting ligands to nanoparticles, charge
based strategies have been pursued to load contrast. Functionalization of SPIO,
covalently or through electrostatic attraction, with cationic materials has been shown to
enable lymphocyte uptake. T cells have been labeled with SPIO particles using poly-Llysine (64) as well as protamine and the HIV-tat peptide (65). The cationic material
mediated loading of particles takes place in vitro and cells are subsequently injected into
another (or back into the cell donating) mouse for subsequent imaging and analysis.
Labeling of lymphocytes without the use of cationic mediators has also been
demonstrated in several ex vivo loading studies. Conjugation of SPIO to a T cell receptor
specific ligand enabled high levels of uptake of these probes through endocytosis into T
cells (CD8+). In vivo delivery of these cells demonstrated longitudinal imaging of
migration to the pancreas in a mouse diabetes model (66). However, the use of cell
specific ligands is restrictive as it involves additional chemical conjugation and
purification steps that result in drastically lower yields.
Visualization of T cells labeled with ultrasmall SPIO (USPIO) has been achieved
ex vivo, without resorting to cationic or targeted labeling means (67). These citrate
coated particles were loaded into tumor directed T cells ex vivo and subsequently
implanted to allow for the high spatial and temporal tracking to the target and nonspecifically to the spleen. Positive contrast detection of lymphocytes, likewise targeted to
tumors, has been demonstrated using manganese salts (the most common T1-w contrast
agent after gadolinium) (68).
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It was shown in Chapter 4 that contrast agent accumulation in non-phagocytic
lymphocytes (cultured human T cells) is possible for a variety of particle formulations. It
was thus possible to determine the loading factors and SPIO characteristics that lead to
optimal cell labeling for MR contrast enhancement (69). We hypothesize that this in vitro
approach can be extended for the sensitive detection and tracking of lymphocytes in vivo.
The robust contrast agent loading of lymphocytes possible using the developed ex vivo
protocol will enable longitudinal, non-invasive in vivo tracking.
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5.4 - Study Design
Our motivation was to determine whether SPIO enhanced MR could be used to
monitor the efficacy of B cell antibody depletion therapy in a mouse model. We sought to
visualize - with high spatial resolution over long times - the migration of B cells using
magnetic resonance (MR) imaging and optical approaches. Four groups of mice were
studied, as indicated in Table 5.2. Each possessed different conditions, with respect to the
combination of contrast employed and/or treatment administered.

Group

GFP B cells NIR dye
(contrast)

SPIO
(contrast)

Anti-CD79
(treatment)

PBS
(treatment)

i

!

!

!

-

!

ii

!

!

!

!

-

iii

!

!

-

-

!

!

-

!

-

iv
!
Table 5.2 - Study Groups.

This framework enabled us to determine if any interfering effects of the SPIO
existed regarding initial distribution or response to treatment. All contrast agents were
loaded into purified GFP B cells in vitro, as illustrated in Figure 5.1A. Validation of the
non-invasive imaging data was made possible through the histological co-localization of
implanted cells, surface NIR dye and internalized SPIO. The use of GFP cells allowed for
the immunohistological staining of B cells in the spleen to be specific for the introduced
population.
Specifically, C57BL/6 mice were imaged over the course of 15 days (Figure
5.1B-C). The contrast-loaded cells were introduced following an initial precontrast
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imaging session. One day following the B cell injection, a treatment of anti-CD79 or PBS
was administered and the effect that each treatment had on the distribution and intensity
of MR and fluorescent signal was quantitatively measured.
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Figure 5.1 - Schematic.
(A) SPIO particles functionalized with amines and subsequently Alexa 680, along with
membrane intercalating near infrared (NIR) dye CellVue NIR815, were incubated with
murine transgenic-GFP B cells. (B) The contrast loaded cells, tail vein injected at t=0 into
C57BL/6 mice, enabled longitudinal imaging by MR and optical techniques. GFP
markers in the implanted B cells allowed for histological correlation of signal and cells ex
vivo. (C) Imaging (in vivo and ex vivo) time points are indicated. Treatment of either
PBS or Anti-CD79 (as indicated) was administered following the t=1 imaging session.
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5.5 - Materials and Methods
5.5.1 - Nanoparticle Synthesis and Modification
Nanoparticles that enabled high levels of MR contrast agent loading into nonphagocytic lymphocytes had been previously prepared (Chapters 3, 4). Briefly, 53.5 nm
diameter iron oxide nanoparticles coated with dextran were synthesized using the coprecipitation technique. All materials were purchased from Fisher Scientific (Hampton,
NH) unless otherwise noted. To 50 mL of dH2O, 25 g of dextran T10 (GE Healthcare;
Piscataway, NJ) was dissolved and heated to 80˚ C for 1 hour. After full polysaccharide
dissolution, mixing overnight and cooling to 4˚ C on ice it was degassed with N2. Iron
chloride salts, FeCl2 (1.5 g) and FeCl3 (4 g), were each rapidly dissolved in 12.5 mL of
degassed dH2O and kept on ice for approximately 10 minutes and added to the dextran
solution. After 30 min of mixing, 15 mL of ammonium hydroxide was added. The
resulting black viscous solution was then heated to 90˚ C for 1 hour then cooled
overnight, followed by ultracentrifugation at 20k RCF for 30 minutes. The supernatant
was continually diafiltrated using a 100 kDa MWCO cartridge (GE Healthcare) on a
peristaltic pump (E323, Watson Marlowe Bredel; Wilmington, MA). The particles were
exchanged into 0.02 M citrate, 0.15 M sodium chloride buffer until all unreacted products
had been removed.
The dextran-coated SPIO were cross-linked in base (25% v/v 10 M NaOH) using
epichlorhydrin (33%) (65). This solution was mixed for 24 hours. Prior to amine
functionalization of the cross-linked dextran shell, a brief 10 minute dialysis into 0.02 M
citrate buffer was performed (8-14 kDa MWCO, 50 mm flat width; regenerated
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cellulose). Following the dialysis, additional ammonium hydroxide was added (25%) to
the activated nanoparticles and mixed for 24 hours. The particles were then exhaustively
purified via diafiltration, against 0.02 M citrate. The resulting particles were amine
functionalized cross-linked iron oxide, SPIO.
Alexa Fluor 680 (Invitrogen; Carlsbad, CA) was dissolved in dimethylformamide
and added to SPIO suspended in pH 9 sodium bicarbonate buffer. The final volume of the
dye was 10% at a 10:1 molar labeling ratio of dye:SPIO. The solution was mixed
overnight and then purified twice through a PD10 gel filtration column (GE Healthcare)
equilibrated with phosphate buffered saline (PBS). Conjugation was verified by
absorbance using a Cary-100 UV-Vis spectrophotometer (Varian; Palo Alto, CA). For
preliminary experiments, fluorescein isothiocyanate (FITC, Pierce Biotechnology;
Rockford, IL) was used in place of Alexa Fluor 680 under identical reaction and
purification conditions.
The cross-linked cationic SPIO functionalized with fluorescent dye will be
referred to as SPIO. This convention is adopted for simplicity and the fact that no other
nanoparticles were utilized in this study.

5.5.2 - Cell Acquisition
Splenocytes were obtained from C57BL/6-Tg(UBC-GFP)30Scha/J (GFP) and
C57BL/6 mice. Animals were culled and their spleen's removed. The spleen was
macerated through a 70 !m strainer placed in a shallow dish. A single cell suspension
was made by running the cells, in Hanks Buffered Saline Solution (HBSS), repeatedly
through a 70 !m screen. The cells were pelleted by centrifugation at 4˚ C, 0.6k rcf for 5
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minutes and resuspended in ACK lysis buffer (Invitrogen), placed on ice for 5 minutes
and centrifuged again.
When required, B cells were purified from splenocytes, derived from the GFP
mice, using a negative selection (70). Harvested splenocytes were centrifuged and
resuspended in PBS + 0.5% BSA + 2mM EDTA (90 !L for every 107 cells). The cells
were then mixed and incubated with CD43 selection microbeads beads (30 minutes) and
isolated using an autoMACS (Miltenyi Biotec; Hamburg, Germany). B cells were those
that failed to bind (i.e. CD43 negative).

5.5.3 - Cell Labeling
B cells were incubated with SPIO (50 !g Fe/mL) in fully supplemented RPMI
1640 (ATCC; Manassas, VA) for 2 hours at 37˚ C, 5% CO2. The cells were washed of
non-internalized SPIO and prepared for CellVue NIR815 dye (NIR, Molecular Targeting
Technologies, Inc; Malvern, PA) labeling by precipitation at 0.5k RCF and resuspension
in protein free media, in triplicate. NIR membrane labeling was conducted following
manufacturers instructions; NIR was diluted from stock by 1/50 to 16 !M in Diluent C,
an iso-osmotic solution with no physiological salts or organic solvents (provided by
manufacturer). The cells were added to this solution rapidly, mixed thoroughly and
incubated covered from light for 4 minutes. Cells were washed from free dye by repeated
centrifugation and resuspension into serum-supplemented media and subsequently PBS.
Fresh 15 mL conical tubes were used for each wash to avoid dye binding to the vessel's
hydrophobic walls. For preliminary experiments, the dye PKH26 (Sigma; St. Louis, MO)
was used under identical loading conditions. PKH26 is a similar lipophilic dye, from
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Success of loading cells with SPIO and dye was verified by fluorescence
microscopy. An Olympus IX 81 motorized inverted fluorescence microscope was used,
equipped with an Ixon (Andor Technology PLC; Belfast, Northern Ireland) monochrome
digital camera, an X-Cite 120 excitation source (EXFO; Quebec, QC) and Sutter
excitation and emission filter wheels.

5.5.4 - Cell Activation
Activation of primary C57BL/6 B cells or splenocytes by incubation with SPIO
was assessed by flow cytometry. In initial experiments to determine whether the SPIO
loading would lead to activation of the B cells, the cells were cultured with SPIO (as
above), washed and maintained in culture for 24 hours. Cells cultured with the SPIO for a
total of 24 hours and cells cultured with increasing doses of PMA (phorbol ester, phorbol
12-myristate 13-acetate; 0.1-10 !g/mL) served as positive control. Cells incubated
without additives represented the negative control. Activation was measured by changes
in surface marker expression. Specifically, fluorescently labeled antibodies against CD40
(PE), CD86 (PE), CD80 (FITC) and MHCII (FITC) were used to label cells after
triplicate purification from culture media to 0.1% BSA in PBS, on ice for 15 minutes
(1/200).
The ability for B cell activation after SPIO loading was determined by loading
splenocytes with SPIO, washing of excess nanoparticles and then incubating with LPS
(E. Coli 055:b5; 0.01 – 10 !g/mL) in fully supplemented media. B cells were identified
from the general splenocyte population by anti-CD19 (APC), and surface marker
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expression was assessed as above. Flow cytometry was performed using a FACSCalibur
(BD Biosciences; Franklin Lakes, NJ).

5.5.5 - Animal Procedures
All procedures were carried out in compliance with the Guide for the Care and
Use of Laboratory Animal Resources (National Research Council, 1996) and approved
by both the University of Pennsylvania's Institutional Animal Care and Use Committee
and the Small Animal Imaging Facility (SAIF) Animal Oversight Subcommittee. All in
vivo fluorescence and magnetic resonance imaging procedures were conducted at their
respective sub-cores at the SAIF at the Department of Radiology in the School of
Medicine.
Four groups of 8 adult (8 week old) male C57BL/6 mice (all mice obtained from
Jackson Laboratories) were placed on AIN-76A low-autofluorescence rodent diet, ad
libidum (Research Diets, Inc.). Six days after food change, animals were tail vein injected
with 20M primary B cells derived from GFP-transgenic mice loaded with either SPIO
and NIR or just NIR.
Three subjects per group were imaged by MR and whole-body fluorescent
imaging at each of the following time points; prior to administration of B cells and , 1
hour, 1 d, 3d, 5d, 7d, 10d and 15 d post-injection. B cell depletion was conducted using
an intraperitoneal injection of 250 !g of Anti-CD79" (HM79-16, Armenian hamster IgG
(39, 71)) immediately following the conclusion of the day 1 imaging session. A
peripheral blood lymphocyte measurement and necroscopy, for ex vivo fluorescent organ
imaging, were performed on one mouse per time point, per group.
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5.5.6 - In Vivo Fluorescence Imaging
Mice were induced with inhalation anesthesia, using in a 4% mixture of
Isoflurane in oxygen. Mice were maintained at a 2% mixture of the gas and shaved on
their left side. Intraperitoneally administered 2-2-2 Tribromoethanol (Avertin; 0.5 mg/g
dose; approximately 200 !L) 10 minutes before imaging was used to keep animals
motionless during acquisition. Spectral fluorescence images were acquired of recumbent
mice, using a Maestro fluorescence imaging system (CRi; Woburn, MA). The red filter
set (excitation range 615 to 665 nm; emission, 700 nm longpass) was used to detect
Alexa680-SPIO and the near infrared filter set (excitation range 710 to 760 nm; emission,
800 nm longpass) enabled detection of the cell membrane bound NIR815. Each spectral
image set was acquired using a 5 sec exposure with acquisition at 10 nm steps through
the emission range. The spectral fluorescence images consisting of the two dyes and the
autofluorescence spectra were then unmixed based on their spectral patterns using
commercial software (Maestro software, CRi). Line intensities were generated through
the long axis of the spleen. Mean intensities of the signal at this organ and background
were computed and averaged for each image.

5.5.7 - MR Imaging
Magnetic resonance imaging was conducted using a horizontal Varian 9.4 T small
animal imaging system (Varian; Palo Alto, CA). Gradient coils were upgraded during the
course of the study, going from a diameter of 14 to 12 cm and an applied field strength of
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10 G/cm to 25 G/cm (both Varian). A dual coil, actively detuned system was employed; a
70 mm receiver volume coil was paired with a 2.5 cm surface coil (InsightMRI, LLC;
Worcester, MA). Mice were induced using inhalation anesthesia, 4% isoflurane, and
maintained for the duration of image acquisition with 2% isoflurane. The animals were
placed on their right side in a split top mouse chamber sled (m2m Imaging; Cleveland,
OH) affixed to a custom built poly-(methyl methacrylate) patient bed. The surface coil
was applied to the left side of the animal and fixed in position using surgical tape to both
the mouse and bed. Temperature and electrocardiography probes were used to monitor
the rats in the 37˚ C environment supplied by an air heating system (SA Instruments, Inc.;
Stony Brook, NY).
Scout scans were used to identify the anatomy of interest. Following recognition
of the spleen axial sections, 1 mm thick, were acquired in a 36x36 mm field of view.
Acquisition sets consisted of np=256, nv=256, under T1-weighted and T2*-weighted
parameters. For the former, a spin echo multi-slice sequence was employed (2 NEX and
TR/TE 2000/40 msec). T2*-weighted scans were taken under two sets of conditions with
increasing echo time (2 NEX, and TR/TE 200/6 (or 200/12) msec). Images were analyzed
by defining an equal area ROI for the spleen and background (paraspinal) muscle. The
relative intensity of the spleen was then calculated and statistical significance for the
image analysis was p<0.05 using a two-tailed parametric analysis.

5.5.8 - Ex vivo Fluorescence Imaging
At each time point, following MR and in vivo fluorescent imaging, one subject
per group was sacrificed. A necroscopy was performed to harvest the spleen, liver, lungs
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and heart. Dual channel (700 nm and 800 nm) fluorescence images were acquired of the
organs on an Odyssey flatbed laser scanning system (LICOR Biosciences; Lincoln, NE).
After imaging was complete, organs were immediately fixed in 4% paraformaldehyde.
The fixation of only one half of the spleen was performed (see below). The mean
fluorescence of each organ was calculated. This value was determined by outlining each
organ from the background using the trace thresholding tool in ImageJ. The mean
intensities of each organ at each time point, for each group, were quantitatively
compared.

5.5.9 - Immunohistology
The excised spleen was bisected prior to fixation (above) and the non-fixed half
was embedded in Optimal Cutting Temperature medium (OCT, Tissue-Tek, Sakura
Finetek Americas, Inc.; Torrance, CA) for cryostat sectioning. Sections (8 !m thickness)
were initially coverslipped under cyanoacrylate ester glue and interrogated for GFP,
NIR815 and Alexa680-SPIO by fluorescence microscopy or using the Odyssey in the 700
nm and 800 nm channels at 21 !m resolution.
The coverslip and glue were subsequently dissolved using an acetone bath for 48
hours which also served to cross-link the tissue. The same slide that had been imaged
using fluorescence microscopy was then imaged for the presence and co-localization of
GFP and nanoparticles. Nanoparticles were revealed by development of samples in
Prussian blue stain. Here, a wash of a 1:1 mixture of 2% potassium ferrocyanide and 2%
HCl for 20 minutes produces blue aggregates at sites of iron oxide (SPIO) deposits.
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Peripheral blood lymphocyte (PBL) counts were determined by flow cytometry.
PBL were obtained from mice at time of organ harvest, purified of red blood cells with
ACK and stained with anti-CD19-FITC (1D3, rIgG2a) and fixed with 4%
paraformaldehyde. Fluoroescent populations (B cells) were assessed using a Guava
Easycyte (Millipore).
The depletion of B cells in the spleen was determined in a similar fashion. A
single cell suspension of splenocytes was obtained from the spleen of treated and
untreated C57BL/6 mice (2 mice per group), 3 days after therapy. The number of B cells
in the spleen was determined by labeling the splenocytes with anti-CD19 (APC) and
measuring the population size on a FACSCalibur.
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5.6 - Results and Discussion
5.6.1 – SPIO Characterization and Cell Loading
Prior to imaging animals using fluorescently modified nanoparticles and dyes, the
spectral characteristics of the cationic 53.5 nm superparamagnetic iron oxide
nanoparticles derivated with Alexa 680 dye (SPIO) were measured. The concentration of
Alexa 680 fluorophores per particle was determined from the difference in absorbance
between labeled and unlabeled SPIO. A spectra of the nanoparticle absorbance
normalized to that of an unmodified particle is shown in Figure 5.2A. Using a standard
curve for nanoparticle concentration and the molar extinction coefficient of the dye
(1840000 M/cm) the number of SPIO and of dye was determined for the absorbance
sample. It was calculated that there were approximately 3 fluorescent molecules attached
per particle.
Primary B cell activation was assessed ex vivo to determine if loading with 53.5
nm SPIO would have a negative impact on the cells' in vivo viability, distribution or
function. Flow cytometry was performed on cells after incubation with particles for 1 or
24 hours and compared to non-labeled and phorbol ester (PMA) incubated B cells, Figure
5.2B. The SPIO did not appear to activate the cells as no increase in CD40, CD86, CD80
or MHCII was observed compared with that of unlabeled control, and expression was
significantly less than activated with 1 !g/mL PMA.
Cells loaded with SPIO and NIR were examined by fluorescence microscopy to
confirm their internalization and the prospects of their in vivo detection, Figure 5.2C-F. It
was found that despite a high iron uptake of the cells (see below) that there was low
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fluorescence from Alexa Fluor 680. It is speculated that this is due to a quenching of the
dye due to its proximity to the iron oxide core of the particles. The labeling of NIR was
rapid and robust, as detection of the cells was achieved with relatively short exposure
time (200 msec).
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Figure 5.2 - Fluorescence Labeling of Particles and Cells.
(A) Normalized absorption spectra of the dye-modified (green) and unmodified (red)
SPIO. The peak at 680 nm is indicative of the presence of the dye. (B) Particles did not
activate primary B cells, as determined by surface marker expression. (C-F) SPIO and
dye loaded primary B cells were imaged, immediately after labeling. (C) White light, (D)
Alexa 680 nm-SPIO, (E) NIR815 and (F) composite. Both contrast agents effectively
labeled cells, however particle-core quenching of the Alexa dye limited its fluorescence.
NIR815 membrane labeling was homogeneous and comparatively bright. All at 20x
magnification.
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MR imaging, initially using mouse cadavers, was carried out in order to develop
the final imaging protocol described in Materials and Methods. Early live animal work
involved both the intraperitoneal and tail vein injection of splenocytes loaded with SPIO
and PKH26. Intraperitoneal injection as a means of administration was abandoned as
migration of the cells to the secondary lymphoid tissues required days. From anecdotal
references and initial imaging results, the slow accumulation of contrast in the spleen was
difficult to verify. In contrast, tail vein injected cells were predominantly found in the
spleen within 24 hours, as seen clearly seen below, in section 5.6.3.
Selection of sequence parameters, through which the T1, T2, T2* or proton-density
weighting could be achieved, was critical for the detection of the contrast agent used. For
SPIO enabled nanoparticle detection of neuroinflammation in a rat model of pain (see
Chapter 6) a T2*-weighted gradient echo multi-slice protocol had been developed. Using
these sequence parameters (echo time; TE = 5.5 msec and repetition time; TR = 200
msec) as a starting point, values were varied in order to investigate effectiveness in
imaging of SPIO-labeled B cells accumulated in the spleen, Figure 5.3. Increase in TR
resulted in significant respiratory motion artifact. Increases in TE enhanced the T2* effect
slightly, however noise increased dramatically. Contrast, determined as the difference in
mean signal between the spleen and background muscle (surrounding the spine), was
assessed for increasing TE. It was found that increasing the TE above 6 msec did not
provide greater splenic contrast. Use of a gradient echo multi-slice sequence with TR/TE
of 200/6, 2 averages, 1 mm thickness and a resolution of 256x256 produced images with
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a CNR of 82.25 for SPIO-B cell injected mice and only 31.67 for PBS injected mice; a
CNR increase greater than two times.
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Figure 5.3 - Preliminary MR and Histology.
(A, B) Representative image acquisitions in the sagittal plane of a mouse injected with
SPIO-loaded B cells. The slices, 1 mm thick, were acquired with a gradient echo
sequence with increasing TE as indicated at the base of each image. Right (rostral) to left
(caudal) organs were identified; including the lungs (Lu), liver (Li), stomach (S), spleen
(arrow and triangle) and kidneys (K) are clearly identified within an isointense region.
Increasing TE produced greater signal decrease at the spleen. (C-H) Evidence of highlyefficient loading of SPIO-FITC and PKH26 into primary B-cells, following their
injection and homing to the spleen. (D, G) PKH26 fluorescence was specific to the
injected animals (562 nm emission). Likewise, (E) FITC channel signal was limited to
autofluorescence in PBS injected as compared to (H) the SPIO-FITC loaded B cells.
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5.6.3 - In Vivo Fluorescence Imaging
Preliminary work confirmed our ability to label primary B cells with both SPIO
MR contrast agents and fluorescent membrane dye. During initial experimentation FITC
and PKH26 were used. These fluorophores are non-ideal for in vivo imaging as they
function at a highly tissue-attenuated region of the light spectrum. For in vivo imaging,
SPIO were subsequently modified with Alexa 680 nm and the cells were membrane
labeled with NIR dyes. Both dyes possess red-shifted excitation and emission profiles
that enable greater tissue penetration (72). The excitation and emission maxima are listed
for each of the fluorescent molecules in Table 5.3.

Fluorophore

Excitation (nm)

Emission (nm)

PKH26

551

567

FITC(SPIO)

494

518

CellVue NIR815

786

814

Alexa Fluor 680(SPIO)

679

702

Table 5.3 - Dye Suitability for In vivo Imaging
Fluorescent molecules for preliminary (top half) and in vivo (bottom half)
experimentation, according to manufacturers (MTTI and Invitrogen).
Using in vivo imaging-suitable dyes, it was possible to detect and monitor the
distribution of B cells in vivo Figure 5.4. All four groups of animals were imaged in the
near infrared red (NIR) channel using a Maestro system. Acquisitions in the deep red
(Alexa-SPIO) channel were also obtained for groups that included SPIO loading. All
mice were placed on a low-autofluorescence diet approximately one week prior to the
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start of the study. This was done to limit background in the deep red channel. However,
even with this precaution, the autofluorescence from (exposed) skin was still significant
in the SPIO channel prior to injection of any contrast, Figure 5.4B. Further, the
quenching of the Alexa Fluor 680 nm fluorescence, through proximity to the iron oxide
core of the SPIO, limited the enhancement of signal following B cell administration. A
similar effect had been noted using in vitro fluorescent microscopy (Figure 5.2).
Prior to injection of cells (day 0) the levels of fluorescence in the NIR channel
were equal to that of background for all groups. Immediately following injection cells
were visualized in the spleen, however there was generally high variability of signal
intensity at this '1 minute' time point. The spleen was easily identified at 1 day, with little
fluorescence observed elsewhere except at sites of the site of the tail vein injection. Here,
it is speculated that a small fraction of the cells and dye may have been injected
subcutaneously and thus required a much longer time to migrate to the spleen or disperse.
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Representative whole animal fluorescence images of mice before and after injection of B
cells loaded with SPIO and NIR contrast. Prior to injection (A-C), significant signal
within the SPIO channel was evident at the dermis (B). Longitudinal imaging of this
mouse, from group A (loaded with both NIR and SPIO; no knockdown), revealed rapid
accumulation of the exogenous population in the spleen and at the sites of the tail vein
injection (D-F). The signal decreased over time to the end time point of the study (J-L).
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To determine the effect of the B cell depleting antibody, anti-CD79, on SPIOlabeled B cells the fluorescent signal intensity in the spleen was quantitatively compared
across the four groups of animals, as outlined in Table 5.2. These groups were antibodytreated and untreated mice with B cells loaded with either SPIO and NIR or NIR-alone:
group i) untreated, NIR and SPIO, group ii) treated, NIR and SPIO, group iii) untreated,
NIR-alone, and group iv) treated, NIR-alone. The mean fluorescent intensity of the
spleen and background and signal-to-background ratio (SBR) were then calculated for
each animal (Figure 5.5). These data revealed that B cells localized to the spleen, within 1
day. In untreated animals that contained B cells membrane labeled with NIR alone, the
signal gradually disappeared over the duration of the experiment (group D). For this
group SBR retention at day 3 was 81.3% of day 1 levels. Untreated mice injected with
cells loaded with both MR and fluorescent contrast (group i) also exhibited a gradual loss
of signal with a SBR on day 3 that was 81.5% of day 1 levels. The continuing loss of
signal over the remaining 11 days for the two groups was also similar.
In animals labeled with NIR-alone and treated with B cell depleting antibody
(group iii) the loss of signal ratio was rapid, with only 41.5% of day 1 SBR ratio
remaining by day 3. While SBR did not return to precontrast levels, likely due to some
residual, non-cleared B cells, the signal continued to decrease gradually over the
remainder of the experiment. However, for mice treated with the B cell depleting
antibody following injection of SPIO and NIR loaded cells (group ii), SBR only
decreased to 68% of day 1 levels at day 3. Continued signal ratio loss occurred on a rate
comparable to that of the non-treated controls.
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Figure 5.5 - In vivo Fluorescence Quantitation.
(A) For quantitative analysis, a user defined line of interest was placed on the (NIR
channel) fluorescent image. (B) The signal intensity along the line was used to generate
values for intensity of spleen signal and background. (C) The signal-to-background ratio,
normalized to the day 1 value by group, demonstrated swift homing of contrast labeled B
cells to the spleen. The ratio decreased gradually over the course of the experiment for
non-knockdown groups (i and iv). In contrast, the metric decreased rapidly for the antiCD79 depleted group containing B cells loaded with only NIR (iii). However, no
depletion was observed in mice injected with cells loaded with both dye and SPIO, as
measured by fluorescence (ii). Groups; i – untreated, NIR and SPIO, ii – treated, NIR and
SPIO, iii – untreated, NIR-alone, and iv – treated, NIR-alone.
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5.6.4 - MR Imaging
The biodistribution of B cells labeled with both SPIO and NIR was also observed
by MR (Figure 5.6). Changes in relative signal normalized to day 0 (pre-contrast)
between the spleen and back muscle changed significantly following injection with
SPIO-loaded B cells (groups i and ii). Over the following two weeks, the normalized
signal ratio gradually increased towards pre-contrast values. There was no statistically
significant change (p>0.05) in the normalized intensity ratio for mice given cells labeled
with NIR-alone (groups iii and iv). Thus, detection of the migration of the exogenous cell
population to the spleen required the presence of SPIO. However, it was observed that the
normalized signal ratio for the spleen gradually decreased following treatment of SPIOfree mice (group iii; NIR-only with anti-CD79 treatment). Possible changes to the MR
T2*-weighted signal of the spleen, through antibody mediated depopulation of the organ,
could have such an effect over time. To our knowledge, this observation has not
previously been presented in the literature regarding rituximab treatment and imaging.
Similar to the observations and measurements of in vivo fluorescence, in animals
with SPIO-labeled B cells, relative signal changes were small between antibody treated
and non-treated groups. There was an observed difference in signal intensity ratio at
approximately 9 days following antibody injection. Nevertheless, for all other time
points, differences between depleted and non-depleted mouse specimens that could be
detected were non-statistically significant.
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Figure 5.6 - MR Imaging of B Cell Distribution
(A-C) Representative axial T2*-weighted images of mice either pre-injection or on the
indicated days following injection of SPIO-loaded B cells (group i). Signal in the spleen
(arrow) decreased following cell introduction but gradually recovered over the duration
of the experiment. (D) Relative signal intensity was calculated as the ratio of spleen and
background muscle (an average) from user defined ROI. (E) Groups given SPIO-labeled
B cells demonstrated rapid and pronounced relative signal changes normalized to precontrast (i and ii). There was no significant change in spleen signal for groups devoid of
SPIO (iii and iv). Echoing the fluorescent data, there was also only limited difference in
the normalized relative signal between treated (ii) and non-treated (i) groups that
possessed SPIO-loaded B cells.
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5.6.5 - Ex vivo Fluorescence
Consistent with findings from whole body fluorescent and MR imaging, the
distribution of B cells as determined by ex vivo fluorescence indicated that homing to the
spleen was rapid. The normalized mean fluorescent intensity (MFI) for each group,
normalized by organ, is shown in Figure 5.7.
Homing of the re-administered B cells was almost entirely within the spleen,
Figure 5.8A (non-normalized MFI). Some fluorescence in the liver, 1 day after cell
injection, was also noted for all groups. In line with in vivo whole body fluorescent and
MR imaging of the spleen, maximum signal was attained in the spleen (and all other
organs) 1 day after injection and gradually decreased thereafter.
These organ specific fluorescent data also confirm that there is no significant
difference between splenic signal in the treated and non-treated SPIO-labeled groups,
Figure 5.8B. B cells were in some way inhibited from antibody-mediated depletion
following intracellular loading of SPIO nanoparticulates. This effect was not a result of
the B cell acquisition and purification protocol, as cells obtained and labeled with NIRalone were robustly and rapidly depleted from the spleen.
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Figure 5.7 - Ex vivo Fluorescence; By Group.
(A-D) The distribution of B cells by organ (spleen, liver, heart and lungs) for each group
is shown, as determined by the mean fluorescence intensity (MFI) normalized to the day
1 intensity of each organ. For groups in which SPIO-labeled B cells had been
administered to mice, there was a gradual decrease in fluorescence over two weeks (ii)
with or (i) without introduction of antibody therapy. This paralleled the slow decrease in
organs of signal from (iii) NIR-only labeled, non-depleted mice. A rapid decrease in MFI
was measured after (iv) anti-CD79 therapy of NIR-only labeled B cells. Here, groups i, ii,
iii, and iv correspond to A, B, C and D. (E) A representative false-coloured organ scan in
the 800 nm (NIR) channel.
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Figure 5.8 - Ex vivo Fluorescence; Absolute and Normalized Splenic Comparison.
(a) The non-normalized MFI, for group B, illustrates the predominance of spleen-targeted
distribution. (B) Normalized MFI of the spleen alone, for each group, is plotted for the
length of the experiment. Little difference was detected between the groups outside of
antibody-treated, NIR-only (SPIO-free) group iii.
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5.6.6 –Cytometric Analysis and Histological Correlation
Through longitudinal MR and fluorescent imaging it was apparent that there
existed a discrepancy between the signal changes of treated animals from SPIO-and-NIR
loaded (group ii) and NIR-alone labeled B cells (group iii). In order to verify that the
anti-CD79 immunotherapy was effective towards the depletion of B cells, blood was
obtained from a mouse at each time point, for each group. The number of B cells, as
detected by fluorescently-labeled anti-CD19, was assessed relative to the total
lymphocyte count, Figure 5.9A. Further, the splenic B cells depletion by antibody was
also investigated, Figure 5.9B. It was apparent from these data that the anti-CD79 was
indeed effective at reducing the number of B cells throughout the organism, if only for a
time.
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Figure 5.9 – Assessment of Depletion.
These figures indicate that the depletion of B cells was successful, using both a (A)
global and (B-D) spleen-specific measure. (A) The peripheral blood lymphocyte
quantification in untreated (i) and treated (ii) mice, into which SPIO and NIR loaded B
cells had been administered. The arrow indicates the time of administration of
immunotherapy (following day 1 image acquisitions). Within the spleen, B cell counts
also decreased significantly following anti-CD79 therapy. (B) Unstained single cell
suspension from spleen. (C) Anti-CD19 (APC) stained splenocytes from untreated
animal. (D) Decreased number of B cells are detected following therapy. Average gated
proportion of population for two mice 4 days after B cell introduction.
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B cells were successfully being depleted by the immunotherapeutic treatment and
not by sham PBS injection. This led to supplementary investigation of what role SPIOloading had on the primary B cells, which apparently reduced their clearance, despite
achieving this effect globally and within the spleen. Specifically, surface marker changes,
as an indication of activation, were assessed to determine if the cells could be activated
following loading by SPIO. LPS was used to activate the cells as a positive control. SPIO
(non-fluorescently labeled, so as not to interfere with flow cytometry) were incubated
with the cells under two conditions. The first was a recapitulation of the preliminary
experiment to determine if the particles, when loaded during a two hour period, led to
activation over the subsequent 24 hours (see section 5.6.1). To assess the ability of loaded
B cells to become activated, SPIO were again loaded over 2 hours, but following washing
away of excess particles, the cells were incubated with LPS for a 24 hour period. The
results, shown in Figure 5.9, indicate that the SPIO do not inhibit the ability of the B cells
to become activated, as assessed by surface marker differentiation.
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Figure 5.10 – B Cell Function and SPIO Loading
Surface marker expression was assessed to determine the ability of B cells, following
SPIO-loading, to activate. The blank group are primary splenocytes cultured for 24 hours
in fully supplemented media. Activated cells were seen following incubation with LPS
over 24 hours (0.1 !g/mL). Loading of cells with particles, SPIO (2h), again assessed the
ability of SPIO to incidentally activate the cells. To determine if B cells could be
activated following SPIO-loading, as used for the in vivo imaging experiments, labeled
splenocytes were incubated with LPS for 24 hours, SPIO (2h LPS). The loaded cells
appear to be able to undergo LPS mediated activation.
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Histological analysis of the excised and axially sectioned tissue was also
performed. These studies were undertake in order to confirm that SPIO, NIR and GFP
signal correlated within the spleen over the course of the anti-CD79-depletion monitoring
experiment. Co-localization of the contrast agents with the exogenous cells is an
important control to verify that the signal (or reduction in signal for MR) detected was
not due to non-specific distribution of the agents outside of the cells following injection.
For example, an initial concern was that anti-CD79 mediated depletion through ADCC
processes would lead to the accumulation of originally-B cell loaded agents in
macrophages.
In the initial examination, a relatively novel protocol was employed in order to
examine fluorescent intensity data from all samples simultaneously, at the sub-organ
scale (54). For our purposes, this allowed for the direct observation of splenic tissue
fluorescence in all groups at multiple time points. Images of the NIR fluorescence
indicated clearly that the signal intensity decreased as a function of time following loaded
B cell injection. Disappointingly however, the lack of SPIO channel fluorescence made it
impossible to directly correlate SPIO and NIR signal within the spleen. Fluorescence
microscopy was also used to co-localize fluorescent signals, Figure 5.12. Despite high
levels of autofluorescence in the GFP channel, correlation between sites of GFP, NIR and
SPIO fluorescence could be made. Further, this signal was specific to GFP-B cell injected
mice.
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Figure 5.11 – Laser Scanning Histology
An application of moderately high-throughput histological laser scanning of splenic
tissues. The samples were embedded in OCT and fresh frozen. Following axial (or axialbiased oblique) sectioning at 8 !m, the samples were placed directly onto an Odyssey
laser scanner. With a resolution of 21 !m, it is possible to discern with moderately-highresolution the fluorescent signal from the spleen. (A-D) (A) No NIR signal is present in
control tissues (mice without B cell injection). The decrease of NIR signal (800 nm
channel) of group i samples (NIR- and SPIO-loaded) from (B) day 1 through (C) day 5
and finally, (D) day 15. All images have identical brightness and contrast values. The
flatbed scanning profile allows for acquisition of numerous samples at the same time,
lower magnification (F).
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Figure 5.12 – Histological Co-localization.
(A-D) Representative images of the spleen of a mouse without administration of B cells.
(A) Despite the absence of any green fluorescent protein, there is still considerable
fluorescence in this low wavelength channel. There is little detectable cellular signal in
the (B) SPIO or (C) NIR channels, as shown on (D) the composite image. (E-F)
Representative images of the spleen an untreated mouse 7 days after injection of B cells
loaded with both SPIO and NIR, group i. (E) Despite the comparable background
autofluorescence in the GFP channel, there were distinct, punctate areas of increased
signal. These localized well with the (F) SPIO and (G) NIR fluorescence channels. The
composite image shows that indeed there is considerable overlap of all three channels
(arrows), apart from the background autofluorescence. All images taken at 40x
magnification.
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5.7 - Conclusion
The immune system is a dynamic and highly coordinated assemblage of proteins
and cell types that protect the body from foreign invaders. Lymphocytes are the
mediators of adaptive immunity and are able to migrate throughout the body as well as to
specific sites of the lymphatic system including the thymus, lymph nodes and spleen. In
order to analyze this complex series of events, procedures are required that can
simultaneously track the migration of lymphocytes into different tissues. This is
especially relevant when the system operates in an abnormal fashion.
Autoimmune disorders, such as systemic lupus erythematosus present a host of
clinical manifestations that impact quality and length of life (73, 74). Successful
application of B cell depleting antibody, which has been shown to be effective in
treatment of non-Hodgkin's lymphoma (1) and rheumatoid arthritis (75), to SLE has been
elusive (9). Understanding the distribution of autoimmune disorder relevant populations,
such as B cells, prior to and following attempted therapy would permit the determination
of effectiveness of treatment with respect to duration and extent. Here, we investigated
the use of non-invasive cellular and molecular imaging approaches for the repeated
measurement of B cells longitudinally.
We have shown the ability to effectively load superparamagnetic iron oxide
nanoparticles (SPIO) into lymphocytes (69). This was accomplished without the use of
potentially toxic exogenous agents (76-78). The 53.5 nm diameter aminated and crosslinked dextran-coated SPIO nanoparticles were able to effectively label non-phagocytic
lymphocytes and showed significant T2*-weighted contrast. When used to label primary
murine B cells no significant activation, as determined by surface marker expression, was
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noted. Cells labeled with these fluorescently-labeled agents could be identified under
fluorescent microscopic observation, however the brightness of the fluorophore used, the
Alexa Fluor 680 nm dye, was apparently quenched by the iron oxide core of the
nanoparticle to some degree. Due to this effect, and a desire to have multimodal cell
tracking capabilities, a second cellular marker was introduced, the CellVue NIR 815 nm
membrane labeling dye (NIR). With NIR we demonstrated the ability to effectively label
the primary B cells with the required concentration to enable in vivo fluorescent
detection.
Contrast loaded B cells homed quickly and specifically to the spleen. This was
determined non-invasively in all groups by a specific signal increase in the spleen by
fluorescence imaging. Here, a signal-to-background ratio of approximately 30 times was
recorded for all groups. Hypointensity of the spleen in MR T2*-weighted imaging for
SPIO and fluorescently labeled cells confirmed a multimodal capability to detect the
presence of an introduced cell population. Relative to pre-injection values, there was an
approximate 40% change in normalized signal intensity ratio 1 day after cellular
administration. This correlated with fluorescent signal increases in both ex vivo imaging
techniques, organ laser scanning and histological evaluation.
For mice in groups that were treated with PBS there was a gradual loss of MR and
fluorescent signal (in vivo and ex vivo) over time. By the final imaging time point, MR
signal ratio had returned to within statistical error of the pre-injection values. Similarly,
after 15 days only 40% of the fluorescent signal (determined by signal-to-background
ratio) remained in the spleen relative to day 0 levels.
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In treated groups, significant differences in the change in signal following
treatment were seen between the MR-and-NIR and NIR-alone loaded lymphocytes, under
all modalities of imaging. MR contrast generation in the spleen had been found to be
specific for SPIO loaded cells; no contrast developed between the spleen and background
muscle when lymphocytes with NIR-alone had been introduced. However, there was no
significant change in signal intensity ratio between the two SPIO-loaded B cell groups;
PBS and anti-CD79 treated. Using fluorescence whole body imaging, these results were
essentially recapitulated. It was seen again that there was little difference in the splenic
signal between the two SPIO-loaded groups.
These results were quite distinct from the fluorescent spleen intensity over time in
animals injected with B cells that had only been label with NIR dye. Unlike the gradual
loss of signal trending towards the pre-injection level, a rapid decrease in signal-tobackground was observed in anti-CD79 treated mice. These results were confirmed by ex
vivo organ and histologically prepared tissues for fluorescent measurements. It was found
that signal from the organs, once resected, reported similar outcomes. Namely, the
fluorescent intensity was specific to the spleen and decreased rapidly only for the antiCD79 treated NIR-only loaded mice.
Flow cytometry of blood at terminal imaging time points was collected in order to
determine the effectiveness of antibody treatment in depleting circulating B cells. From
these data it was seen that depletion therapy was successful in removing a significant
proportion of the circulating B cell population. This outcome was seen in both treated
groups (dual-labeled and NIR-only), while the peripheral blood lymphocyte values varied
little for the PBS injected animals. Further, splenic B cell quantification, also by flow

Chapter 5
210
cytometry, indicated that the number of B cells decreased significantly following
treatment, as compared to untreated control. With the knowledge that the antibody was
indeed effective upon administration it was apparent that the SPIO nanoparticles were in
some way influencing the depletion of the labeled, introduced B cells in the location to
which they had accumulated, the spleen. Determination of the biochemical or physical
means of this inhibition is extremely difficult. It is impossible to mimic the specific and
complex microenvironment of this organ ex vivo. This would be required in order to
discern the role that each chemical, mechanical and biological factor may have in the
therapeutic efficacy of the antibody mediated depletion. However, in an initial attempt to
determine the possible effect of SPIO loading on B cell function, a post-loading
activation study was presented. Here, it was shown that B cells can be activated by LPS
as determined by surface marker expression in flow cytometry.
These results indicate clearly that detection and tracking of an introduced
population of B cells is possible using SPIO nanoparticles. However, the outcome of little
apparent signal ratio change in either MR or optical modalities indicates that the
approach of ex vivo loading these contrast agents are inadequate to the task of monitoring
therapeutic efficacy. This is a particularly interesting conclusion from the standpoint of
the application of nanomaterials in biological, and especially biomedical, settings. It also
serves to highlight a concern for the use of MR approaches to track lymphocytes in a
similar fashion to the extant drawbacks associated with radiotracer and optical
approaches.
In a recent study comparing bioluminescent and SPIO approaches to non-invasive
cell tracking, it was found that the SPIO used exhibited an extended residence lifetime in
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vivo, regardless of the presence or state of the cells they were supposedly meant to track
(79). This led to the conclusion that bioluminescent proteins were a better marker of
myocardial cell survival kinetics than MR through SPIO. We have found that the change
in signal from MR and optical techniques do not mimic the distribution profile of cells
tracked without SPIO. It should be noted that the present study’s findings do not correlate
exactly with the recently published work finding fault with SPIO. We were able to
determine a co-localization of SPIO, NIR and B cells. And in fact, others have indeed
shown that SPIO and bioluminescene are both effective imaging approaches to determine
the presence of stem cell transplants to injured cardiac tissue (80).
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CHAPTER 6. Comparative Analysis of Nanoparticle-Antibody Conjugations:
Carbodiimide Versus Click Chemistry
6.1 - Abstract
Ex vivo labeling of contrast agents into cells affords high levels of loading for
subsequently sensitive in vivo detection. However, as we have shown in the previous
chapter, the ex vivo loading of superparamagnetic iron oxide (SPIO) nanoparticles into B
cells inhibited the cells ability to be depleted using an antibody therapy. In vivo targeting
of cells offers an alternative approach; wherein the cells are labeled in vivo using
systemically delivered particles. While achieving lower contrast delivery per cell, these
methods still allow for non-invasive detection. The major advantage of this strategy
applied for the monitoring of B cell response to immunotherapy would be to avoid the
onerous requirements of extracting, purifying and loading B cells, and their possible
dysfunction as a result.
Typically, in vivo applications require functionalizing the nanoparticles directly
with targeting agents. The ability to modify the physical, chemical, and biological
properties of nanoparticles (NPs) has led to their widespread use as multi-functional
platforms for drug delivery and diagnostic applications. Antibodies (Ab) remain an
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attractive choice as targeting agents because of their large epitope space and high affinity;
however, implementation of Ab-NP conjugate strategies are plagued by low coupling
efficiencies and the high cost of reagents.
Click chemistry may provide a solution to the problem of Ab-NP probe
manufacture with reported coupling efficiencies nearing 100%. While click chemistries
have been used to functionalize nanoparticles with small molecules, they have not
previously been used to functionalize nanoparticles with Ab. Concerns associated with
extending this procedure to Ab is that reaction catalysts or the ligands required for crosslinking may result in loss of functionality. Here, we document the evaluation of the
efficiency of conjugations between Ab and superparamagnetic iron oxide NPs using click
chemistry. Results were compared with conjugates formed through carbodiimide (EDC)
cross-linking. The click reaction allowed for a higher extent and efficiency of labeling
compared with EDC thus requiring less Ab. Functional assessment of these probes in an
in vitro cell labeling schema has also been performed. In comparison to EDC, conjugates
prepared via the click reaction exhibited improved binding to target receptors.
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Nanoparticles (NPs), commonly defined as organic or inorganic materials with at
least one length dimension below 100 nm, are being widely investigated as drug delivery
vehicles and/or imaging agents. Interest in NPs largely stems from their ability to carry a
large therapeutic payload (or ample amounts of contrast agent), the ability to finely tune
physicochemical

properties,

which

can

influence

their

pharmacokinetic

and

pharmacodynamic profiles, and the ability to functionalize their surface with molecularly
specific targeting agents. For both diagnostic (1) and therapeutic (2) purposes, including
immune cell relevant applications, it is becoming increasingly recognized that specific
targeting of NPs is critical towards their effective use.
Ex vivo loading of a particulate agent is a proficient means to achieve high
intracellular payloads of contrast or therapetic agents. An example of this approach was
detailed for in vitro (Chapter 4) and in vivo (Chapter 5) applications. However, this
method requires that the cells of interest be removed, often quite abrasively from an
organism or patient, for example in the case of splenocyte purification. Such an approach
is well suited for some applications, but not in situations when invasive attainment of a
cell population would be detrimental to its further study.
In vivo targeting of NP is a more sophisticated approach wherein agents are
directed with some engineered-specificity towards cells of interest. When targeted,
reduced amounts of therapeutic and imaging agents are required compared with
systemically delivered non-specific vehicle (3). Furthermore, targeting greatly reduces
nonspecific background signal from accumulation of contrast agents at undesirable sites
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when compared to non-targeted NP. Together, lower dose and greater specificity reduce
undesirable toxicity and lead to improved efficacy of therapeutics.
Superparamagnetic iron oxide nanoparticles (SPIO) are a widely used NP system
affording T2*-weighted contrast for magnetic resonance (MR) imaging applications (4).
Recently, SPIO have been conjugated to a variety of targeting ligands to provide cellular
and molecular specificity for in vitro diagnostic (5) and in vivo imaging (6) applications.
Strategies for targeting SPIO most often include the use of peptides, endogenous ligands
and monoclonal antibodies (7-9).
Despite their relatively large size (roughly 150 kDa) antibodies remain an
attractive choice because of their combinatorially large epitope space (of approximately
1015) and their high affinity for targets with Kd’s often on the order of nM (10).
Antibodies also have the additional advantage of being widely pursued for use in pre- and
clinical applications for the therapy of prevalent disorders. Antibody therapies for cancer
such as Trastuzumab (targeting Her2/neu) (11), for inflammatory disorders such as
Infliximab (an anti-TNF antibody) (12) and antiviral antibodies such as Palivizumab
(targeting respiratory syncytial virus) (13) are used to study and treat disease globally.
Currently, one of the greatest obstacles facing the use of NP-antibody conjugates
is the low efficiency of Ab coupling to NPs, which can result in the need for large
quantities of antibody and prohibitive costs (14). One example of a common approach
used for conjugation of antibodies to NPs involves carbodiimide cross-linking (15). The
zero length cross-linker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC) reacts with carboxylated NPs in the presence of sulfo-N-hydroxylfosuccinimide
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(sulfo-NHS) to form amine-reactive sulfo-NHS esters. Subsequent addition of antibodies
results in coupling between the NPs and primary amines on the antibody via a stable
amide bond. Unfortunately, the reaction is non-ideal as it is highly inefficient and thus
requires a high excess of antibody. Typically, only about 1-20% of the antibody used
during the conjugation procedure will be coupled to the NP (9, 16, 17).
Click chemistry refers to modular chemical conjugations with an emphasis on
simple reactions that can take place under a range of conditions with stereospecificity and
high efficiency (18). Recently, the emergence and adoption of the click chemistry
philosophy has had a large impact in drug discovery and materials synthesis. The rapid
rise of click chemistry is evident from its novel use in a variety of disciplines including
medicinal chemistry (19), materials and polymer science (20, 21) and molecular imaging
(22, 23). The most widely adopted reaction of this type, the CuI-catalyzed terminal
alkyne-azide cycloaddition (CuAAC), was developed by the Sharpless and Meldal groups
independently in 2002 (24, 25).
Previously, it has been shown that the coupling of low molecular weight species
such as peptides (26) and fluorophores (27) to SPIO can be accomplished with CuAAC.
However, evidence that functional antibodies can be coupled to SPIO through CuAAC is
lacking. Likewise, reference of large protein linkage to any NP system using a click
approach is scarce. Gupta et al. have briefly described holo-transferrin bound viral
capsids, although this was reported by way of TEM (transmission electron microscopy)
micrographs (28). Lipases have been conjugated to gold nanoparticles and retained their
function (29), however a major concern with using CuAAC for NP-antibody coupling
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reactions is that the antibodies will be irreversibly degraded and/or modified during the
reaction. For example, it has previously been shown that the CuAAC reaction can result
in the irreversible degradation of viral capsids (30) and nucleic acids (31). Further,
antibodies could become non-functional due to modification of the innate protein with
click reactive ligands.
In this work we evaluated the use of CuAAC for conjugation of SPIO to antiCD20. Anti-CD20 is a clinically approved chimeric monoclonal antibody that has been
therapeutically approved for use in treating B cell lymphoma. This antibody has also been
used previously to target SPIO to CD20 expressing tumors (32). We have sought to
comparatively assess the utility of the CuAAC reaction for antibody targeting of SPIO
against an accepted method, that of carbodiimide conjugation. Particle labeling was
assessed for both strategies by means of the efficiency and extent of protein-to-particle
labeling and by functional cell-targeting assays. It is our expectation that determination of
best practices for Ab-NP production will significantly impact their ability to be applied in
biomedically relevant situations.
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6.3.1 - Materials
Azido-dPEG12 NHS ester and Propargyl-dPEG NHS ester were purchased from
Quanta BioDesign Ltd., (Powell, OH). The nanoparticle coating material, dextran T10,
was purchased from Amersham Biosciences (now GE Healthcare, Piscataway, NJ).
Reagent grade IgG (Immunoglobulin G) from rat serum was acquired from Sigma
Aldrich (St. Louis, MO), while anti-CD20 antibody, Rituximab, (Genentech, South San
Francisco, CA) was a gift of the Eisenberg group. Human lymphoma B cells (Burkitt
GA-10) were obtained from ATCC (Manassas, VA). Bathocuproinedisulfonic acid (BCS)
was acquired from Acros Organics (Geel, Belgium). All other reagents were purchased
from Thermo Fisher Scientific (Waltham, MA), unless otherwise noted.

6.3.2 - SPIO Synthesis and Amination
SPIO were prepared by chemical co-precipitation, as previously described in
Chapter 3 and reference (33). Briefly, 0.7313 g FeCl2 and 1.97 g FeCl3 were each
dissolved in 12.5 mL diH2O and added to 25 g dextran T10 in 50 mL diH2O at 4˚C.
Ammonium hydroxide (15 mL) was slowly added to this mixture turning the light yellow
colored solution black. This nanoparticle slurry was then heated to 90˚C for 1 h and
cooled overnight.
Purification of SPIO was accomplished by ultracentrifugation of the mixture at
20K RCF (relative centrifugal force) for 30 min. Pellets were discarded and the
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supernatant was subjected to diafiltration against greater than 20 volumes of 0.02 M
citrate, 0.15 M sodium chloride buffer, using a 100 kDa cutoff membrane filter (GE
Healthcare). The purified particles were then cross-linked by reacting the particles (10
mg Fe/mL) with 25% (v/v) 10 M NaOH and 33% epichlorohydrin. After mixing for 24
hours, the particles were briefly dialyzed and then functionalized with amines by adding
25% ammonium hydroxide. This reaction was allowed to continue for another 24 h
followed by diafiltration as above.

6.3.3 - SPIO Characterization
The hydrodynamic diameter of the nanoparticles was measured using a Zetasizer
Nano-z (Malvern Instruments, Malvern, UK) through dynamic light scattering (DLS).
SPIO particles were diluted in PBS to a concentration of approximately 0.5 mg Fe/mL
and read in triplicate. The values reported for all samples are the intensity peak values.
The longitudinal (R1) and transverse (R2) relaxivity of each particle was
calculated as the slope of the curves 1/T1 and 1/T2 against iron concentration,
respectively. T1 and T2 relaxation times were determined using a Bruker mq60 MR
relaxometer operating at 1.41 T (60 MHz). T1 measurements were performed by
collecting 12 data points from 5.0 to 1000 msec with a total measurement duration of
1.49 minutes. T2 measurements were made using ! = 1.5 msec and 2 dummy echoes, and
fitted assuming a monoexponential decay.
The number of amines per particle was determined following the general
procedure described by Zhao et al. (34). Briefly, iron oxide particles at a concentration of
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2 mg/mL Fe were reacted with excess N-Succinimidyl 3-(2-pyridyldithio) propionate
(SPDP, Calbiochem, San Diego, CA) for 4 hours. SPIO were washed of excess SPDP
through repeated precipitation in isopropanol and resuspension in PBS. The particles
were then run through a 50kDa MWCO centrifugal filter (YM-50, Millipore, Billerica,
MA) either with or without the addition of the disulfide cleavage agent (tris(2carboxyethyl)phosphine) (TCEP). The difference of the absorbance of these two samples
at 343 nm was used to determine the concentration of SPDP in the filter flow. Adjusting
for dilution, the number of amines per particle was determined.

6.3.4 - FITC Modification of SPIO
Fluorescein-isothiocyanate (FITC) was used to fluorescently label aminefunctionalized cross-linked SPIO by reacting at a molar ratio of 19:1 FITC to iron. The
unbound FITC was washed from the FITC-SPIO using a PD10 gel filtration column (GE
Healthcare) equilibrated with phosphate buffered saline (PBS). All particles were FITClabeled prior to subsequent modification, ensuring that all particles had equal fluorescent
labeling.

6.3.5 - Carboxylation of SPIO
A schematic outlining the carbodiimide cross-linking procedure is illustrated in
Figure 6.1A - strategy i. FITC labeled, amine-functionalized NPs (as shown in Figure
6.1B) were derivatized to acid residues following reaction with an excess of succinic
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anhydride in basic solution. Specifically, 200 !L of NH2-SPIO (5 mg Fe/mL) in 0.02M
citrate buffer, pH 8 was added to 10 !L of 1 M NaOH followed by 10 !L of 4 M succinic
anhydride in DMF. The reaction was allowed to mix for 4 hours. Carboxylated-SPIO
(COOH-SPIO) were subsequently precipitated three times in 4 volumes of isopropanol to
remove free reactants.
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Figure 6.1 - Schematic of Antibody-SPIO Conjugation Strategies.
(A) Fluorescently labeled, amine functionalized SPIO were reacted along one of two
routes to produce antibody-SPIO conjugates. In strategy (i) carbodiimide chemistry is
utilized, following the conversion of the surface amines to COOH groups utilizing
succinic anhydride. In strategy (ii), antibody-labeled SPIO are produced by employing
CuI-catalyzed terminal alkyne-azide cycloaddition (CuAAC). Azide-modified SPIO are
“clicked” to alkyne-labeled antibodies in the presence of copper. (B) Schematic
illustrating the preparation of FITC-SPIO. (C) Schematic illustrating the alkyne-PEG
modification of antibody, which was necessary for the CuAAC reaction.
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6.3.6 - Carbodiimide Conjugations
Carbodiimide coupling reactions were accomplished with FITC labeled COOHSPIO in 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 6.0. To 50 !L of SPIO
(2 mg Fe/mL), 10 !L each of 200 mM EDC and 500 mM sulfo-NHS was added.
Solutions mixed for one hour at 25˚C, were then precipitated in 500 !L of isopropanol. A
resuspension of the NPs in 100 !L of 10 mg/mL antibody solution in PBS, pH 7.4 was
allowed to react at 15˚C overnight. Purification was carried out using a MS magnetic
column in PBS.
The BCA Protein Assay was used for protein concentration of conjugate
solutions, after correcting for background with unlabeled SPIO. To determine number of
protein per particle, the molarity of SPIO was assessed spectrophotometrically by
dissolving the NPs and oxidizing the iron with 6M HCl and 3% H2O2. Absorbance at 410
nm was compared to a standard curve and particle concentration was calculated assuming
8924 Fe atoms per particle, as previously determined (33).

6.3.7 - Azide Modification of SPIO
A schematic outlining the CuAAC cross-linking procedure is found in Figure
6.1A - strategy ii. FITC-SPIO was reacted with the amine-reactive azido-dPEG12 NHS,
diluted 10 times from stock in dimethyl sulfoxide (DMSO), in 0.1 M sodium phosphate
buffer, pH 9. The linker was added at 100 times molar excess to the SPIO. After mixing
for 4 hours, the SPIO were purified twice on PD10 columns equilibrated with PBS.
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Azide-SPIO was then concentrated on an Ultracel 30k centrifugal filter (Millipore,
Billerica, MA) in PBS.

6.3.8 - Alkyne Functionalization of Antibodies
Alkyne functionalization of antibodies, for both IgG and Rituximab as seen in
Figure 6.1C, was accomplished by addition of 10% v/v propargyl-dPEG-NHS in DMSO
to 10 mg/mL antibody in 0.1M sodium phosphate buffer, pH 9. The concentration of
propargyl-dPEG-NHS was varied to provide different degrees of labeling per antibody.
Antibody was purified on a PD10 column equilibrated with PBS and then re-concentrated
using Ultracel 30k filters. Antibody concentration post-purification was assessed
spectrophotometrically at 280 nm using a molar extinction coefficient of 210000 M-1cm-1.

6.3.9 - CuAAC Conjugation
SPIO was conjugated to alkyne functionalized IgG and anti-CD20 using the same
procedures. FITC labeled N3-SPIO (3 mg Fe/mL) was mixed with varying volumes of 10
mg/mL alkynated-antibody, 5 mM BCS, 1 mM CuSO4 and 5 mM sodium ascorbate.
Final volumes of the reactions were brought to a constant level with the addition of PBS.
The samples were mixed for 4 h at 15˚ C. Samples were cleaned of the reaction additives
using an YM-50 spin column. The antibody-linked nanoparticles were then purified from
unbound protein on a MS magnetic column (Miltenyi Biotec, Bergisch Gladbach,
Germany). Protein per particle labeling was determined as above.
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6.3.10 - Cell Labeling and Assessment
SPIO were incubated with 100 !L of 1x106 cells/mL Burkitt’s GA-10 lymphoma
B cells for 30 minutes at 37˚C, 5 % CO2 in a 96 well plate. SPIO were added at final
concentrations of 50 !g Fe/mL and 10 !g Fe/mL for carbodiimide- and click-conjugated
SPIO, respectively. In the antibody inhibition experiments, 50 !g/mL (final
concentrations) of free anti-CD20 was added prior to the addition of the antibodyconjugated nanoparticles. The free, unbound particles, were purified from the cells
through three PBS washes at 1k RCF for 5 minutes each. Cells were finally resuspended
in 300 !L of PBS and placed in a 96-well plate to be read using a Guava Easycyte Plus
system (Guava Technologies, Hayward, CA). Flow cytometry data was analyzed using
FlowJo (TreeStar Inc., San Francisco, CA).
Click-conjugated particles at a concentration of 50 !g Fe/mL were incubated with
cells as above, using 30x103 cells. Images were acquired with an Olympus IX 81 inverted
fluorescence microscope using a LUC PLAN 40x objective (NA 0.6; Olympus) following
fluorescein excitation by and an X-cite 120 excitation source (EXFO, Quebec, QC).
Micrographs were taken using a back-illuminated EMCCD camera (Andor Technology
PLC, Belfast, Northern Ireland).
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6.4.1 - Antibody Modification
Antibodies were coupled to SPIO using either conventional carbodiimide
chemistry or CuAAC, as shown in Figure 6.1A. The SPIO used throughout the present
study possessed an average hydrodynamic diameter of 33.4 nm and R1 and R2 values of
13.56 mM-1sec-1 and 71.00 mM-1sec-1, respectively. The SPIO were also aminated (~185
NH2 per particle), making this probe well suited to modification with dye and proteins.
Initially, all CuAAC conjugations were carried out using rat IgG so that the reaction
parameters could be optimized in a cost-effective manner. Further, FITC dyes were
bound to the particles prior to any subsequent protein modification. This served to
eliminate interference of fluorescent labeling by proteins or click-ligands at a later stage.
A series of biochemical cross-linking experiments were performed in order to
determine the optimal binding efficiency of antibody to SPIO using the CuAAC strategy.
The first parameter to be varied was the number of alkyne groups introduced onto IgG.
This was accomplished by varying the labeling ratio of alkynating reagent, CH-PEGNHS, to IgG from 15:1 to 100:1. In a separate reaction, azide-labeled SPIO were
prepared by reacting aminated SPIO with a 100-fold molar excess of N3-PEG-NHS, as
seen in Figure 6.2. Following appropriate purification procedures, alkyne-labeled IgG
were coupled to the azide-SPIO through CuAAC in a catalytic copper solution. For this
reaction, the molar ratio of IgG per SPIO was held constant at 17.5:1. After a 4 hour
incubation, unbound IgG were removed by magnetically purifying the SPIO and the
average number of IgG coupled to each SPIO was quantified. It was found that the
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number of IgG per SPIO increased with the degree of alkyne incorporation, to a
maximum labeling of 10-13 IgG per SPIO for this series of reactions. The maximum
number of IgG per SPIO was achieved when IgG was reacted with >35-fold molar excess
of CH-PEG-NHS. Therefore, all subsequent alkynating reactions were carried out
utilizing these lowest saturating conditions.
It can be seen that there is significant variability in the reaction as we approach
the saturation labeling plateau. This is a result of cross-linking of N3-SPIO and CH-IgG
into large aggregates. The occurrence of this phenomenon was difficult to overcome
because purification of excess protein is required in order to assess how much remains
bound. Purification is not possible when the particles are no longer soluble. It was found
that aggregation could be minimized through application of several careful steps during
and after the reaction.
Specifically, immediate mixing of all reactants after each was added helped
reduce aggregation. The order of addition was not important, however it was kept
constant. Additional PBS was added prior to any purification, which appeared to aid in
preventing the loss of all material if any precipitate had formed. Further, as noted in the
materials section, a filtration step was added prior to the magnetic purification. It appears
counterintuitive that sedimentation would help particles remain in solution, but it has
been found that aggregation in solution is more likely to result in strong column binding
during the magnetic purification step (even after removal from the magnet). Therefore,
removal of such material (which will form a film on the filter), as well as excess
reactants,

prior

to

application

to

the

magnetic

column

was

beneficial.
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Figure 6.2 - Effect of IgG alkylation on conjugation to SPIO.
To determine the minimally required alkyne residues on IgG necessary to achieve
maximum conjugation with SPIO, IgG was reacted with increasing amounts of CH-PEGNHS. The alkyne-IgG samples were then “clicked” to N3-SPIO and the degree of labeling
was assessed. The degree of antibody labeling began to level off at an approximate
starting labeling ratio of 35 CH-PEG-NHS:IgG.
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6.4.2 - Saturation Labeling
An important reported advantage of pursuing CuAAC reactions has been the high
efficiency of conjugations. This is a particularly desirable property when procedures
involve large and expensive proteins such as antibodies. As such, we next determined the
conjugation efficiency between IgG and SPIO for labeling ratios of alkyne-IgG to azideSPIO ranging from 2.5:1 to 35:1. As shown in Figure 6.3, there was nearly a 100%
coupling efficiency when the labeling ratio was less than ~20 IgG per SPIO. At higher
labeling ratios, the number of IgG per SPIO did not improve, likely because there was
insufficient space on the SPIO surface for additional conjugations. Utilizing this
information, subsequent conjugation of the clinically approved anti-CD20 was materially
conserved, as a labeling ratio of only 15 antibodies per SPIO was used.
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Figure 6.3 - Efficiency of CuAAC-Based IgG-SPIO Conjugations as a Function of
IgG Concentration.
The click reaction between protein and SPIO was performed with increasing molar
excess of IgG to SPIO. The labeling efficiency was ~100% for all conjugations up to a
labeling ratio of 20 IgG per SPIO. Higher labeling ratios did not result in any increase in
the number of conjugated antibodies.
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6.4.3 - Bioconjugation Comparison
To this point all reactions had seen rat IgG coupled to FITC labeled SPIO by
CuAAC. Prior to assessment of whether antibodies that have been coupled to SPIO
remain functionally active following the CuAAC reaction, antibody (anti-CD20) was
coupled to SPIO using CuAAC. For comparison, the same antibodies were also coupled
to SPIO using carbodiimide chemistry. Each step of the carbodiimide reaction was
conducted under saturating conditions to maximize the conjugation efficiency.
Specifically, carboxylated SPIO were reacted with an excess of EDC and sulfo-NHS in
MES buffer, pH 6.0 for 1 hour in an attempt to achieve complete activation of all
available carboxyl groups. To minimize subsequent hydrolysis of the NHS-activated
SPIO, unreacted cross-linking agents were removed as rapidly as possible (~2-5 minutes)
by precipitating the SPIO with isopropanol. The SPIO were then resuspended directly in
an excess of anti-CD20 in PBS, pH 7.4 and mixed overnight.
As shown in Figure 6.4A, the copper catalyzed ligation of anti-CD20 to SPIO
after 4 h yielded approximately 6.85 anti-CD20 per SPIO. Carbodiimide cross-linking
only resulted in 2.77 anti-CD20 per SPIO. The labeling efficiency for each conjugation
strategy, defined as a percentage of conjugated protein per SPIO over total protein per
SPIO is presented in Figure 6.4B. The click chemistry reaction achieved 45.6%
efficiency, while the carbodiimide reaction resulted in a labeling efficiency of only 8.3%.
It was surprising that despite a relatively high degree of labeling by the protein through
CuAAC, this was significantly less than achieved with rat IgG.
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It is hypothesized that the reduced efficiency may stem from a lower
incorporation of alkynes onto the anti-CD20 compared with IgG, perhaps due to subtle
differences between the proteins. Nonetheless, CuAAC still resulted in a 5.5-fold
improvement in the efficiency of labeling compared with carbodiimide chemistry.
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Figure 6.4 - Comparison of SPIO Labeling with Anti-CD20 Using CuAAC and
Carbodiimide Conjugation Procedures.
(A) Extent of reaction as measured by final number of antibody per SPIO. Following the
optimization of IgG-SPIO conjugation using CuAAC, anti-CD20 antibodies were
“clicked” to SPIO. The average number of antiCD20 per SPIO was determined by BCA
Protein Assay to be 6.85 molecules per particle. Labeling of SPIO by anti-CD20 was also
accomplished using the classic carbodiimide method; however a lower final labeling ratio
of 2.77 antibodies per SPIO particle was achieved, despite using more antibodies during
the conjugation procedure. (B) Percent efficiency of reaction by conjugation method.
Here, the ratio of final protein per NP with respect to the initial value has been plotted as
a percent. For the CuAAC-mediated cross-linking of anti-CD20 the reaction approached
50% efficiency, while the EDC conjugates reached almost 10%.

Chapter 6

242

6.4.4 - Functional Application
Binding of anti-CD20-conjugated SPIO to CD20-positive B cells was assessed by
flow cytometry. All SPIO were fluorescently labeled prior to the respective conjugation
protocols to enable fluorescence detection. The same fluorescently labeled SPIO were
used for both the CuAAC and carbodiimide reactions to ensure that total cellular
fluorescence could be correlated to the extent of SPIO binding. Thus, it was possible to
quantitatively compare the equally fluorescent EDC- and CuAAC-particle strategies.
As shown in Figure 6.5 (top row), it was found that at a concentration of 10 !g
Fe/mL, anti-CD20-targeted SPIO prepared using click chemistry could be used to
successfully target B cells. Specificity was confirmed by competitively inhibiting SPIO
binding using an excess of free anti-CD20 antibodies. Surprisingly, anti-CD20-targeted
SPIO prepared using carbodiimide chemistry did not result in any appreciable B cell
labeling using equivalent concentrations (10 !g Fe/mL; D-F). In fact, similar levels of B
cell labeling could only be achieved when the iron concentration was increased to 50 !g
Fe/mL (Figure 6.5, bottom row). Again, for both concentrations of the carbodiimideconjugated targeted nanoparticles, specificity was confirmed by competitively inhibiting
SPIO binding using an excess of free anti-CD20 antibodies. This data suggests that the
anti-CD20-labeled SPIO prepared using click chemistry have a higher affinity for the
CD20 receptors on B cells compared with analogous nanoparticles prepared using
carbodiimide chemistry. It is likely that this increase in affinity is due to the greater
number of anti-CD20 per particle.
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Figure 6.5 - B Cell Labeling with Anti-CD20-SPIO.
Functional targeting of SPIO to B cells was accomplished for click- and carbodiimidecross-linked anti-CD20-SPIO conjugates. Top row shows the flow cytometric analysis of
B cells that were incubated with 10 !g Fe/mL of CuAAC conjugated (A) IgG-SPIO, (B)
anti-CD20-SPIO, and (C) anti-CD20-SPIO in the presence of excess free antibody.
Labeling of cells with the EDC conjugated particles (10 !g Fe/mL) is found in the second
row (D-F). Cells labeled with EDC conjugated particles at a higher concentration (50 !g
Fe/mL) were analyzed in the final row (G-I). Antibody mediated binding was observed
for anti-CD20 SPIO using both conjugation strategies; however, cell labeling with
CuAAC nanoparticles was achieved with a significantly lower concentration of
nanoparticles. Solid lines refer to unlabeled B cells, dashed to cells incubated with NP of
type indicated by row and column.
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Overall, the data presented here provide strong evidence that CuAAC reactions
can be used for highly efficient and effective labeling of nanoparticles with antibodies,
without any noticeable loss in antibody functionality. Fluorescent micrographs of click
conjugated SPIO particles incubated with B cells are also shown (Figure 6.6). Labeling of
the cells was found to be specific, as IgG-SPIO conjugates do not bind to the cells, nor do
anti-CD20-SPIO when inhibited with excess free antibody.
It should be noted that the incubation of anti-CD20-SPIO with the B cells, and
especially in the presence of free anti-CD20, appeared to have a negative effect on the
health of the cells, if only inferred from cell morphology. No cytotoxological studies
were conducted using the constructs created in this work as this targeting agent is itself
administered to deplete cells. Logically this could lead to a further functionality study
wherein each conjugate, EDC and click, is viability tested for B cells in vitro or in vivo.
This related study would be interesting; however, as the mechanism of anti-CD20
mediated cell death is not fully understood, it is beyond the scope of this work.
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Figure 6.6 - B Cell Labeling; Fluorescence Micrographs.
Cells were incubated for 30 minutes with 50 !g Fe/mL of (A) IgG-SPIO, (B) anti-CD20SPIO and (C) anti-CD20-SPIO in the presence of excess antibody, and then washed in
triplicate. The fluorescently labeled particles are found bind to cells specifically, as
competition for ligand curtails cell signal. All images at 40x magnfication.
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Advanced applications in the areas of diagnostic imaging and drug delivery stand
to benefit from antibody- or protein-based targeting of nanoparticle carriers. Preparation
of such targeted nanoparticles can however be inefficient and costly. Here, we have
shown that the utilization of the CuAAC for the production of antibody-nanoparticle
conjugates permits materially efficient and functionally competent targetable probes. In
comparison to classic carbodiimide-conjugates, CuAAC adds a valuable alternative to the
toolbox of the bioconjugate chemist. This mechanistically simple and highly efficient
reaction, which is generally insensitive to reaction conditions, is expected to allow for an
expansion in applications for nanoparticle-targeted systems in the clinic.
The products of the click reaction were functionally specific for B cells in vitro, as
demonstrated by inhibitory competition with free protein. A preferred targeting ligand for
this work is a non-depleting antibody to a receptor that internalizes cargo once bound,
and recycles to the surface. This work has implications towards the use of targeted
nanoparticle conjugates following the choice of such a suitable targeting vector. This
would allow for the intracellular accumulation of the contrast agent. Coupled to a NP for
diagnostic or tracking purposes, such an agent would be a powerful means to image the
distribution of specific cell types in vivo.

Chapter 6
6.6 - References
1.

247

Helmick L, Antunez de Mayolo A, Zhang Y, et al. Spatiotemporal response of
living cell structures in Dictyostelium discoideum with semiconductor quantum
dots. Nano Lett 2008; 8:1303-1308.

2.

Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment
modality for cancer. Nat Rev Drug Discov 2008; 7:771-782.

3.

Pettit DK, Gombotz WR. The development of site-specific drug-delivery systems
for protein and peptide biopharmaceuticals. Trends Biotechnol 1998; 16:343-349.

4.

Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide
nanoparticle probes for molecular imaging. Ann Biomed Eng 2006; 34:23-38.

5.

Sun EY, Josephson L, Kelly KA, Weissleder R. Development of Nanoparticle
Libraries for Biosensing. Bioconjugate Chemistry 2006; 17:109-113.

6.

Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the
Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.
Magn Reson Med 2003; 49:403-408.

7.

Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as
magnetic resonance contrast agent for tumor imaging via folate receptor-targeted
delivery. Acad Radiol 2004; 11:996-1004.

8.

Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R.
Detection of vascular adhesion molecule-1 expression using a novel multimodal
nanoparticle. Circ Res 2005; 96:327-336.

9.

Tsourkas A, Shinde-Patil VR, Kelly KA, et al. In vivo imaging of activated
endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug Chem
2005; 16:576-581.

10.

Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343357.

11.

Hudis CA. Trastuzumab -- Mechanism of Action and Use in Clinical Practice. N
Engl J Med 2007; 357:39-51.

Chapter 6
248
12.
Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a
mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-1453.
13.

desJardin JA, Snydman DR. Antiviral Immunotherapy: A Review of Current
Status. BioDrugs 1998; 9:487-507.

14.

Molday RS, MacKenzie D. Immunospecific ferromagnetic iron-dextran reagents
for the labeling and magnetic separation of cells. Journal of immunological
methods; Journal of immunological methods 1982; 52:353-367.

15.

Hermanson GT. Bioconjugate techniques. San Diego: Academic Press, 1996.

16.

Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using
PLGA nanoparticles surface modified with monoclonal antibody. J Control
Release 2007; 120:18-26.

17.

Natarajan A, Gruettner C, Ivkov R, et al. NanoFerrite particle based
radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.
Bioconjug Chem 2008; 19:1211-1218.

18.

Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function
from a Few Good Reactions. Angew Chem Int Ed Engl 2001; 40:2004-2021.

19.

Hein CD, Liu XM, Wang D. Click chemistry, a powerful tool for pharmaceutical
sciences. Pharm Res 2008; 25:2216-2230.

20.

Jean-Francois Lutz. 1,3-Dipolar Cycloadditions of Azides and Alkynes: A
Universal Ligation Tool in Polymer and Materials Science. Angewandte Chemie
International Edition 2007; 46:1018-1025.

21.

H. Nandivada XJ, J. Lahann,. Click Chemistry: Versatility and Control in the
Hands of Materials Scientists. Advanced Materials 2007; 19:2197-2208.

22.

Baskin JM, Prescher JA, Laughlin ST, et al. Copper-free click chemistry for
dynamic in vivo imaging. Proc Natl Acad Sci U S A 2007; 104:16793-16797.

23.

McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of
multifunctional magnetic nanoparticles. Nanomed 2007; 2:153-167.

Chapter 6
249
24.
Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A stepwise huisgen
cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and
terminal alkynes. Angew Chem Int Ed Engl 2002; 41:2596-2599.
25.

Tornoe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of
terminal alkynes to azides. J Org Chem 2002; 67:3057-3064.

26.

von Maltzahn G, Ren Y, Park JH, et al. In vivo tumor cell targeting with "click"
nanoparticles. Bioconjug Chem 2008; 19:1570-1578.

27.

Sun EY, Josephson L, Weissleder R. "Clickable" nanoparticles for targeted
imaging. Molecular imaging 2006; 5:122-128.

28.

Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG.
Accelerated bioorthogonal conjugation: a practical method for the ligation of
diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem
2005; 16:1572-1579.

29.

Brennan JL, Hatzakis NS, Tshikhudo TR, et al. Bionanoconjugation via click
chemistry: The creation of functional hybrids of lipases and gold nanoparticles.
Bioconjug Chem 2006; 17:1373-1375.

30.

Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB, Finn MG.
Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am
Chem Soc 2003; 125:3192-3193.

31.

Gierlich J, Burley GA, Gramlich PM, Hammond DM, Carell T. Click chemistry
as a reliable method for the high-density postsynthetic functionalization of
alkyne-modified DNA. Org Lett 2006; 8:3639-3642.

32.

Baio G, Fabbi M, de Totero D, et al. Magnetic resonance imaging at 1.5 T with
immunospecific contrast agent in vitro and in vivo in a xenotransplant model.
MAGMA 2006; 19:313-320.

33.

Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron
oxide particles by non-phagocytic cells. Biomaterials 2008; 29:3583-3590.

Chapter 6
250
34.
Zhao M, Kircher MF, Josephson L, Weissleder R. Differential conjugation of tat
peptide to superparamagnetic nanoparticles and its effect on cellular uptake.
Bioconjug Chem 2002; 13:840-844.

Chapter 7

251

CHAPTER 7. SPIO Enabled Detection of Transient Cervical Nerve Root Injury
7.1 - Overview
Cervical radicular pain is a widespread neurologic condition resulting from the
compression of a cervical nerve root. The impact on quality of life and economic cost of
persistent states of pain are massive. Current diagnostic imaging approaches fall short in
their ability to accurately correlate pain symptoms to evidence of neuropathy.
This chapter focuses on our aim to utilize systemically administered SPIO for
enhanced identification of injured nerve roots in a rat model. The chapter begins by
detailing the salient epidemiological and economic impact resulting from back and neck
pain. An introduction to the anatomic and biomechanical foundations of transient nerve
root compression and the resulting axonal degenerative effects are also discussed. A rat
model of neuroinflammation following transient nerve compression that has been
previously shown to produce sustained states of hypersensitivity is outlined. In order to
visualize neuroinflammation in vivo it was necessary to develop a magnetic resonance
(MR) imaging protocol suited to the task of utilizing SPIO as contrast. Preliminary
experiments were conducted to ensure that a high-field strength small animal MR system,
a surface-receive coil and a T2*-weighted gradient echo sequence would enable detection
of cell loaded SPIO.
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The sequence parameters and animal handling protocol were initially optimized to
enable detection of accumulated SPIO. These settings were then utilized for detection of
neuroinflammation from a painful transient compression of the C7 nerve root following
SPIO administration. Pre- and postcontrast scanning sessions were conducted following a
6 day recovery period from surgery. Imaging at the site of C7 nerve root injury using
SPIO resulted in an average postcontrast enhancement of 72.9±31%, measured as the
difference in normalized relative signal intensity (nrSI) between ipsilateral (compressed)
and contralateral roots. This was significantly greater than the 5.3±12.9% difference in
nrSI of injured animals precontrast. Finally, implications of this work regarding future
development of imaging in pre-clinical pain models as well as clinical relevance for
patient management are discussed.
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7.2 - Introduction
7.2.1 - Epidemiology and Impact
Low back pain and neck pain are among the most common physical conditions
requiring medical care globally. The healthcare burden for treating spinal pain is
considerable, making it the most common physical condition for which a patient elects to
see his/her doctor in the United States (1).
The affected portion of the population is large as cervical neck pain has a lifetime
prevalence reported to be as high as 71% (2, 3). Further, there is no specific
epidemiological demographic; four out of five neck pain diagnoses (81%) were for
persons between the ages of 18 and 64 (4). The corresponding economic impact is
equally large, with estimates of annual societal costs of $29 billion (5) and work days lost
to back pain has been estimated at 186.7 million for 2004 in the US (1).

7.2.2 - Relevant Cervical Anatomy
The central nervous system (CNS) proximal to the cervical spine, consists of 7
vertebrae and 8 pairs of cervical nerve roots (in both rodents and humans). The purpose
of the vertebrae are to contain and protect the spinal cord, support the skull and enable
diverse head movement. The spinal cord passes through the spinal canal and is
surrounded by a protective dural sheath. The spinal cord consist of tracts of white and
grey matter. The white is responsible for conveyance of information to and from the
brain, while gray matter houses cell bodies and unmyelinated axons. The first two
cervical vertebrae have a unique structure in comparison with other components of the
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spine, however the lower (C3-C7) vertebrae are similar. The vertebra progress in size
from cephalad to caudad with C7, the vertebra prominens, possessing a spinous process
larger than the process associated with the first thoracic vertebra (6).
In the schematic of the fifth cervical vertebra (C5; Figure 7.1A), the space
through which the C6 nerve roots exit are labeled as the transverse foramen. It should be
noted that the nerves of the cervical spine take the name of the pedicle above which they
exit (unlike nerves in the thoracic and lumbar spine). The exception is the eighth cervical
nerve root, which exits between C7 and T1. The nerve roots of the cervical spine pass
laterally at each level to exit from the spinal canal at the same foraminal level as their
origin from the spinal cord, Figure 7.1B.
Each level sees six to eight rootlets exit the spinal cord to be joined together and
surrounded by the dura to form the nerve root (Figure 7.1C). The dorsal nerve roots are
approximately three times as thick as the corresponding ventral roots, except at C1 and
C2, because of the greater amount of sensory fibers. The roots of a particular level
contain axons whose cell bodies reside in the corresponding dorsal root ganglion (Figure
7.1C). Each dorsal root level enervates a specific area of skin. These often overlapping
areas are the dermatomes. A dermatome map for the cervical and first thoracic nerve root
levels is shown in Figure 7.1D. Although variability differences can complicate diagnosis
(7), pain in a particular dermatome can enable distinction of the compromised nerve root
level in an injured patient (8).
The upper quarter of the foramen is filled with areolar tissue and small veins. In
addition, small arteries arising from the vertebral arteries and the sinuvertebral nerves
traverse the canals (6). The intervertebral foramen is also in close proximity to the
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uncovertebral and the apophyseal (facet) joints (anteromedially and posterolaterally,
respectively). These features, the somewhat dense vasculature and adjacency of joints,
are noted because they are potential causes of canal (neuroforamenal) restriction. There
exist a host of causes that produce neck pain including degenerative conditions, strain
injury and direct trauma (9, 10). Cervical radicular pain is distinguished as pain derived
from insult to the nerve roots (11). The incidence of either a lesion or contact by the
uncinate processes, facet joint or pedicles will result in compression of the nerve roots or
spinal nerve which may result in this painful injury, as will be discussed in the following
section.
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Figure 7.1 - Cervical Neural and Vertebral Anatomy.
(A) Description of the cervical vertebral architecture. (B) Schematic of the spinal cord
with nerve roots passing laterally through the neuroforamen to enervate the body. (C)
Schematic of the rootlets as they branch together to form the roots and subsequently the
spinal nerve. (D) Anterior and posterior dermatomes of the cervical spinal nerves and
first thoracic level.
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7.2.3 - Cervical Radicular Pain
Cervical radicular pain is a neurologic condition characterized by dysfunction of a
cervical spinal nerve, the roots of the nerve, or both. It usually presents with pain in the
neck and one arm often severe enough to compromise patients' functional abilities (12).
Impact on the quality of life of patients exhibiting symptoms can be severe (13). The
condition manifested as pain, sensory loss and motor weakness in the affected dermatome
(14) and these symptoms can last for as long as months or even years (15).
Chronic neck pain caused by nerve root injury is common as these roots are at
particular risk for mechanical insult (see above). Their risk of compression due to the
foraminal shape changes that may occur during some vertebral motions is high (16).
Cervical radiculopathy may result from herniation of the nucleus pulposus, however this
is less frequent than in the lumbar spine (17). Prevalent causes of such trauma leading to
persistent pain include rear-end automobile accidents (18) and contact-sports injuries (1921). Extensive, large sample population studies have been conducted to determine the
effect of suspected risk factors on predisposition to cervical radiculopathy. These are
thought to include tobacco-use, psychological health, trauma, sex, age and degenerative
disc changes (15). However, the condition also can arise in patients devoid of putative
risk factors (17).
The most commonly reported injured spinal nerve or nerve root level is that of
C7, at the C6-C7 vertebral level. One study revealed that in a population of 561 patients,
the frequency of surgically confirmed cervical radiculopathy at C7 alone was 46.3% (17).
Injury at this level produces pain distributed on the affected side along the shoulder,
posterior of arm and forearm and along the third finger of the hand (22).
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7.2.4 Imaging Techniques in Nerve Root Injury
Clinical criteria for diagnosis of cervical radicular pain lacks a universal standard
(23). Application of guidelines following a physical examination are used to screen
patients' symptoms from life-threatening pathologies (such as spinal tumors or cerebral
infections) (24, 25). These tests, which help confirm or eliminate clinical diagnoses, also
serve to localize the injured spinal level by analyzing the affected dermatomal area.
Clinical imaging modalities of all types are employed in determination of the
cause of severe and chronic neck pain. The first line of diagnostic tests to evaluate
suspected radiculopathy are often conventional radiographs. These may be helpful in
assessing for abnormalities such as fractures or instability. However, this technique is of
limited utility as it lacks soft-tissue distinction and the degenerative hard-tissue changes
in geriatric cases further complicate diagnosis (26, 27). While not immune from
asymptomatic findings, magnetic resonance (MR) imaging is the modality of choice for
cervical radiculopathy (28, 29). This is a result of the excellent soft-tissue contrast
achievable through application of different sequence protocols.
Radiological evidence of neural impingement, such as disc collapse and/or
protrusion, spondylosis, or foraminal occlusion, is seen in as many as 44% of lower back
pain (30) and 68% of neck pain cases (17). However, in most of the remaining cases, no
noticeable neuropathology is detectable.
The challenge of diagnosing this clinical syndrome is exacerbated by the high
rates of positive radiological findings in asymptomatic subjects (31-33). It has been
estimated that the prevalence of cervical spondylosis for men above 75 is approximately
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95% (34, 35). Patients who report no pain symptoms are commonly found to have
degenerative spinal features, which may include nerve root impingement (12). This
further impairs the utility of current clinical imaging approaches as it is difficult enough
to determine the presence of injury, let alone distinguish extent or response to treatment
over time.
It is also possible that this pain is the product of a transient mechanical injury or
presence of chemical factors that are not apparent through conventional diagnostic
radiology. Nerve root insult originating from these sources may not result in cervical
neural or musculoskeletal deformation that can be detected using conventional
radiographic approaches. We have hypothesized that the application of a cellular MR
imaging strategy leveraging the accumulation of systemically injected SPIO to generate
inflammation specific contrast can be used to identify the site of a pain producing injury.

7.2.5 - Neuroinflammation
It is generally accepted that radicular pain results largely from mechanical or
chemical insult of the nerve roots (36-38). Trauma to the neural tissues results in both
pain and Wallerian degeneration (39-42). In lumbar radiculopathy models of pain,
behavioral hypersenstivity is immediate and has been correlated to axon cytoskeletal
damage, cytokine production and glial activation (43-46). Contributing to persistent pain
is the neuroinflammatory cascade that sees recruitment of macrophage to the injured
region to phagocytize myelin debris (40, 47, 48) followed by further production of small
molecule pain mediators (45, 49-51).
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Sustained neuroinflammation can be induced by even transient mechanical
injuries to neural tissues (36, 45) and may explain the lack of correlation between
radiologically evident pathology and pain. In a rat model of cervical radiculopathy,
transient compression of the C7 cervical dorsal nerve root produced persistent behavioral
sensitivity, as measured by mechanical allodynia (sensitivity to an otherwise non-painful
mechanical stimulus) (52-54).
Similar to transection and crush models, transient compression produces
Wallerian degeneration, along with the hallmarks of neuroinflammation, including
increased upregulation and expression of neuropeptides, growth factors, and cytokines,
and sustained inflammatory cell activation at the injury site and in the spinal cord (45, 50,
55). Infiltrating macrophage ingest axonal debris at the injury and have been shown to be
a principal element in development of pain (48, 56, 57). The inflammatory response
associated with pain states incited by transient neural tissue trauma may provide an
opportunity for identification and diagnosis of injury in subjects that present no
radiological abnormalities.

7.2.6 - SPIO Accumulation at Sites of Inflammation
Superparamagnetic iron oxide (SPIO) nanoparticles are a widely used T2*weighted MR contrast agent. They enable detection of sites of their accumulation through
enhanced proton dephasing (darkening), as they function as strong magnetic
inhomogeneities in vivo (58). They have been applied in numerous academic and clinical
studies in a wide range of models for the detection of inflammation. Imaging of these
sites using SPIO has been previously shown to rely upon the accumulation of the
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particles at sites of activated immune cell activity; specifically they are sequestered by
monocytes (59-61). Following sufficient accumulation in foreign-body phagocytosing
macrophage, SPIO have enabled detection of otherwise radiologically indistinguishable
inflammatory processes. These include pathologies such as soft-tissue infection (59, 62,
63), implant rejection (64) and atherosclerosis (60, 65-68).
The agents have also been widely used in several central nervous system disorders
for the detection of inflammatory cells. One of the most widely studied applications is the
detection of cerebral lesions in multiple sclerosis (69-72). In humans, sites of
inflammation following stroke have also been visualized through SPIO contrast (73).
Peripheral and central nerve injury models have been investigated as well. The
distribution of macrophages into a mechanically crushed sciatic nerve in a rabbit were
tracked following SPIO administration (74, 75). SPIO have been used in the cord injury
models to enable visualization of either macrophage in vivo or to track ex vivo loaded
macrophage or stem cells to the injury (76, 77).
There are currently no reports of in vivo cellular imaging studies investigating the use of
SPIO to identify and/or localize the anatomical location of pain resulting from transient
neural injury. As indicated above, a painful cervical nerve root compression model has
demonstrated that transient compression of sufficient force is able to produce a sustained
inflammatory response (36, 45). It is the aim of this chapter to utilize SPIO to exploit the
phagocytic activity of macrophage infiltrating the injury site as schematically illustrated
in Figure 7.2. Prior to the application of SPIO, it was necessary to determine optimum
MR scanning logistical and sequence parameters for cell-accumulated SPIO detection.
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Figure 7.2 - Schematic of SPIO Uptake.
It is hypothesized that systemically injected long circulating dextran-coated SPIO will be
able to accumulate in phagocytic macrophage at the site of nerve root compression.
Transient compression (red clip) of the C7 dorsal nerve root has previously been shown
to lead to neuroinflammation and the presence of activated macrophage (purple). SPIO
(black) have been widely used to visualize sites of tissue injury through accretion of
nanoparticulate contrast within macrophages.
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7.3 - MR Protocol Development
The noninvasive high-resolution imaging of living subjects is a primary advantage
in utilizing MR imaging for preclinical studies. A major difficulty, and the underlying
motivation for the application of contrast agents, is inherently low signal-to-noise (SNR).
This is often the reason for long scan duration in the clinic, as an initially long acquisition
must be averaged several times to reduce background noise from otherwise useful
information. The aim here was to visualize the accumulation of nanoparticulate contrast
agents at sites of neuroinflammation, a difficult task from an SNR standpoint. This was
due in large part to the complex biomechanical function of the cervical spine.
A precise assemblage system of bone, cartilage, ligaments, tendons, nerves and
muscles all exist to enable both a high degree of flexibility and protect the spinal cord
from injury. To perform successful neuroinflammatory imaging, the relevant structures
need to be defined with adequate resolution. The substantial artifact that can arise from
the presence of bone is also a significant concern. Finally, the spinal nerve roots are
located at some distance from the back of the neck in the rat. The further the structure of
interest is from the receiver coil, the more signal that is lost for image formation. In order
to ensure that equipment parameters were properly configured for SPIO detection
sequence, high field strength, sequence selection and the use of specialized coils were
examined.
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A constant feature throughout the history and development of magnetic resonance
imaging systems has been implementation of greater field strengths. Industrial production
of clinical scanners have progressed from 0.2-0.3 T systems to 1.5 T and now the current
standard of 3 T. Higher field strength produces images of better quality as a result of
improved signal-to-noise. This is a result of the the differing effects on signal and noise
with increasing field strength (B), as they have different magnetic field-dependencies
(78).
Strength of signal from a voxel is proportional to voxel volume. The SNR is
proportional to voxel volume multiplied by the square root of the acquisition time.
Attainment of greater SNR, using higher magnetic field strength, thus results in reduced
time and means that voxel volumes can be reduced to achieve the same signal as at a
lower field strength for the same amount of time (79). The resulting features of higher
strength fields are faster scans and higher resolution. Faster scans have the added
advantage of reducing artifacts from patient motion, as the likelihood of movement
increases with duration. Thus, all of the work in this thesis (excluding contrast agent
characterization) was conducted at high field strength, using a 9.4 T small animal
imaging system (Varian; Palo Alto, CA).

7.3.2 - Coils
When surface coils are applied it is often the case that separate coils are used to
excite the subjects’ protons and to receive signal for detection. These two coils are
referred to as the transmitting-volume coil and the receiving-surface coil. Surface coils
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function as antennas to achieve greater SNR in MR imaging. The closer proximity to the
tissue of interest to be imaged allows for less signal to be lost. The reduced field of view
also serves to reduce noise from surrounding tissues in the volume excited by the body
coil.
In this work a custom built surface coil was utilized in conjunction with a volume
coil. The volume coil was a transmit-and-receive design built by Insight Neuroimaging
Inc. (now InsightMRI), Worcester, MA. This coil was used solely in the transmit mode.
The dimensions were 7 cm in inner diameter and approximately 9 cm in length. The
surface coil was applied directly to the surface of the rodent proximal to the tissue of
interest. This receive-only coil and was detunable with a linear, single-loop coil with
remote tuning and matching. The dimensions of the surface coil (antenna only) were 2.54
cm in long axis, curved to a 1.5 cm radius.

7.3.3 - Sequence Selection
The usefulness of MR imaging in the clinical and research spheres is greatly
enhanced by its ability to visualize and distinguish many different tissues. This capacity
is derived from the application of radiofrequency pulses and magnetic gradients in order
to provide distinction of tissues and tissue states of interest. The direction, strength and
timing of the pulses and gradients used to acquire an image is referred to as a sequence.
Sequences are essentially exercises in choosing between speed, contrast and SNR in
order to visualize items of interest. This is relevant here as choice of the sequence in
order to emphasize the presence of susceptibility generating contrast agents is often
necessary. Determination of favorable parameters for detecting intracellular SPIO
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contrast agents was thus required prior to any attempt to visualize transient nerve root
compression.
Initialization of a susceptibility enhancing sequence, and all subsequent imaging
was performed on the University of Pennsylvania Department of Radiology small animal
31 cm diameter 9.4 T MR system (Varian, Palo Alto, CA). Initial results, using the
volume/surface coil setup detailed above, indicated high SNR at sufficient tissue depth
(maximum visualization of approximately 3.5 cm). A gradient echo multi-slice (GEMS)
sequence was selected as multiple animals were to be imaged in each group (requiring
efficient scan duration) with thin slice selection (0.5 - 1 mm) along with the desire for a
susceptibility bias. In other words: fast, selective and T2*-weighted.
The fast scanning time results from several GEMS features including a non-90˚
flip angle and absence of a 180˚ rephasing pulse (as is utilized in spin echo imaging).
This angle (!), selected as 20˚, is used to decrease the time required to return to
equilibrium magnetization. This is the result of the decreased magnitude of the transverse
magnetization, as compared to a 90˚ or hard flip wherein the entire magnetization vector
is (at least initially) in the xy-plane. The shorter recovery period allowed for repetition
and echo times (TR and TE, respectively), as shown in Figure 7.3. This has the advantage
of minimizing acquisition time and limits breathing and other motion artifacts. As long as
a non-steady state longitudinal magnetization does not interfere with imaging (a possible
interfering side effect of <90˚ flip angle when the TR < T2) the slice thickness chosen can
be as thin as the gradient allows (on the system used the minimum was 0.5 mm).
A final advantage of the GEMS sequence is that T2*-weighting is present. There
is only a single radiofrequency pulse delivered (to flip) and no 180˚ refocusing pulses (as
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there would be in, for example, a spin-echo sequence). Thus, relaxation process from
magnetic field inhomogeneities (such as SPIO) are not corrected for. The trade-off of
such a feature is that a dephasing gradient needs to be applied prior to the readout
gradient. This process, in addition to the lack of rephasing pulses, results in some loss of
signal.
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RF
GSS
GRO
GPE
ADC
Figure 7.3 - Gradient Echo Sequence.
The radiofrequency (RF) pulse used in the gradient echo sequence to flip the net
magnetization vector into the xy-plane is by some (non-90˚) angle !. The value used for
all imaging was 20˚. This limits the time for recovery of longitudinal magnetization
allowing shorter TR and TE to be used. No 180˚ refocusing pulse is applied, which
further speeds scanning time and also does not correct for magnetic inhomogeneities.
This results in T2* rather than T2-weighting. In the absence of a refocusing pulse the echo
is created by applying a dephasing gradient during slice selection (GSS) before the signal
is read during application of the readout gradient (GRO). This generates an echo when the
the data is acquired by the analog to digital converter (ADC). The phase encoding
gradient (GPE) is varied in order to fill the k-space. Adapted from the Vnmrj user manual.
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7.3.4 - GEMS Parameter Optimization
The GEMS sequence was selected as a partial flip angle reduces acquisition time
and enhances susceptibility artifacts. However, there exists a significant compromise in
the application of gradient echo protocols with the TE parameter. The T2*-weighting
produced due to the lack of rephasing pulse means that signal loss is rapid and there is a
low SNR. To maintain the advantage of a fast acquisition time, it was undesirable to
resort to reliance on extensive averaging to recover lost image quality. In order to
determine a sequence parameters that balanced T2*-w and image quality a mock SPIOintracellular-accumulation experiment was conducted.
Initial experiments had indicated that sufficient signal could be obtained from the
dual-coil setup with TR in the range of 100-200 msec. Longer TR resulted in extensive
breathing artifacts (see Figure 7.4F). Very short TR were not feasible because of the thin
slice selection requirement; adjacent thin slices interfered with each other with short TR
due to presence of remnant magnetization. After qualitative experimentation, a TR of 200
msec was chosen for the following experiments.
As TE optimization was intended to maximize distinction of the presence of
SPIO, a simulated in vivo SPIO-cell experiment was devised and analyzed. Specifically,
cationic, cross-linked and aminated SPIO (33 nm diameter, R2 of 72 mM-1Sec-1) at 100
!g Fe/mL were incubated with confluent human embryonic kidney (293T, ATCC) cells
for 1 hour. These cells have previously been shown to be excellent candidates for
transfection through relatively efficient uptake of nanoparticles during incubation (80,
81). The cells were washed of excess SPIO after the 1 hour incubation, trypsinized and
washed twice in PBS. The cell suspension, containing approximately 2.5x106 cells, was
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delivered by injection intramuscularly to the back of the rat neck, at a depth of
approximately 1 cm.
The anesthetized animal was placed into a custom-built stereotactic restraint
device after induction at 4% isoflurane in oxygen. The surface coil was fixed proximal to
the general area of the injected cells. A coaxial delivery and vacuum system was used to
maintain the animal at 1 L/min of a reduced (2%) gas mixture. The animal was then
placed on a custom-built patient bed and centered in the 7 cm inner diameter volume coil.
Initial scouting scans were acquired in all three directions in order to determine
the relative position of the injected SPIO-loaded cells. Sagittal scans (13 slices) were then
acquired using the following parameters under the GEMS sequence: TR = 200 msec, np
= 256, nv = 256, N = 4, a field of view of 60 mm2 and a flip angle of 20˚. A span of TE
values from the minimum (2.72 msec; bounded by bandwidth constraints) to the
maximum (11.25 msec; bounded by TR) were then used for acquisitions. Representative
images of the scanning results are found in Figure 7.4A-E.
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Figure 7.4 - TE Optimization Using SPIO-Cell Implant.
The determination of an echo time (TE) for the applied gradient echo sequence was
necessary. This parameter allows for distinction of the presence of iron oxide
nanoparticle labeled cells, while balancing other affects that impact image quality.
Images (A-E) are of the same animal with increasing TE and the following parameters;
256x256, 4 averages and TR = 200 msec. The TE was varied from 2.77, 3.88, 5.00, 10.00
and 11.25 msec. Contrast to noise measurements were conducted to determine the
optimal TE. Longer TR times, for example 400 msec (as shown in F) resulted in
significant artifact from animal respiration.
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Quantitative analysis was undertaken to determine the TE value that provided
T2*-weighting with sufficient image integrity. Using ImageJ (NIH; Bethesda, MD) the
images were converted to a useable lossless format in the Multi FDF Opener plug-in
(Shanrong Zhang, University of Texas Southwestern Medical Center). A constant area
(15 pixel diameter) circle ROI was placed on the injected cells, adjacent back muscle and
in a noise-field surrounding the animal, as illustrated in Figure 7.5A. The contrast-tonoise ratio (CNR) was computed for each of the acquisitions.
The results indicated that a TE between 3.88 and 10 msec provided the greatest
CNR, Figure 7.5B. Longer TE times (Figure 7.4D-E) were qualitatively the most striking
as greater time for susceptibility artifact generated hypointensity of the spinal vertebral
column as well as the bones of the rat forepaw. It should be noted that T2*-weighted
inhomogeneities are generated by both bone and SPIO contrast. Thus, increasing the
effect for one serves to enhance the other. Bone's artifact generating properties are a
result of several factors including a lack of water, a sharp interface with soft-tissue and
radiofrequency penetration and reflectance. This presents a dilemma to the operator or
radiologist as images of anatomical features that may be highlighted with nanoparticles
which are close to or bounded by bony structures may suffer from interference and
degraded image quality. Gains in contrast enhancement between the SPIO and
surrounding tissue is offset by the distortion and artifact generated by the bone.
Lower TE times provided sharper distinction of tissues as there was less signal
lost, however the midrange TR applied (200 msec) coupled with a very short TE (for
example 2.7 msec) limits the T2-weighting of the scan. Using a TE of approximately 5-6
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msec in practice enabled excellent soft-tissue distinction, acceptable bone susceptibility
artifact and sensitive SPIO-cell detection.
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Figure 7.5 - Analysis of TE Adjustment.
(A) An illustration of the ROI used to calculate the CNR for determination of acceptable
values. Three ROI, of equal area, were placed on each image; SPIO-loaded cells (dotted),
a background tissue (solid) and the noise (double-lined) ROI are shown. For each image
the placement was nearly identical however small changes in the location of features
resulted from animal movement and TE choice from scan to scan. (B) The results of CNR
are plotted, as a function of TE. CNR values were found to be maximum between values
of 3.88 and 10 msec.
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7.4 - Materials and Methods
7.4.1 - Nanoparticle Synthesis and Characterization
SPIO were prepared using the chemical co-precipitation technique (82). All
chemicals and equipment were purchased from Fisher Scientific (Pittsburgh, PA), unless
otherwise noted. Briefly, a solution of iron salts, 1.97 g of FeCl3 and 0.7313 g of FeCl2
(each in 12.5 mL of dH2O) were dissolved in the presence of 25 g dextran-T10 (GE
Healthcare; Waukesha, WI) in 50 mL dH2O under nitrogen gas. The vessel was cooled to
4˚ C and 15 mL of ammonium hydroxide was added. This solution was then heated to 90˚
C for 1 hour, cooled overnight and then purified from aggregates by ultracentrifugation at
20 kRCF. The supernatant containing nanoparticles was diafiltrated against greater than
20 volumes of 0.02 M citrate, 0.15 M sodium chloride buffer, using a 100 kDa cutoff
membrane (GE Healthcare). Finally, particles were exchanged into pH 7.4 phosphate
buffered saline (PBS), 0.2 !m syringe filtered and stored at 4˚ C.
SPIO were characterized by dynamic light scattering (DLS) to determine
hydrodynamic diameter using a Zetasizer Nano-S (Malvern Instruments; Malvern, UK).
The transverse relaxivity, R2, of the particles was calculated as the slope of the 1/T2
against iron concentration. T2 relaxation times were determined using a Bruker mq60 MR
relaxometer (Bruker; Milton, Ontario) operating at 1.41 T (40˚ C) using a standard CarrPurcell-Meiboom-Gill mulitecho sequence (!=1.5 msec and 2 dummy echoes) fitted
using a monoexponential decay.
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Male Holtzman rats (Harlan Sprague-Dawley; Indianapolis, ID) were housed
under USDA- and AAALAC-approved conditions with free access to food and water. All
experimental procedures were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee and carried out under the guidelines of the Committee
for Research and Ethical Issues of the International Association for the Study of Pain
(83). At the time of surgery all rats weighed between 275-332 g, Table 7.1.
number

date

type

weight (grams)

48

12/10/08

compression

298

49

12/10/08

compression

298

52

12/10/08

sham

298

53

12/10/08

sham

290

74

4/2/09

compression

302

75

4/2/09

compression

303

76

4/2/09

sham

275

77

4/7/09

sham

280

90

4/15/09

compression

300

91

4/15/09

compression

308

Table 7.1 - Participating MR Imaged Rats.
Rat subjects used in this study are labeled by their chronological surgery number (by
neurosurgeon Christine Weisshaar). The date of surgery (day 0; see Figure 7.6) is given.
All compressions were as described; 15 minutes at 10 gmf. The weights reported are
immediately prior to surgery.
Surgical procedures were performed under inhalation anesthesia using 4%
isoflurane for induction and 2% for maintenance. The transient unilateral nerve root
compression injury has been previously described and reliably induces sustained
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behavioral sensitivity that lasts for nearly 3 weeks (16, 40, 84, 85). Briefly, a
hemilaminectomy and facetectomy were performed at the C6-C7 level of the right side to
expose the C7 roots. For painful injury, a microvascular compression clip (World
Precision Instruments, Inc.; Sarasota, FL) was used to apply a 10 gmf compression to the
dorsal nerve root for 15 minutes (n=6; Figure 7.6A). Identical surgical procedures were
carried out for the sham group except that the nerve root was exposed only, without any
compression (n=4). The surgery site was sutured and closed with surgical staples. Rats
were continuously monitored following surgery.
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Figure 7.6 - Experimental Design.
(A) The painful injury is provoked by transient compression of the right-side C7 dorsal
nerve root. A haemostatic compression clip (*) is applied proximal to the dorsal root
ganglion (DRG), following the disclosure of the nerve root. The ventral ramus (VR) and
dorsal ramus (DR) are also indicated. (B) The timeline for the experiment shows that 6
days following surgery precontrast images of the animals are acquired in a 9.4 T MR.
SPIO are tail-vein injected following the pre-contrast imaging session and a postcontrast
scan is performed 24 hours later.
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7.4.3 - MR Imaging
All experiments were performed using a 9.4 T horizontal small animal MR
equipped with a 25 G/cm gradient insert (Varian; Palo Alto, CA) at the Small Animal
Imaging Facility in the Department of Radiology at the University of Pennsylvania.
Imaging was performed using a dual-coil system; a 7 cm diameter volume coil was
actively detuned for use with a 2.5 cm loop receive-only surface coil (InsightMRI;
Worcester, MA).
Rats were anesthetized prior to imaging, as described above, and placed supine
into a custom-built stereotactic restraint device that held the surface coil to the cervical
spine. A coaxial breathing apparatus delivered anesthetic throughout the scan and
removed CO2 and excess isoflurane. Temperature and electrocardiography probes were
used to monitor the rats in the 37˚ C environment supplied by an air heating system (SA
Instruments, Inc.; Stony Brook, NY).
Precontrast image sets were acquired at day 6 following surgery (Figure 7.6B).
After the precontrast imaging session, 10 mg Fe/kg (approximately 300 !L) was
delivered systemically by tail vein injection. Postcontrast image sets were acquired 24 h
later, on day 7 following surgery (Figure 7.6B). Identical imaging procedures were used
for both of the pre- and postcontrast imaging sessions. In vivo MR microscopy of the C6
and C7 spinal cord and nerve roots was performed using the VnmrJ software (Varian).
The MR imaging protocol consisted of several scout sequences to locate the C6 and C7
nerve roots. This was followed by a T2*-weighted gradient echo multislice sequence (TR
200 msec, TE 5.5 msec, 20˚ flip angle) in the axial plane. Greater T2*-weighting, while
desired, was precluded due to proximity (and enclosure) of interrogated anatomy to bone.
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Fifteen interleaved slices were typically acquired, with a thickness of 0.5 mm, NEX = 8,
nv = 256, np = 256 and a field of view of 5 cm x 5 cm.

7.4.4 - Image and Statistical Analysis
Image sets were analyzed using ImageJ (NIH; Bethesda, MD), following their
conversion using the Multi FDF Opener plug-in (Shanrong Zhang, University of Texas
Southwestern Medical Center). User defined ROI of equal area were set for the ipsilateral
and contralateral (control) C6 and C7 nerve roots, as well as two background (paraspinal
muscle) locations, under radiologist-blind (pre-, postcontrast, injured or sham)
conditions.
On a slice-specific basis, the relative signal intensity, rSI, was calculated by
division of the mean intensity of the ROI at each nerve root by that of the paraspinal
muscle. For each subject, this value was then normalized to the rSI maxima of the C6
nerve root to give the normalized rSI (nrSI) for ipsilateral and contralateral roots.
Quantitative comparison of the pre- and postcontrast C7 nerve roots, as well as between
injured and sham groups, was made possible by then computing the difference of the
normalized rSI peak and immediately adjacent slices'. MR findings, the presence or
absence of enhancement, were considered significant if p < 0.01. A two-tailed MannWhitney test was used.
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Tissue was harvested from all rats immediately following the final imaging
session on day 7 (Figure 7.6B). Transcardiac perfusion was performed using PBS and
then a 4% paraformaldehyde-in-PBS mixture; the cervical spinal cord was exposed and
the C7 level was bisected to enable removal of the nerve roots and spinal cord en bloc on
each of the ipsilateral and contralateral sides separately. Tissue samples were embedded
in paraffin to enable axial sectioning (10 !m thick). Nanoparticles were localized in the
tissue by Prussian blue staining for iron oxide using a wash of a 1:1 mixture of 2%
potassium ferrocyanide and 2% HCl for 20 minutes. Sections were rinsed in dH2O,
dehydrated, cleared in Citrisolv and then cover slipped using Permount. Serial sections
were also immunostained to co-localize macrophages with SPIO; activated macrophages
were stained using an antibody against the CD68 receptor (ED-1, Serotec; Oxford, UK).
A horse anti-mouse secondary antibody (Vector; Burlingame, CA) was used and
developed using the ABC kit (Vector). Sections were dehydrated, cleared and then
mounted.
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7.5 - Results and Discussion
Precontrast images were acquired after 6 days of recovery from surgery. Dextrancoated SPIO, with a 29 nm hydrodynamic diameter and R2 of 104 mM-1sec-1, were then
injected at a dose of 10 mg Fe/kg. The following day imaging was repeated. The cervical
nerve roots at the C6 and C7 NR levels were visualized with 0.5 mm thin axial slices in
series using a T2*-w multi-slice gradient echo sequence.
Representative axial acquisitions from each group, pre- and postcontrast, are
shown in Figure 7.7. Scans of the rat cervical spine show the spinal cord at the center
surrounded by vertebral bone enclosed in muscle. Careful axial slice selection afforded
visualization of both the ipsilateral and contralateral roots in the field of view, allowing
for an inherent control (contralateral root) to be included throughout imaging. Bilateral
roots can be readily identified in the precontrast images for both injured and sham
groups. There is a clear loss of signal in the ipsilateral (compressed; Figure 7.7D) root in
the postcontrast imaging session.
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Figure 7.7 - Imaging SPIO-Induced Hypointensity at Injury.
Representative MR acquisitions of spinal cord and nerve root level C7 (C6 vertebral
level). Use of a dual coil arrangement afforded high resolution imaging at tissue depths of
several centimeters. The spinal cord (SC), vertebrae (V; especially the anterior tubercle),
disc (IVD), nerve roots (ipsilateral and contralateral; Ip, Co respectively) and wind pipe
are clearly visible for each subject. Soft tissue filling of the void created upon
hemilaminectomy bone removal to expose the nerve roots is present to differing degrees
(indicated below symbol ! in A). The pre- and postcontrast images for the sham animal,
A and B respectively, show little signal difference in nerve roots on the exposed side. In
contrast, the pre- and postcontrast acquisitions for the injured subject, C and D, differ at
the transiently loaded NR. Indicated by the arrow, a signal void is present at the NR
following administration and accumulation of SPIO.
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The placement of ROI used for quantitative analysis is given on a representative
acquisition in Figure 7.8A. Here, the spinal cord with roots passing through the
surrounding vertebrae at C7 is shown. The spinal level of interest was localized using the
landmarks of soft-tissue injury and anterior tubercles. ROIs were drawn for each dorsal
root as well as at sites in the surrounding back muscle. If no nerve root was visible, the
ROI was placed in the linearly inferred position between successive roots.
The flexibility of the rat neck in multiple directions meant that axial plane
alignment of both ipsilateral and contralateral nerve roots was not always feasible,
despite the use of a stereotactic restraint device. Therefore, to ensure that the signal loss
at the injured root was a result of SPIO accumulation rather than from imaging artifacts,
such as partial volume effects, a series of sequential slices were acquired for each rat to
include nerve roots through the C6/C7 levels. A representative series of such acquisitions
is shown in Figure 7.8B-F. These five adjacent slices at C6 from a C7-compressed rat
show that there is no evidence of signal loss in the ipsilateral root at one level above the
injury.
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Figure 7.8 - Nerve Root Injury Visualization.
(A) A representative axial image is presented, overlaid with ROI for the ipsilateral (Ri)
and contralateral (Rc) roots as well as background paraspinal muscle (B1 and B2). The
ROI are have been slightly enlarged for clarification. Analyses investigated relative
signal through a series of sequential acquisitions to avoid artifactual errors, such as partial
volume effects, from distorting the results. An example of 5 consecutive 0.5 mm slices
through the C5 vertebral level (C6 nerve roots) are shown raustral to caudal in B - F.
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The normalized relative signal intensity (nrSI) computed for each imaging slice
in the rostral-to-caudal direction of an animal are shown in Figure 7.9. The periodic
maxima reflect the appearance of the nerve roots, while the minima reflect the presence
of bone. Qualitatively, it is evident that there is little discrepancy between the ipsilateral
and contralateral nrSI in the precontrast series. An example of slight offset of roots, as
described above, is seen in Figure 7.9B; here, the bilateral C6 roots are in different
imaging planes. Decrease of the nrSI at C7 in the postcontrast injured rat, resulting from
SPIO accumulation, is substantial (Figure 7.9D).
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Figure 7.9 - Signal Ratio Through Roots.
Raustral-to-caudal NR signal (relative to paraspinal muscle) for a representative sham;
precontrast (A) and postcontrast (B), and an injured animal; precontrast (C) and
postcontrast (D). Values of relative signal intensity were normalized to C6 maxima. In an
evaluation of the nerve root rSI, periodic increases of signal were found to correlate with
the appearance of roots. The signal minima correspond to bone and intervertebral tissue.
Sham and precontrast injured subjects did not demonstrate discrepancy in normalized
signal ratio intensity between C6 and C7 nerve roots for the ipsilateral (dashed) and
contralateral (solid) sides. When investigating postcontrast injured animals a large
difference in the C7 nerve root signal intensity ratio was observed, (NR = nerve root)

Chapter 7
288
To quantitatively compare the sham and injured groups, pre- and postcontrast, the
percentage difference between the contralateral and ipsilateral nrSI was calculated
(double ended arrow, Figure 7.9D). These values are plotted as percent change in Figure
7.10. SPIO accumulation over 24 hours led to local hypointensity and a difference in nrSI
between the roots in the injured case of 72.9±31%. No significant change in precontrast
images of nrSI was detected between ipsilateral and contralateral nerve roots in the
injured (5.35±12.9) or sham (-10.8±5.4) animals. This result essentially recapitulates the
deficit in clinical MR imaging of radiculopathy; there is no visible difference between
injured and healthy nerve roots (without contrast). Further, the sham group showed no
significant nerve root enhancement (2.8±14.1%) 24 hours after the SPIO injection.

Chapter 7

289

Enhancement Between
Nerve Roots (%)

125

!

100

*
**

nrSIc " nrSIi
#100%
nrSIc

75
50

*

**

Post

Pre

25
0
-25
Pre

Sham

Post

Injured

Figure 7.10 - SPIO Enhanced Detection of Nerve Root Compression.
The quantification of normalized relative signal intensity (nrSI) differences between the
ipsilateral and contralateral nerve roots is shown. Precontrast subjects (filled symbols)
and postcontrast (open) normalized differences are plotted along with the mean of each
group (bold line) and the standard error for each group. Significant enhancement (p <
0.01) between the (**) pre- and postcontrast nerve roots in the injured group as well as
between the (*) sham and injured post-contrast roots was found.
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Histological evaluation of the nerve roots and spinal cord was performed to
identify the presence or absence of activated macrophages and iron oxide particles.
Representative micrographs of dorsal roots and spinal cord are shown in Figure 7.11. The
detection of SPIO and macrophage by immunostaining was observed in the injured C7
root (Figure 7.11E-F). Very few inflammatory cells and little accumulated iron oxide
was observed at the ipsilateral C6 root above the nerve root injury (Figure 7.11G-H).
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Staining of dorsal nerve roots was performed for both macrophage and iron following the
final imaging time point. Representative ipsilateral (Ipsi) C7 roots of sham animals were
stained for macrophage and iron oxide (A and B, respectively). Neither immune cells, nor
SPIO were detected. This was also the case for the C7 nerve roots on the contralateral
(Con) side of injured animal (C and D). Activated macrophage staining (E) and
corresponding iron (F) was evident on the transiently injured nerve root (ipsilateral side
of C7). Finally, limited inflammatory cell infiltration and corresponding iron oxide was
found in the C6 ipsilateral root of the injured subjects (G and H). The scale bar in H
(equivalent to 100 !m) applies for (A through H). (I) Lower magnification section
showing dorsal root ganglion (DRG), dorsal and ventral nerve roots (DNR and VNR,
respectively), the dura matter (DM) and one half of the spinal cord (SC). Box denotes
approximate area of magnification for (A-H). Scale bar in (I) is also 100 !m.
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Generally, the iron oxide was co-localized with macrophages at the injury site;
however, the density of macrophage and extensive Prussian blue staining of iron oxide
made 1:1 co-localization difficult. A 1:1 localization of iron to macrophage was observed
further along the NR, at less dense sites of macrophage infiltration (Figure 7.12A-B).
Inflammatory cells and accumulated SPIO were absent in the C7 roots of the sham and
the contralateral root of the injured animals. Furthermore, no Prussian blue staining was
observed in the injured roots in the absence of SPIO, Figure 7.12C-D.
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Figure 7.12 – Macrophage and Iron Oxide Specificity.
(A) Macrophage found at the site of a nerve root compression at day 7 after insult by
anti-CD68 immunohistochemistry. (B) These macrophage co-localize with the presence
of iron oxide as revealed by Prussian blue stain development in the less macrophage
dense regions further distal from the injury site along the nerve root (towards the dorsal
root ganglion). Histological investigation of the nerve root reveals that for (C)
macrophage, again at 7 days after the injury, there is (D) no non-specific iron oxide
accumulation in the absence of a SPIO administration.
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7.6 - Conclusion
MR imaging of the cervical spine provides high-resolution visualization of the
spinal cord, nerve root and skeletal architecture. However, the difficulty in using this
information to identify the anatomic origin responsible for cervical radiculopathy or to
correlate pathology with pain symptoms is a significant challenge in clinical patient
management (12). Noninvasive markers for the detection of neuroinflammation have
significant potential to impact clinical practice through detection and monitoring of
therapy for cervical pain.
In animal pain model studies which involve the ligation (44), compression (86) or
chemical irritation (46) of neural tissue, hypersensitivity of the affected enervated area is
assessed through behavioral responses to mechanical and/or temperature stimuli. In the
painful injury model investigated here, compression of the C7 nerve root induces
sustained behavioral sensitivity that radiates to the forepaw, mimicking the clinical
presentation of radicular persistent pain (57). This same mechanical loading of the nerve
root also leads to macrophage infiltration at the root and release of inflammatory
cytokines, further contributing to persistent behavioral hypersensitivity (50). In our study,
we used SPIO contrast for the in vivo cellular detection of neuroinflammation (53).
It was found that one day following the administration of SPIO, hypointense
signal was observed at the injured site on a T2*-weighted image. Inflammation, signified
by either hyper- or hypointensity was not detectable at injured roots prior to contrast
enhancement (Figure 7.7A-B). Further, non-injured roots exhibited no significant change
in signal ratio following contrast delivery. Confirmation that the decrease in signal at the
injured site was due to the specific presence of SPIO was accomplished by co-localizing
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the iron from the particles to the activated macrophage surface marker CD68 (Figures
7.11-12).
Comparison of nrSI between the ipsilateral and contralateral roots of the injured
group revealed a significant change (72.9±31%) in the injured root after SPIO
accumulation. No significant percentage difference of nrSI was determined outside of the
injured postcontrast group. Small quantities of iron oxide and macrophage were detected
by histology at the ipsilateral C6 root of the rats in which the C7 root was compressed;
however, this extent of SPIO accumulation was below the MR detection limit. This
provides motivation for use of this technique as being specific for detecting the site of
injury, providing the potential for adoption as a means to guide surgical interventions for
treatment of radiculopathy patients. However, it should be noted that future use of the
nrSI metric, which is dependent on C6 root signal intensity, requires that the injury be
localized to a single level. This problem could potentially be alleviated through the
imaging of additional nerve roots.
In the present study, MR imaging was limited to only two vertebrae for each rat
due to the flexibility and depth of the cervical spine, which is situated further from the
back than the thoracic or lumbar spine. The surface coil was positioned with the C6 and
C7 roots in the field of view, in order to evaluate both a non-injured and potentiallyinjured level at the same time.
Previous work using SPIO enhanced MR imaging of nerve injury reported
hyperintensity at the injury site following compression, followed by darkening upon
contrast administration (74). The hyperintense signal feature was not observed here and
may have been masked by the bone surrounding the root or may only be present with of
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the production of edema which occurs for more severe insults, such as used in that model.
A further difference between the two studies was that contrast enhancement was only
possible if SPIO were administered 1 day following injury, while the imaging studies
here were not performed until 6 days after the initial injury. Earlier investigations of the
model employed in this study have revealed macrophage accretion continues for at least 7
days following transient injury (57).
While the work presented here needs to be validated at clinically relevant
scanning strengths, it should be noted that many of the anatomic challenges and
limitations presented by the rat are not present to the same extent in humans. Cervical
vertebrae are well visualized and aligned in the supine position (87). Furthermore, the
much larger diameter of the roots in the human (approximately 0.5 cm) would enable
greater distinction of bony versus neural tissues and identification of SPIO accumulation.
The setting for which the neuroinflammation detected using SPIO was preclinical. However this protocol may provide a basis for the clinical radiologist to correlate
cervical nerve root injury to pain. These data indicate that the source of painful
neuropathy can be identified 1 day following administration of SPIO and can enable
diagnosis of the source of radiculopathy in patients that do not have obvious pathologies.
This has been accomplished here using an analogue of commercially available and
clinically approved agents (for example the 20-40 nm diameter Ferumoxtran (88)). MR
cellular imaging of the site of injury might also allow for personalized, quantitative and
real-time monitoring of anti-inflammatory treatment strategies aimed at alleviating
radicular pain.
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CHAPTER 8. Summary and Future Directions
8.1 - Introduction
Use of magnetic resonance (MR) for the tracking of immune relevant cells and
delineation of their activity is a challenging engineering task. The potential impact that
such techniques possess for enhancing the clinical diagnostic ability of MR and for the
understanding of biological phenomena is a powerful impetus for continued
advancements in the field. In this dissertation, an adaptable, derivitizable iron oxide
nanoparticle platform was developed and applied in several cellular and animal systems.
Under a variety of physical, chemical and electromagnetic examinations the
manufactured superparamagnetic iron oxide (SPIO) were well characterized. Several
nanoparticle formulations were applied in the determination of key SPIO parameters that
affect non-phagocytic cell uptake. Labeling of B cells was accomplished ex vivo. SPIO
were used, in conjunction with a near infrared dye to track implanted B cells in vivo with
and without the application of B cell depleting antibody. Particles were also utilized to
visualize neurinflammation in a rodent cervical persistent pain model. Finally the SPIO
were derivatized to accomplish highly efficient, functional, antibody labeling to facilitate
in vivo targeting of B cells. The major findings of the work are catalogued in this chapter.
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This is followed by a discussion of the likely implications of this work, suggestions for
future work and a concise conclusion of results.
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8.2 - Significance of Findings
Control over the starting synthesis parameters used in the co-precipitation of the
iron salts in the presence of complexing agent was required to produce SPIO of desirable
characteristics. Parameters of essential importance were found to include; inert
atmospheric conditions, the relative ratio of iron-to-dextran, the rate of addition of
reductant and rigid purification practices. The multi-component core (and resultant
magnetic properties) and overall diameter of the particles could be modified by altering
components of the reaction listed above.
Transmission electron microscopy, dynamic light scattering, viscometry,
magnetic relaxation tests and a variety of surface charge probing methods were
performed. The manufactured particles possess a non-ideal crystal lattice core of iron
oxide likely in a mixed form of maghemite and magnetite, coated in a shell of dextran.
SPIO ranging from approximately 20 nm through to 150 nm were synthesized. The
surface layer of dextran was altered post-synthesis first through cross-linking the
individually FeOH-complexed dextran macromolecules and functionalized with charged
residues. Finally, these surface expressed groups were exploited to 1) directly conjugate
fluorophores and proteins and 2) as points of conjugation for advanced ligation
chemistries, such as the copper catalyzed azide alkyne cycloaddition.
Demonstrated in this work was the ability to functionalize particles with a range
of surface properties (with respect to surface charge and expressed groups), physical
characteristics (overall diameter, inner core components and magnetic properties) and
conjugated moeities. These include but are not limited to fluorophores such as fluorescein
isothyiocyanate, Cy5.5 and Alexa 680; amine reactive and characterizing molecules such
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as N -Succinimidyl 3-(2-pyridyldithio)-propionate; click reactive molecules such as
amine-reactive propargyl and azide conjugated PEG cross-linkers; and proteins and
peptides such as the polyamine protamine and human B cell targeting anti-CD20.
We examined the T2-weighted contrast that resulted from by loading nonphagocytic cells with SPIO. The SPIO properties were varied, according to surface
charge, hydrodynamic diameter, concentration and time of incubation in order to
determine the relevant factors for SPIO labeling of immortalized human T cells. The
procedure was verified for primary murine B cells. These cells were then labeled by both
SPIO and near infrared (NIR) dye for the purpose of monitoring B cell distribution in
vivo in a mouse. The homing of cells to the spleen was verified by both MR and optical
methods. The distribution following administration of a B cell depleting antibody was
also monitored. These results indicated that SPIO may interfere with the biological
process of antibody mediated B-lymphocyte cytotoxicity.
Finally, SPIO were utilized for the identification of the site of neurological insult
in a transient compression model. It has previously been observed that transient
compression of the rat C7 dorsal nerve root resulted in hypersensitivity of the affected
dermatome (1-3). This has been correlated to the infiltration of activated macrophage into
the neural tissue (4-6). The presence of these macrophage, was detected through the
active uptake of long circulating (non-aminated) SPIO. The degree of contrast
enhancement resulting from SPIO administration was determined semi-quantitatively.
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8.3 - Future Directions
From both a materials engineering and biomedical study design standpoint,
several avenues are available for extending the work completed in this dissertation. Areas
of advancement include the refinement of the nanoparticle architecture itself, in vivo
targeting of immune system relevant cells and further study of SPIO application to
neuropathy.

8.3.1 - Refinement of SPIO
Much of the work in this thesis demonstrated control over the production and
physicochemical properties of SPIO for biomedical applications. Advances in materials
engineering, however, mean that SPIO with augmented beneficial properties can be
constructed. Extending out of the tight control of heterogeneous layered nanoparticles
such as type II quantum dots (7), investigation and manipulation of the core-shell
relationship has become a major area of research in its own right for magnetic
nanoparticles. Two materials in particular would be relevant to coating of iron oxide
nanoparticles, gold (8) and silica (9). While no longer a novel prescription, coating the
iron with a thin layer of either silica or gold is hypothesized to allow for more robust, and
eased, functionalization as the gold-sulfhydryl and silica-binding conjugation chemistries
have considerable literature (10, 11).
Advantages of such an approach include better core crystallinity resulting in
greater magnetic moment for the particles. This, coupled with the greater functionality,
are significant assets when tracking particles or attempting to bind targets in the body.
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The disadvantage of such strategies is that synthesis routes are undoubtedly more
complex than the iron salt co-precipitation method. If significant work can be completed
towards good manufacturing processes of core-shell magnetic nanoparticles, better
signal-to-noise, lower dosage and more effective targeting vehicles may be developed.

8.3.2 - In vivo targeting of B cells
The ex vivo loading of SPIO resulted in an apparent inability to detect antibody
mediated depletion of B cells in the spleen. This reveals the possibility that an in vivo
targeting approach may be better suited for MR detection of B-lymphocyte population
migration or demise. The preliminary work towards this strategy has been accomplished.
Probes consisting of B cell targeting antibody-SPIO conjugates have been manufactured.
This process was determined to make highly efficient use of starting protein. Further, the
functionality of the antibody was not degraded. Antibody-SPIO conjugates labeled B
cells in vitro with greater avidity than particles developed using the conventional covalent
amide linking approach.
The determination of B cell distribution in vivo using antibody-SPIO targeting
conjugates is theoretically possible. No study to date has utilized SPIO to specifically
label a cell population as populous as B-lymphocytes. However, selection of a targeting
ligand (antibody or otherwise) that demonstrates high specificity for B cells with likewise
low non-specific adherence to other tissues should allow for identification of sites of B
cell concentration. The ability to repeatedly administer a targeted imaging agent should
provide a means to identify the change in B cell distribution over the course of a
depletion therapy. Furthermore, if the probe is itself benign and well tolerated, it is
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conceivable that this SPIO contrast agent could be applied for the study of B cell
distribution and response in other autoimmune disease and therapy models.
In a different direction, an interesting observation regarding spleen signal
intensity in T2*-weighted imaging was made. It was noted that the spleens of mice
subjected to the immunotherapy protocol, but devoid of nanoparticle MR contrast agent,
darkened. This hypointensity was slight and developed over time, however it provides an
noteworthy, hitherto unremarked-upon, example of MR imaging of B cell depletion
therapy. Any clinically relevant conclusions are certainly premature at this juncture.
However if it can be correlated to other therapeutic response markers this phenomenon
may provide a non-invasive, agent free, means to determine treatment efficacy.

8.3.3 - Advanced Imaging of Painful Neuropathy
There are several interesting areas in which our work on the in vivo imaging of
transient nerve root injury in the rat could be continued. The goal of this work was to
address a current deficit in the ability to identify nerve root injury causing radiculopathy
in the absence of permanent and gross anatomical changes, such as nucleus pulposa or
vertebral degeneration. This preclinical study could be a basis from which to conduct
either larger animal (dog or non-human primate) or even human trials. While certainly a
leap, human trials may not be beyond the scope of this work in the intermediate future.
This assertion is based on the fact that the administered SPIO agents have clinically
analogues with similar physical, chemical and magnetic properties that likely would
experience comparable accumulation at the site of a pain producing neuropathy (12).
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From a cell migration standpoint, it may be possible to repeatedly image the
injury in the rat, from insult through to full regeneration of the nerve. This would enable
study of the entire process from initial injury to neuroinflammation to an amelioration of
that condition. The study model employed for the detection of pain producing
neuroinflammation was controlled with respect to the load applied (sufficient to provoke
persistent hypersensitivity) and on the days that imaging was carried out. The dates that
the imaging was conducted was limited by several factors; namely, the wound closing
materials were metallic and it was required that they be removed prior to MR imaging.
However, if an alternative could be found and approved, it would be of interest to noninvasively determine, perhaps through repeated SPIO administration, the temporal
infiltration of macrophage at early time points following insult.
Imaging approaches also provide a means to perhaps image the severity of injury,
which is dependent on several factors such as magnitude of insult and pharmacological
management. In the current study, the load and duration of compression were fixed at 10
gmf and 15 minutes respectively. However, it has been previously shown that behavioral
outcomes and spinal cellular responses depend on the magnitude of nerve root
deformation (13-15). The application of SPIO as an in vivo diagnostic for the gradation
of neuropathy could be of significant clinical relevance. In a related capacity, the
application of non-invasive imaging techniques could be of tremendous pre- and clinical
application to the monitoring of therapeutic efficacy. It has been shown that
pharmacological treatment parameters have a significant behavioral and cellular impact
in rat pain models. SPIO administration may allow for both imaging of the dynamics of
reduction in inflammation following treatment, comparison of therapies and possibly
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from a clinical standpoint evaluation of best practices for management of cervical
radiculopathy.
Finally, it may be possible to administer magnetopharmaceuticals beyond the
unmodified SPIO used in the CNS injury detection studies performed here. Positive
contrast agents, such as Very-small SPIO (VSPIO) and Gadofluorine M (an amphiphilic
macrocyclic gadolinium complex of relatively low molecular weight) have recently been
used to visualize and grade severity of CNS injury in rat encephylitis models (16).
Likewise, we have recently developed a nanoparticle formulation that provided excellent
tumor signal increase in T1-weighted imaging. This gadolinium-conjugated dendritic
nanocluster system has the potential to undergo inflammatory site accumulation through
macrophage uptake similar to that observed for SPIO administered in the transient nerve
root injury study (17).

Chapter 8

315

8.4 - Conclusion
The foremost goal of this thesis was to observe the presence and distribution of
immune relevant cells in vivo. We have demonstrated development of a functional
nanoparticle contrast agent for use in magnetic resonance imaging. It was determined that
agent properties could be controlled either during the synthesis or subsequently through
modification of the surface properties and functionalities of the coating material.
Investigations of the interaction between cellular systems and the produced SPIO
revealed that size, concentration and surface charge were critical towards labeling of nonphagocytic cells. An optimal labeling configuration of particle was determined from these
studies. In a surprising result, given the widespread use of 20 - 50 nm SPIO, and recent
focus on larger micron-sized SPIO, our results indicated that a highly cationic particle of
approximately 100 nm standard-SPIO (SSPIO) enabled maximum contrast. The T2weighted contrast enhancement as measured by a benchtop relaxometer operating near
clinical field strength for the optimal particle labeling configuration was approximately
an order of magnitude greater than the 33.4 nm ultrasmall-SPIO. Contrast was nearly two
orders of magnitude greater than conventional micron-sized SPIO.
To enable lymphocyte tracking in vivo we progressed from an in vitro
immortalized cell line to labeling of primary B cells for in vivo administration. In order to
avoid detrimental biological effects the less charged smaller particles of 53.5 nm
diameter were used. These SPIO and a cell surface membrane labeling near infrared dye
enabled MR and optical monitoring of administered B cells in vivo. The primary goal of
using these agents to determine B cell distribution in vivo was successfully
accomplished. The presence of MR contrast agent in the spleen was confirmed by T2*-
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weighted imaging using a dual surface and volume coil imaging configuration. The
detection of hypointensity of the spleen was specific for SPIO loaded B cells. A ratio of
splenic signal intensity over background (paraspinal muscle) signal was used to quantify
the contrast enhancement. No significant change in signal was determined for controls.
The homing of B cells was corroborated by fluorescent signal detection in the spleen
from the near infrared dye. Contrast decreased from both modalities over time, as the
particles and dye were apparently cleared.
The determination of a change in B cell distribution following administration of
anti-CD79 B cell depleting antibody was evident only using the optical approach.
Evidently, while the presence of SPIO accumulated in the B cells using the ex vivo
loading approach enabled in vivo detection, it also prevented B cell depletion. No
significant signal ratio change was detected between the SPIO B cell groups with or
without depleting antibody.
We have applied SPIO in a rat pain model and demonstrated cellular visualization
of an otherwise occult painful neural injury. The injured nerve roots were readily
identified 24 hours following the injection of the contrast. Ratiometric assessment of
nerve-to-background tissue specified a significant difference in the normalized signal
intensity ratio (nrSI) following administration of SPIO. Imaging at the site of nerve root
injury using SPIO resulted in an average postcontrast enhancement of 72.9 ± 31%,
measured as the difference in nrSI between ipsilateral and contralateral roots. This was
significantly greater than the 5.3 ± 12.9% difference in nrSI of injured animals prior to
SPIO administration.
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Future studies will seek to utilize SPIO enhanced MR imaging in order to monitor
treatment efficacy and study the 'root' causes of radicular pain. The research reported
herein is preclinical, however the protocols established may provide a basis for the
clinical radiologist to correlate cervical nerve root injury to pain. These data indicate that
the source of painful neuropathy can be identified and may provide the means to diagnose
the source of radiculopathy in patients that do not have obvious pathologies. MR cellular
imaging of the site of injury might also allow for personalized, quantitative and real-time
monitoring of anti-inflammatory treatment strategies aimed at alleviating radicular pain.

Chapter 8

318

8.5 - References
1.

Hubbard RD, Winkelstein BA. Transient cervical nerve root compression in the
rat induces bilateral forepaw allodynia and spinal glial activation: mechanical
factors in painful neck injuries. Spine 2005; 30:1924-1932.

2.

Rothman SM, Huang Z, Lee KE, Weisshaar CL, Winkelstein BA. Cytokine
mRNA expression in painful radiculopathy. J Pain 2009; 10:90-99.

3.

Hubbard RD, Martinez JJ, Burdick JA, Winkelstein BA. Controlled release of
GDNF reduces nerve root-mediated behavioral hypersensitivity. J Orthop Res
2009; 27:120-127.

4.

Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neuropathic pain responses
in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A 2003;
100:7947-7952.

5.

Myers RR, Heckman HM, Rodriguez M. Reduced hyperalgesia in nerve-injured
WLD mice: relationship to nerve fiber phagocytosis, axonal degeneration, and
regeneration in normal mice. Exp Neurol 1996; 141:94-101.

6.

Hubbard RD, Winkelstein BA. Dorsal root compression produces myelinated
axonal degeneration near the biomechanical thresholds for mechanical behavioral
hypersensitivity. Exp Neurol 2008; 212:482-489.

7.

Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots
for sentinel lymph node mapping. Nat Biotechnol 2004; 22:93-97.

8.

Jaeyun Kim, Sungjin Park, Ji Eun Lee, et al. Designed Fabrication of
Multifunctional Magnetic Gold Nanoshells and Their Application to Magnetic
Resonance Imaging and Photothermal Therapy13. Angewandte Chemie
International Edition 2006; 45:7754-7758.

9.

Taboada E, Solanas R, RodrÌguez E, Weissleder R, Roig A. Supercritical-FluidAssisted One-Pot Synthesis of Biocompatible Core(gamma-Fe2O3)/Shell(SiO2)
Nanoparticles as High Relaxivity T2-Contrast Agents for Magnetic Resonance
Imaging. Advanced Functional Materials 2009; 19:2319-2324.

10.

Weihong Tan, Kemin Wang, Xiaoxiao He, et al. Bionanotechnology based on
silica nanoparticles. Medicinal Research Reviews 2004; 24:621-638.

Chapter 8
319
11.
Kumar S, Aaron J, Sokolov K. Directional conjugation of antibodies to
nanoparticles for synthesis of multiplexed optical contrast agents with both
delivery and targeting moieties. Nat Protoc 2008; 3:314-320.
12.

Leung K. Ferumoxtran (USPIO). In:Molecular Imaging and Contrast Agent
Database (MICAD) [database online]. Bethesda (MD): National Library of
Medicine (US), NCBI; 2004-2009. Available from: http://micad.nih.gov,
Accessed 2007.

13.

Winkelstein BA, DeLeo JA. Mechanical thresholds for initiation and persistence
of pain following nerve root injury: mechanical and chemical contributions at
injury. J Biomech Eng 2004; 126:258-263.

14.

Winkelstein BA, Rutkowski MD, Weinstein JN, DeLeo JA. Quantification of
neural tissue injury in a rat radiculopathy model: comparison of local
deformation, behavioral outcomes, and spinal cytokine mRNA for two surgeons. J
Neurosci Methods 2001; 111:49-57.

15.

Hashizume H, DeLeo JA, Colburn RW, Weinstein JN. Spinal glial activation and
cytokine expression after lumbar root injury in the rat. Spine 2000; 25:1206-1217.

16.

Bendszus M, Ladewig G, Jestaedt L, et al. Gadofluorine M enhancement allows
more sensitive detection of inflammatory CNS lesions than T2-w imaging: a
quantitative MRI study. Brain 2008; 131:2341-2352.

17.

Cheng Z, Thorek DLJ, Tsourkas A. Gd-Conjugated Dendrimer Nanoclusters as a
Tumor-Targeted T1 Magnetic Resonance Imaging Contrast Agent. Angewandte
Chemie International Edition (2009); In revision.

Appendix A

320

APPENDIX A. T1 Contrast Agents
A.1 - Gadolinium(III)
The most widely used magnetic resonance (MR) contrast agent (CA) is the
paramagnetic lanthanide ion gadolinium (III), referred to herein as Gd. Other
paramagnetic ions that perform less well as CA, but are still of interest primarily at the
bench-top, are magnanese(II), copper(II) and iron(III) for the same reasons described
below. Paramagnetic relaxation of surrounding water protons occurs as the dipole-dipole
interaction between the spins of the ion's unpaired electrons and the dipole moments of
the surrounding 1H. In its unfilled d and f shells; the Gd has 7 unpaired electrons, the
greatest of any stable ion (1). The resulting effect is a shorter T1; the nuclei regain their
longitudinal magnetization faster and are thus brighter, or hyperintense, on all
conventional T1-w images.
Contrast agents’ ability to relax surrounding protons affects both T1 and T2
processes. Gadolinium(III) is a T1-w contrast agent as the R2/R1 ratio of approximately 12 means the signal change for T1-w imaging is much greater than it would be for T2-w
imaging. For comparison, common iron oxide T2-w contrast agents, discussed in detail
throughout this dissertation, often effect an R2/R1 of 10 (2).
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The enhanced spin-lattice relaxation mechanism of paramagnetic ions has been
described in the Solomon-Bloembergen theory (3). Here, observed T1 is due to a
combination of the intrinsic T1 of the diamagnetic sample (the protons) and the T1 caused
by the presence of the Gd. This latter T1 is composed of two terms, the inner and outer
sphere effects. The inner sphere describes the relaxation of the 1H directly bound to
(hydrating) the paramagnetic ion, and the outer sphere describes the interactions between
the 1H diffusing as water closely by the Gd (4). The outer sphere effects are difficult to
control given that they depend on tissue properties.
Numerous parameters affect the relaxivity of Gd-based MR CA, as demonstrated
in Equation A.1, the description of the inner sphere term. For a fixed radiofrequency
(RF), f, the R1 is a function of the inner sphere water coordination number, q (the number
of bound water molecules per Gd), the effective magnetic moment, !eff, the internuclear
distance of the water proton, r, and the correlation time, Tc.
Equation A.1

f R1 =

2
q " µeff
Tc
6
r

The correlation time can be represented through the rotational correlation time (Tr),
! time (T ) and the inner sphere exchange correlation time (T ), as
electron spin relaxation
1e
m

shown in Equation 1.9.
1

Equation A.2

1
1
1
Tc = Tr + T1e + Tm

A schematic illustration of these parameters, in an physical sense, is given in Figure A.2.
!
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Figure A.1 - Schematic of water molecule interaction with gadolinium(III).
Critical parameters affecting Gd relaxivity. One inner sphere molecule of water (within
the radius depicted by the dashed line) is depicted interacting with the Gd ion. The proton
exchange rate is depicted by the bold double arrows. The rotational correlation time of
the molecule is shown by the arrow. Adapted by Thorek from (5) and (4).
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A.2 - Gd-Chelates and Toxicity
A major issue for use of Gd is that of safety; lanthanide ions are extremely toxic.
They must be chelated for biological use to prevent uptake (as well as to provide
solubility). Retention of Gd has been shown to cause nephrogenic systemic fibrosis
(NSF) in patients with renal conditions (6). NSF is found to cause renal failure, organ
complications, skin induration and ultimately death. Confirmation of the diagnosis is
primarily made through skin biopsy revealing presence of gadolinium long after
administration (7).
Gd-chelating compounds must have very high stability (logKGd ~ 20) so that the
entire agent may be cleared prior to release or replacement of the ion by a metal found in
the body (8). Chelation does not abrogate all health risk issues, as transmetallation may
still occur to free the ion (9). Clinically relevant chelators can be classed into three
primary groups that describe their structural chelation of the Gd as well as their stability,
as shown in Figure A.2. In order of most stable (least likely to release Gd) to least stable
(weakest chelator), there are: cyclical, ionic linear and non-ionic linear.
While required to prevent cellular uptake of the ion, chelates' osmolality
following injection is an issue. Magnevist, for example, is highly hypertonic (Bayer
HealthCare Pharmaceuticals, Inc. product information). The agent has an osmolality 6.9
times that of plasma (1973 mOsmol/kg versus 285 mOsmol/kg). Table A.1 contains a list
of pharmacological parameters for four of the six U.S. Food and Drug Administration
(FDA) approved gadolinium(III) agents.
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The agents deemed safe for human use, and thereby approved for use by the FDA,
are based on either diethylene triamine pentaacetic acid (DTPA) or 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Both of these materials occupy
8 of the gadolinium(III) binding sites, leaving a single site for water interaction. The
limitation of binding sites required to stabilize the ion for in vivo use is to the detriment
of the ions use as a paramagnetic T1-w contrast agent. For example the longitudinal
relaxivity of the commonly used Dotarem, is R1=3.1 (mM!sec)-1 at 1.41 T (10).

Table A.1 - Gd-CA Properties; 37˚ C
Generic name

Trade name

logKeq

T1/2

Osmolality
(Osmol/kg)

Viscosity
(cP)

R1
(mM!sec)-1

-1

M
Gadoteridol

ProHance

23.8

1.3 d

1.91

3.9

3.7

Gadodiamide

Omniscan

16.9

<2s

1.90

3.9

3.8

Gadopentetate

Magnevist

25.8

<2s

5.85

> 30

3.8

Gadoterate

Dotarem

25.8

95 d

4.02

11.3

3.5

General features of Gd-chelates are listed above. The T1/2 dissociation times are for
solutions at acidic pH, where d is days and s is seconds; where macrocycles demonstrate
reduced dissociation proclivity. In vivo the situation is more complex, as pH is generally
higher and the presence of competing endogenous ions are heterogeneous. Osmolality
measurements were conducted at 1.0 M of agent.
Consolidated and adapted from (11).
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A.3 - Gd-CA Applications and Cellular Imaging
Gadolinium(III) based contrast agents have found use in a wide variety of clinical
applications; particularly for the detection, diagnosis and staging of heart disease, cancers
and neurological diseases.
Neurological imaging applications have found great use for gadolinium(III)
contrast. Initial diagnosis sensitivity is enhanced when using conventional Gd-CA (12,
13). The agents benefit diagnosis through their accumulation in extracellular spaces
allowing for visualization of disruptions of the blood brain barrier (BBB). Further, the
CA can be used to monitor the course of !-interferon treatment (14, 15).

A.4 - Gd-CA Limitations
There exist several significant difficulties when using conventional Gd-chelates to
enhance tissue contrast. The agents require much higher concentration than radioisotope
or optical probes used for (primarily tumor) detection, often in the micromolar range
(16). This is a problem resulting from the generally low sensitivity of MR. Attempts to
overcome this problem have largely centered on nanoparticle and polymer platforms that
seek to deliver higher local concentrationos of Gd.
Conjugation of Gd to larger molecular weight structures, such as proteins (17-19)
or dendrimers (20), or as particles (21), is an approach that seeks to effectively increase
the rotational correlation time of the Gd-complexes. Another strategy is for the
encapsulation of Gd within a nanocarrier to amplify local concentration (and therefore

Appendix A
327
signal), using liposomes (22), polymersomes (23) or micelles (24). There is often a
tradeoff with both approaches that result in either long retention times (and fears of
toxicity) or decreased access to tissues or pathological sites (due to pharmocological
factors).
A more recent approach, generally seen as suitable only for research applications,
is to modify chelates such that they are able to access and accumulate intracellularly. The
main focus of this strategy has been to use individual Gd-chelates synthesized with
highly cationic polypeptides (such as the HIV-Tat or polyarginine sequences). These
chelates are able to gain access to the cellular compartment. The accumulation of chelates
was not found to have appreciable toxicity on cultured cells, however application in vivo
has not occurred (25, 26).
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